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ABSTRACT 
 
 
Precision Medicine (PM) seeks to customize medical treatments for patients based 
on measurable and identifiable characteristics. Unlike personalized medicine, this effort 
is not intended to result in tailored care for each patient. Instead, this effort seeks to 
improve overall care within the medical domain by shifting the focus from one-size-fits-
all care to optimized care for specified subgroups. In order for the benefits of PM to be 
expeditiously realized, the diverse skills sets of the scientific community must be brought 
to bear on the problem. This research effort explores the intersection of quality 
engineering (QE) and healthcare to outline how existing methodologies within the QE 
field could support existing PM research goals. Specifically this work examines how to 
determine the value of patient characteristics for use in disease prediction models with 
select machine learning algorithms, proposes a method to incorporate patient risk into 
treatment decisions through the development of performance functions, and investigates 
the potential impact of incorrect assumptions on estimation methods used in optimization 
models. 
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CHAPTER ONE 
 
INTRODUCTION TO RESEARCH 
1.1 Introduction 
 
1.1.1 Research Motivation and Scope 
 
In 2008, the National Academy of Sciences outlined the top 14 priorities for 
research in the “Grand Challenges for Engineering.” Of the research priorities highlighted 
in the document, three challenges are directly related to healthcare: advanced health 
informatics, engineering better medicines, and reverse-engineer the brain (National 
Academy of Engineering, 2018). The inclusion of healthcare challenges reflects the 
importance of medical advancements in comparison to other national and global issues. 
In spite of the research progress in this area, there remains a significant need for 
continued refinement in the understanding of how the human body operates and 
development of improved treatment techniques for identified ailments. Finding solutions 
to the identified healthcare research challenges necessitates a multidisciplinary effort that 
spans partners in government, industry and academia. 
The primary aim of this dissertation is to outline the potential role of quality 
engineers in addressing healthcare challenges. Chapter 1 will briefly outline the 
motivation for this research endeavor by touching on the financial implications to society 
of the current healthcare system. In the following section, a brief explanation of prevision 
medicine, a relatively-new initiative aimed at improving medical care through by 
providing tailored care for groups of people with matching characteristic profiles. If 
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successful, this research effort will spur current innovators in the field of quality 
engineering to consider future healthcare centric research projects. 
1.1.2 Drivers for Systematic Improvement within Healthcare 
 
The cost of healthcare in the United States consumes a larger percentage of available 
wealth with each fiscal year. In 2015, United States’ healthcare spending reached $3.2 
trillion and accounted for 17.8% of the gross domestic product (Martin et al., 2016). 
While the rising healthcare costs are attributable to a wide range of causes, the three 
primary contributing factors were the rising percentage of the population using available 
healthcare resources, increased utilization of services by the individual, and growing cost 
for specific medical services (Martin et al., 2016). The increased cost for specific medical 
procedures most likely reflects changes to healthcare policy, adjustment to patient 
treatment protocols, or attempts by the medical establishment to more accurately 
distribute overhead costs to the individual consumer. One example of a procedure whose 
total cost increased over the past decade is pediatric spinal fusion. From 2000 to 2013 the 
price of the procedure grew from $29,930 to $56,920 (National Center for Health 
Statistics, 2016). 
The relentless growth of healthcare costs has fueled concerns regarding long-term 
affordability of national healthcare programs at the national level and affordability of care 
by individuals. By addressing inefficiencies within the domain of healthcare delivery, 
research teams may potentially stabilize or decrease the total cost of healthcare to the 
nation and for individuals. 
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1.1.3 Precision Medicine: Emerging Approach for Transforming Healthcare 
 
As identified by Berwick et al.(2008), addressing the cost of healthcare will 
necessitate improving quality of patient treatment and developing additional preventative 
measures for disease. The accomplishment of these two objectives results in a reduction 
of per-capita care costs. In order to reach these goals, research teams must first focus 
improving understanding of the complex system that is the human body and how the 
system reacts to both disease and treatment. 
Medical professionals have a limited number of diagnostic tools and treatment 
options at their disposal with which to assess and treat patients. In the healthcare system 
that exists today, misdiagnosis, missed diagnoses, and poor response to treatment still 
occur. The reasons for each of these issues vary. However, at the heart of the matter is the 
need to be able to measure patient’s health characteristics, the ability to relate the 
characteristics to a set health complication, and to be able to provide the patient a 
treatment protocol that will have a positive effective. 
In 2015, the federal government launched the Precision Medicine Initiative (PMI), a 
research effort aimed at changing the treatment of patients from a one-size-fits-all 
approach to a treatment approach that takes into account individual differences between 
patients. Precision medicine (PM) is defined as “an approach to disease treatment and 
prevention that seeks to maximize effectiveness by taking into account individual 
variability in genes, environment, and lifestyle” (Hudson et al., 2015). The research 
initiative has been touted for its potential to revolutionize the treatment of disease. In his 
2015 State of the Union address, President Obama ignited interest in PM by stating 
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“Doctors have always recognized that every patient is unique, and doctors have always 
tried to tailor their treatments as best they can to individuals. You can match a blood 
transfusion to a blood type – that was an important discovery. What if matching a cancer 
cure to our genetic code was just as easy, just as standard? What if figuring out the right 
dose of medicine was as simple as taking our temperature?”(Obama, 2015). His words 
provided a compelling vision of how the advancement of PM could revolutionize the care 
of patients and improve medical outcomes.  
As the underlying knowledge needed to support the application of PM grows and as 
the application of PM becomes more common place within the healthcare system, more 
medical professionals will able to use patient features to select the best treatment protocol 
based on likelihoods of positive treatment response for populations with similar features. 
To that end, research is needed to illuminate which patient factors are the best indicators 
of health for each disease and additional research needs to assess treatment protocol 
response for groups identified by common patient characteristics. It is in this area of 
healthcare research that quality engineers will find a problem set that matches their skill 
set. The combination of the statistics, decision analysis, optimization, and process 
development are all critical components of increasing the probability of applying the best 
treatment for each individual at the right price within the shortest window of time 
possible. 
PM is poised for greater gains in the coming years due to the increase of existing 
biologic repositories, improved analytic methods to identify subpopulations, and the 
refinement of computational tools used to find optimal solutions (Collins & Varmus, 
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2015). Unique patient groups routinely examined in medical research are defined by 
common patient features which may include genetic differences, environmental factors, 
or lifestyle choices. The study of response differences between patient groups allows 
researchers to identify patients groups who are more susceptible to a disease or respond 
differently to specific treatment plans. One significant advancement in the medical field 
that greatly affected the future of precision medicine was the ability to map an 
individual’s deoxyribonucleic acid (DNA). Since DNA is unique to the individual and 
dictates how that particular body functions, this knowledge may explain why treatments 
are effective in some patients, but not in others. By determining which genes affect drug 
metabolism, an individual’s genes can be used to screen out treatments which will not be 
effective. This course of action will increase the likelihood of a patient receiving 
immediate relief instead from the prescription medication and decrease the likelihood of a 
repeat office visit. There remains a need to find additional differences between 
individuals which affect treatment response so that patient profiles may be used to inform 
treatment selection to predict an individual patient’s response to a specific drug treatment. 
1.1.4 Overlap of Precision Medicine and Quality Engineering 
 
Precision medicine will transform medical care in two ways. First, it will improve 
prevention and diagnosis by improving the ability to identifying differences between 
individuals that are healthy, at risk for a future complication, or have a health 
complication. Secondly, it will improve the likelihood of assigning the patient an optimal 
treatment strategy with the least number of remedial visits for the same ailment. In order 
for PM to be effectively applied in practice, medical professionals must have the ability 
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to compare the likelihood of effectiveness of different treatment regimens for different 
patient profiles. Quality engineers have the requisite skills to make significant 
contributions to in both of these areas. 
Quality engineers have knowledge to explore possible causes for variance within 
treatment response and assess patient risk when undergoing treatment. In the past, quality 
engineers have focused primarily on applications within the manufacturing sector but 
their knowledge is frequently applied in other applications areas. The quality engineering 
field is well known for the design of processes, a tool which enables production at 
consistent high quality outputs with few defects. Quality engineers analyze processes to 
determine how to produce predictable and accurate results. In the advancement of 
precision medicine, quality engineers can help the medical community to determine the 
optimal level of a measurable characteristic for a specific subpopulation, investigate 
optimal treatment strategies that take into account multiple ailments and combinations of 
drugs, and predict the impact of treatment strategies were based on incorrect assumptions. 
A literature review of major quality engineering journals revealed that most of the 
previously published research which combined these domains are editorials or offer an 
analysis at the macro scale. While the author cannot definitively provide a rationale for 
the lack of overlap, one reason might be the qualitative nature of medicine in the past 
century. At the start of the twentieth century, doctors were reliant on a limited number of 
sources to obtain information about s patient’s health when making a diagnosis. Medical 
providers would gain data from a visual inspection of the patient, measurements from a 
limited number of medical tests, and qualitative information from the patient’s 
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perspective regarding ailment and treatment response. The scope and sensitivity of 
measurement tools available to medical professionals continue to improve as technology 
continues to advance. As a result, practicing medical professionals now have more “data” 
at their fingertips than medical professionals had fifty years ago. In order to optimize 
patient care, doctors are in need of improved methods of analyzing data and advisement 
on how best to integrate the results into the decision making cycle. Quality engineers 
have both the technical acumen and comfort of operating in uncertainty to provide 
support to the medical community as it moves forward. Another reason for the lack of 
involvement of quality engineers within the medical domain could also be due the nature 
of the problem. In manufacturing endeavors, engineers seek to improve the output of a 
process. The variability between products is limited and the changes to the assembly line 
are assumed to impact items on the line in similar fashion. Unlike manufacturing, the 
product examined in the medical system, an individual’s health, is measurable in a vast 
number of ways. In addition, the target value for a measured characteristic cannot be 
precisely determined. Instead, healthcare providers have utilized a range of values to 
assess an individual’s health. The turn to precision medicine could reduce the measured 
differences between individuals as smaller subgroups are identified. The advancements to 
reducing variability in treatment response based on newly-measured characteristics could 
be as impactful as the improvement to transplant success once blood type differences are 
recognized. 
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1.2 Research Outline and Objectives 
This dissertation explores how best to use quality engineering tools within the 
healthcare domain. Three separate, viable pathways for pursuing improvements in 
healthcare are examined with an eye toward evaluating patient risk. To start, chapter 2 
summarizes literature published within the past five years which used machine learning 
for research on T2DM. The two most important outcomes are a consolidated list of the 
research goals and a summary of research limitations from the point of view the 
researchers. Next, in chapter 3, a new method for risk quantification using an adaptation 
of quality loss functions is described. Whereas quality loss functions were developed for 
point targets, a new performance loss function could be used for risk assessment when 
measure characteristics are evaluated within a target range. Performance functions would 
allow medical professionals to assess the potential impact of a treatment on a patient 
across multiple characteristics of interest. The last chapter explores the impact of 
incorrect assumptions during parameter estimation on optimization outcomes. In total, the 
dissertation provides insights into the potential impact and the challenges of medical 
research. Each of the chapters is summarized in more detail in the following paragraphs.  
Chapter 2 is a systematic review of the use of machine learning efforts that 
support the advancement of precision medicine for a selected disease. This chapter 
outlines a basic methodology for assessing the state of medical research for an analytic 
tool as applied on a specific disease. Type 2 diabetes mellitus (T2DM) was selected as a 
focus area because of its high prevalence within the population. As of 2017, an estimated 
9.4% of the United States’ adult population is afflicted with diabetes mellitus (DM), a 
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group of chronic diseases which affect insulin production within the human body (Center 
for Disease Control and Prevention, 2017). In the most recent published assessment of 
the financial impact of DM by the American Diabetes Association, the organization 
estimated that DM cost United States at least $245 billion annually (American Diabetes 
Association, 2013). The tally includes both the cost of medical treatment for DM and cost 
of lost workforce productivity. To mitigate the future impact of DM, researchers must 
develop more effective means of preventing the development of the disease in more 
patients and improve treatment methodologies to improve patient outcomes. To achieve 
those goals, researchers are exploring the potential of PM, an emerging approach to 
patient care that seeks to customize medical treatments based on measurable and 
identifiable characteristics. If the promise of PM is realized, the shift of medical care 
from the one-size-fits-all convention to optimized care for specified subgroups will 
improve medical outcomes. This literature review examines the use of machine learning 
to achieve PM aims for T2DM. The paper outlines major T2DM research areas, the most 
common algorithms utilized for research, and the measures of effectiveness used to 
assess their performance. This work also provides insights into the limitations that 
decrease the potential of the current research efforts.  
Chapter 3 lays out the motivation for continued research at the convergence of 
healthcare and quality engineering. It examines the state of healthcare, the needs which 
have motivated new research, and past efforts of quality engineers to influence medical 
research. At the end of the chapter, areas for potential research are identified. 
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In Chapter 4 the potential of robust design is examined when it is paired with 
conditions based selection of regression estimators. At the start of the chapter, alternative 
methods of estimating parameters when the underlying distribution is unknown are 
compared and contrasted. If the researcher’s assumptions regarding the underlying 
distribution are correct, results found using optimization models developed using the 
estimated parameter will not be impacted. However, if the researcher’s assumptions 
regarding the parameter are proven incorrect, the results of optimization efforts using the 
parameters will be impacted. This chapter explores the potential impact of inaccurate 
assumptions made during parameter development phase of research. For illustrative 
purposes, the hypothetical research team assumes that the underlying distribution is 
normal when, in actuality, the underlying distribution is skew normal. This chapter also 
provides insight into the impact of incorrect assumptions during made during early 
phases of research on final recommendations. The analysis is particularly important for 
parameter estimation supporting medical applications since researchers may not know the 
underlying distribution. While medical researchers work to better describe physical 
phenomena, a parallel effort within the engineering community should focus on the 
development of improved methodologies for parameter estimation when the distribution 
may be non-normal. 
Each chapter practically describes how quality engineers could apply their skills 
to support the development of precision medicine. Chapter 2 explores how machine 
learning is being applied to bridge identified research gaps for one prevalent disease. The 
three most important products from this chapter are a list of research needs, an 
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assessment of the types of quality characteristics being used to gauge health, and 
assessment of the limitations of current research due to limited data availability. Chapter 
3 illustrates how informed adaptation of current QE methodologies could improve the 
assessment of patient risk when undergoing treatment with known, measurable side 
effects. Chapter 4 critically considers the impact of incorrect assumptions early in the 
analysis. The dissertation provides a foundation from which other quality engineers will 
be able to craft innovative research efforts for the continued development of tools needed 
for PM.  
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CHAPTER TWO 
TYPE 2 DIABETES MELLITUS: OBTAINMENT OF THE PROMISE OF 
PRECISION MEDICINE WITH MACHINE LEARNING METHODS 
 
2.1 Precision Medicine Applied to Diabetes Mellitus 
 
The term diabetes mellitus (DM) refers to a group of chronic diseases 
distinguished by hyperglycemia, abnormally high blood glucose. The rise of glucose 
within an individual’s blood stream can be either attributed to the insufficient production 
of insulin within the body, a physical resistance to insulin, or a combination thereof 
(American Diabetes Association, 2017). The increased blood sugar negatively affects the 
function of important organs to include the heart, eyes, vessels and kidneys among others 
(Pippitt & Li, 2016). 
The importance of the disease may be attributed to the prevalence of the disease 
worldwide and the resultant costs. From 1980 to 2014, the number of individuals with 
DM has risen from approximately 108 to 422 million (World Health Organization, 2016). 
As of 2017, 7.2% of the United States’ adult population was diagnosed with DM (Centers 
for Disease Control and Prevention, 2018). An additional estimated 7.2 million adults 
have the disease, but have not been diagnosed. In 2012, the American Diabetes 
Association funded research to quantify the total cost of DM for the United States. The 
final report estimated that within the United States over $176 billion was annually spent 
for direct medical costs of DM and another $69 billion was lost due to decreased 
productivity (American Diabetes Association, 2013). The DM related medical costs to 
the individual is estimated to be significant as well. The average annual medical 
expenditure for a patient diagnosed with diabetes in 2012 was on average $13,700 with 
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$7,900 of that cost directly relating to diabetes. Past research efforts have shown that 
early diagnosis and proper management of the disease can improve an individual’s health 
and reduce risk for further complications. 
Current medical research continues to focus on early diagnosis and treatment of 
DM. Within the field of medicine, one particular area, PM has shown promise for 
advancements in patient treatment. PM focuses on finding the best treatment for a patient 
based on the individual’s characteristics which may include “genetic, biomarker, 
phenotypic, or psychosocial traits” (Jameson & Longo, 2015). The success of PM hinges 
on the ability to classify individuals into groups of susceptibility and treatability for a 
particular disease or a combination of diseases using measurable characteristics. Two 
challenges to PM include resolving competing healthcare system stakeholder interests 
and the challenge of dealing with a vast, continuously growing, and complex data set 
(Jameson & Longo, 2015). The first challenge will require changes to government policy 
to realign stakeholder interests into a more mutually beneficial system. To overcome the 
second challenge, efficiently and quickly, the involvement of other parts of the scientific 
community will be required. This challenge involves wrestling large medical data 
repositories in an attempt to find new medical knowledge through the identification of 
subpopulations and unpredicted responses to treatment plans. As such, the size of the data 
and the complexity of the problem should make working on medical problems a desirable 
application area. The complexity of medical care provides an interesting area for 
application of other skill sets. Hence, the classification of a disease within a patient will 
depend on more exact definitions requiring adjustment to decision algorithms.  
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Machine learning (ML) is a branch of artificial intelligence that gives machines 
the ability to learn and automate analytical models for classification and predictions with 
big data. PM research efforts focused on DM are making significant progress in 
identifying the portion of the population most at risk for developing DM and in 
improving treatment methodologies. This chapter seeks to document the state of current 
ML research efforts using published literature. It will outline the general research goals 
for type 2 diabetes mellitus (T2DM), the types of approaches, sources for data, and 
limitations of recent work. It is the hope of the author that this work will provide a 
foundation for future research efforts involving T2DM and ML, the study of algorithms 
to uncover insights within a dataset and to develop models for prediction. 
In the following sections, an overview of DM and basics of ML will be discussed. 
Section 2.1.1 provides a brief overview of the disease and outlines the reasons for 
narrowing the scope of this research effort on T2DM, a single variant. Section 2.1.2 
examines the broad categories of ML and briefly discusses the most common types of 
ML algorithms. The section is concluded with research considerations when attempting 
to use ML. Section 2.2 provides a methodology for the literature review. Specifically this 
section covers the search criteria, inclusion and exclusion criteria. Section 2.3 
summarizes the results of this research effort. Section 2.4 provides a way ahead for 
T2DM research involving ML and suggestions for how to improve medical data 
repositories. 
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2.1.1 Diabetes Mellitus Overview 
As stated earlier, the disease DM is caused by malfunctions affecting the amount 
of insulin within the human body. Insulin is a hormone produced by beta cells in the 
pancreas. The hormone regulates the amount of glucose within the blood stream. Too 
little insulin within the body results in high levels of glucose which is known as 
hyperglycemia. The impact of DM on the patient’s health is affected by a variety of 
factors including the severity of type of DM, the speed with which DM is diagnosed and 
treated after initial onset, the effectiveness of the treatment protocol, and the patient’s 
adherence to the prescribed treatment protocol. If a glucose level with the patient’s blood 
stream remains above the recommended threshold for an extended period of time, the 
patient is at greater risk for serious health complications to important organs. The disease 
is linked to damage to eyes, kidneys, nerves, and the heart. 
The most prevalent types of DM are defined by their etiopathogenesis and are 
referred to as type 1, type 2, and gestational diabetes. Classification is important since the 
disease progression for each variant of DM is different. Type 1 diabetes mellitus (T1DM) 
occurs when the immune system produces antibodies which attack beta cells in the 
pancreas. The presence of antibodies within the blood stream is an indicator of T1DM 
(American Diabetes Association, 2017). The disease progression for T1DM depends on 
the how early antibodies are detected and the number of antibodies detected. Once a 
patient has type 1 diabetes, the patient requires treatment with exogenous insulin to 
facilitate metabolic survival (Atkinson, 2014). T1DM affects approximately five percent 
of the population diagnosed with DM (Centers for Disease Control and Prevention, 
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2017). In comparison, T2DM occurs when either the body does not produce enough 
insulin or the body is resistant to the effects of insulin. This variant of DM accounts for 
approximately 90-95% of the DM cases (Centers for Disease Control and Prevention, 
2017). The disease most often appears in individuals once they reach adulthood with only 
132,000 people under the age of 18 in the United States diagnosed with any form of DM 
(American Diabetes Association, 2017). Like T1DM, this form of the disease creates an 
increase in glucose within the patient’s blood stream. Unlike T1DM, insulin is typically 
only required for disease management, but not necessarily survival. The third most 
common form of DM is referred to as gestational diabetes (GD). GD occurs during 
pregnancies and is considered a temporary condition. Most often, the clinical signs of 
gestational diabetes will disappear after the birth of a child. Some patients, however, do 
progress from diagnosis of GD to T2DM after the birth of a child. 
While the impact of all three forms of DM is significant, this chapter will focus 
specifically on T2DM because it affects a greater portion of the population. Of the 23.1 
million people in the United States diagnosed with DM, 90-95% of those patients have 
T2DM (Centers for Disease Control and Prevention, 2017). This form of the disease is 
considered progressive with symptoms becoming more intense over time. The initial 
onset of the disease is not always recognized by the patient because the short-term 
symptoms may not be distinguishable. T2DM symptoms may include increased thirst, 
weight loss, or increased need to urinate more frequently. The impact of the 
hyperglycemia, the presence excess glucose in the bloodstream, on the patient, may 
progressively get worse over time as either the individual’s resistance to insulin grows or 
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as the gap between the insulin needed by the body to regulate glucose and the amount of 
insulin produced increases. Long-term complications of having hyperglycemia may result 
in additional complications including blindness, loss of limbs due to poor blood flow, or 
kidney failure. However, unlike T1DM, T2DM may be partially preventable through 
behavior changes and the disease may go into remission given a reduced severity of the 
form of DM and patient response to treatment protocol. Accordingly, early detection of 
the disease and proper management is critical for the health of the patient. The continued 
investment in PM research for T2DM is made with the goal of improving detection of the 
disease and determining of the best treatment protocols for specific patient profiles. 
Given the prevalence of the disease, the medical community has collected a vast 
amount of data concerning T2DM. As stated earlier, one of the primarily challenges of 
PM is how to effectively use the data to develop insights that illuminate patient 
characteristics which best align with increased incidence of the disease. Within recent 
literature, one prevalent method for investigating T2DM has been the use of ML. The 
following section provides a brief overview of the topic. 
2.1.2 Machine Learning: The Basics 
The field of ML exists at the intersection of computer science and data science. 
ML was built on the premise that computer systems have the ability to improve the 
specified task completion without the necessity of successive improvements to the initial 
implementation being programmed by the user. Computer systems use algorithms to 
develop knowledge about a dataset. Feedback on performance enables the computer to 
make adjustments to calculated predictions or decision recommendations. The increased 
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computational power realized over the past thirty years has added increased capability to 
the field. As a result, feedback on performance enables the computer to make adjustments 
to calculated predictions or decision recommendations. 
Today ML is used to develop a greater understanding in research areas with a vast 
amount of data. The tool also helps researchers identify patterns within the dataset that 
are not obvious. In fact, ML has been applied to a broad spectrum of areas. It has been 
used for identification, speech recognition, and statistical arbitrage (Pazzani et al, 
1998)(Graves et al., 2013)(Galindo & Aamayo, 2000) . ML also provides a means of 
quickly detecting oil spills from radar images of the ocean’s surface (Kubat et al, 1998). 
Moreover, ML has helped to close the gap between automatic speech recognition systems 
in comparison to human performance (Deng & Li, 2013). In addition, ML has also been 
heavily relied upon to develop quantitative training strategies for financial assets to 
include hedge funds, the field referred to as statistical arbitrage (Krauss et al, 2017). The 
investment strategy looks for patterns within financial data streams to identify patterns 
for exploitation. The field of ML is growing quickly due to high interest from both the 
government and industrial sectors. In 2016, McKinsey Global Institute estimated that 
machine learning received between $5 and $7 billion dollars in investment funding 
(Bughin et al, 2017). 
The term “machine learning” encompasses a broad field of work which uses 
multiple techniques for a wide range of applications. Within the field, learning is 
classified as one of three major tasks: supervised, unsupervised, or reinforcement. A 
supervised learning task infers a relationship between inputs and outputs. Algorithms 
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classified as “supervised” require feedback during the training stage. The training dataset 
includes both the input data and associated outputs, also termed “supervisory data.” The 
algorithm uses the training data to develop an inferred function that relates inputs to 
outputs. Once a base model is formed, the model is tested using a validation dataset, a 
portion of the training dataset held in reserve. Performance is then judged on the ability 
of the algorithm to correctly link inputs to outputs. The parameters of the model are then 
adjusted to improve the accuracy of the model, and the model is used for prediction or 
classification purposes. Common metrics used to compare supervised ML performance 
between algorithms are accuracy, sensitivity, and specificity. Robust functions will have 
the capability of correctly analyzing samples that were not specifically included within 
the training data set. Unlike supervised ML, unsupervised learning algorithms only use 
input data to develop knowledge about the data set. The algorithms deduce relationships 
between the predictor variables. Since this type of learning does not have known 
outcomes, there is no means of evaluating the accuracy of the final model. The third type, 
reinforcement learning examines the trade space between exploration and exploitation. 
When discussing ML, the three most important aspects are the purpose of the 
algorithm, the type of learning, and the data set used to train the algorithm. Typically 
supervised ML algorithms are used to perform two types of tasks: classification or 
prediction. For classification, a model is developed that assigns inputs into the system 
into a predefined class in the system. For diabetes research, classification algorithms can 
be used to determine if a patient is at risk for developing diabetes. Whereas classification 
algorithms are used to predict the correct group, regression modeling is used to 
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strengthen the ability of predictive analytics. For diabetic research, machine learning can 
be helpful in determining the proper dosage of insulin for patients based on individual 
characteristics. In this way, ML has the potential to provide power to the application of 
PM within healthcare. This tool has proven effective for the use of both continuous, 
discrete, and mixed data sets. 
2.1.2.1 Supervised Learning Algorithms 
There are a wide variety of algorithms in use today within the field of ML. It is 
commonly acknowledged that there is no single algorithm that works better across the 
wide variety of supervised learning problems. This type of ML is used for both 
classification and regression purposes. For classification methods, the output value is a 
category. One example of classification for T2DM research is that based on input data a 
patient could either be classified as either having diabetic retinopathy or not having 
diabetic retinopathy. For the purposes of regression, however, the output value from the 
model would be a real number. If considering the application within PM, this type of 
model could be used to determine the optimal dose of insulin for a patient. When 
applying supervised ML techniques, researchers must be aware of two typical issues that 
commonly occur. First, the researcher finds a balance between over-fitting and under-
fitting the data. This is often referred to as the bias-variance trade-off. Under-fitting 
occurs when bias exists causing the algorithm to not identify a relationship between the 
independent variables and their associated dependent variables. Contrarily, over-fitting 
occurs when the developed model fits the training data too closely. When the model is 
subsequently used with other data, these exists high sensitivity to small changes in the 
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input variables. Analysis of the bias-variance may be captured in a discussion of the 
algorithm’s expected generalization error. Secondly, the final outcome is dependent on 
the quality of the training dataset used to develop the ML algorithm. The algorithm is 
used to develop a function to be used for predictions or classification by relating known 
input and output values. Training datasets that are too small may not provide enough 
instances for which the resultant model may not be robust to a variety of input 
combinations. If the training dataset has a large number of input variables, the chosen ML 
methodology must be able to effectively judge which features are critical to optimal 
model development. In addition, the dataset may have missing entries, infeasible values 
or outliers. Researchers must determine how to best process the data to ensure that it is 
adequate for the intended purpose. 
For supervised learning, the comprehensive analysis of a dataset is extremely 
important in the development of the inferred solution because the training dataset 
connects the input data to output values. The supervised learning process is iterative. 
After the algorithm develops a solution based on the training input, the algorithm learns 
by comparing its generated output, the prediction for a given set of input values, against 
the true output value. The algorithm is “correct” if the function’s output matches the 
training set output. Training stops when the algorithm reaches an acceptable level of 
performance based on output values. The algorithm’s performance is then validated with 
the portion of the available data held in reserve. Development of a training methodology 
for model development and development of a validation strategy to assess model 
performance are critical steps in supervised learning. Probably the most important factor 
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to take into consideration when conducting supervised learning is the size of the training 
dataset. If the set is large, the researcher may choose to just divide the available data into 
two subsections: a training dataset and a validation dataset. The parameters for the model 
will be developed using the training set and the model will then be verified with the 
validation dataset. While an established standard for the division of the dataset does not 
exist, common convention dictates that the data be divided proportionally 2/3 to 1/3 
(training to validation). The other method, known as cross-validation, divides the dataset 
into mutually exclusive sections of equal size. Iteratively, one of the sections will be held 
for testing performance of the algorithm trained by the other subsets. The final model will 
be formed by combining the results of each iterations. The following paragraphs provide 
a brief overview of the most prevalent ML algorithms. 
a. Naive Bayes Algorithm 
The naïve Bayes (NB) algorithm uses training data to develop frequencies for 
each possible outcome which provides the class prior probability (Rish, 2001). The 
algorithm can then determine the posterior probability for each of the possible outcomes. 
The outcome with the highest posterior probability then becomes the prediction. NB 
needs less training data in comparison to other types of algorithms. Three considerations 
when utilizing the NB algorithm are the necessity for independence of predictors, the 
reliance on all outcomes being observed in the training data, and the known performance 
of NB in producing estimators. If a variable is not observed in the training dataset, the 
probability for that outcome will be zero and the ability to make a prediction is 
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eliminated. The algorithm has proven to be valuable for both real time predictions and for 
instances where there are multiple classes. 
b. Decision Tree Algorithm 
The decision tree (DT) algorithm is one of the most prevalent ML algorithms and 
as such it has been extensively studied in literature. DT is non-parametric, simple to use, 
and can effectively be implemented with large datasets. The algorithm has been put to 
use for purposes of classification and regression. A decision tree is sequentially formed 
by segmenting the dataset into smaller groups based on the values of successive features 
of the data. The end result is a hierarchy of features with each node representing where in 
the decision process a specific features affects the final process outcome. The branches 
departing a node represents the split of the dataset based on the outcome of the test. 
The use of DT algorithms is not constrained by the data type as it can be used 
with categorical and continuous variables. The methodology of how to split the data is 
dependent on the associated probability of a set outcome. For regression decision trees, 
sum squared error for the training samples is used to select the order of the predictor 
variables within the tree. For classification trees, the Gini function is used to determine 
the best choice of splits. It is a measure of difference between values of a frequency 
distribution. 
Implementation considerations when using this type of algorithm are the size of 
the final tree (number of nodes) and the level of accuracy expected from the algorithm. If 
too few nodes are included in the model, the accuracy of the model decreases. If too 
many nodes are included, the model’s accuracy is higher, but the researchers run the risk 
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overfitting the dataset. Two possible methods for coping with the risk of overfitting are 
either artificially limiting the number of levels within the tree or pruning the tree once the 
algorithm has been run. While there are many alternative methods for how to best 
determine the split attribute, three highly effective methods include the greedy, gain ratio, 
or the distance-based measure. Finally, another option is to use the gain ratio which 
considers how broadly and uniformly the features splits the data. One drawback of using 
this algorithm is that DTs can have problems with high variance or increased bias. 
c. Support Vector Machines 
Support Vector Machines (SVM) are supervised learning models that examine 
data for classification or regression. SVM adds a dimension to the dataset as a way to 
make classes linearly separable (for linear applications). Simply put, a class is a subset of 
data identified by a common feature, or input variable. Given a classification context, 
SVM inserts a hyperplane between two classes. The selection of the best hyperplane to 
divide the dataset into classes is the difficult part of this method. In theory, the 
hyperplane is able to separate the two classes without error and the greatest margin. 
However, an error often occurs when a member of one class appears on the same side of 
the hyperplane as the second class. The margin is the distance between the closest point 
of each class and the hyperplane. When the data is non-linear, the SVM uses a kernel to 
convert a low dimensional feature space to a higher dimensional feature space, 
transforming the data, and enabling separation of classes by a hyperplane. In addition, 
SVM is known for being robust for outliers. 
d. k-Nearest Neighbors Algorithm 
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The k-nearest neighbors (k-NN) algorithm is a non-parametric method used for 
classification and regression. The value or class of a point of interest is approximated 
“locally” within a defined feature space. The feature space is comprised of a set number 
of training points, denoted by k, closest to the point being examined that will be used to 
classify the test point. Small values of k can create many small regions which could lead 
to non-smoot decision boundaries or overfitting of the data. However, large values of k 
will leave larger regions and possible under-fitting of the data. For use in classification, 
the k-NN input is the k training examples that are closest to the point of interest and the 
output is a class membership. The class of the point of interest is determined using a 
similarity measure. The similarity measure for continuous variables is the distance 
between the test point and the point of interest. The similarity measure for categorical 
variables is the Hamming distance. If there is a mix of variable types, one solution is to 
use standardized distance on the same training set. For use in regression, the output value 
is the average of the selected feature of the k closest points. One method to validate the 
choice of k is to use cross-validation. A variant of the k-NN algorithm is the use of 
weights to weigh the values of the surround k points based on the distance from the 
selected point. 
e. Random Forest Algorithm 
The random forest (RF) algorithm is a form of ensemble learning. It is used to 
rank the importance of variables for either regression or classification problems. Initially 
developed by Breiman and Cultler (2007), the algorithm incorporates the results of 
several runs of the DT algorithm, each constructed with a unique subset of the initial 
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dataset, into a single result in order to decrease variance, decrease bias, or improve 
predictive power. The RF algorithm produces a final tree which combines the most 
common nodes. For the construction of trees using the DT algorithm, the dataset is 
sampled with replacement. When choosing the attribute from which to create the node, 
only a small, random subset of the available attributes is considered. Each tree within the 
forest is restricted to a subset of characteristics, thus reducing the dimensionality of the 
problem. This method is considered an improvement over decision trees because it 
reduces the tendency for overfitting that is often seen with decision trees. RF is 
considered robust to inclusion of irrelevant features and it is known to be capable of 
classifying a large quantity of data accurately. 
Researchers typically find a balance between the performance, processing time 
and memory. The number of trees is related to the number of variables. The greater the 
number of variables, the greater the number of trees that may be developed for the 
dataset. However, it has been noted that increasing the number of trees does not 
necessarily improve performance. Research by Amit and German (1997) illustrated that 
the accuracy of RF algorithms is dependent on the individuals trees and the dependence 
between the trees. One advantage of using RF is that the method is capable of 
maintaining accuracy even with missing data. Common variants to this method include 
kernel RF, centered RF, and uniform RF. 
f. Artificial Neural Network Algorithms 
Artificial neural network (ANN) algorithms can be constructed for both 
supervised and unsupervised learning. The concept behind the algorithm was to create a 
 27 
learning process modeled after the human brain. For example, if an artificial neural 
network is used to classify patients as diabetic using electronic health records, it develops 
its own set of relevant characteristics from iterations with the training dataset. This 
algorithm is best defined as a combination of optimization theory and statistical 
optimization. It seeks to find the best model from the set of models that minimizes the 
cost to traverse the network. 
2.1.2.2 Unsupervised Learning Algorithms 
Unsupervised learning assumes that there is a hidden structure within the data. As 
opposed to supervised learning in which input data is paired with supervisory data, 
unsupervised learning depends only on the input data. The goal of unsupervised learning 
is to learn more about the dataset. It is primarily used for clustering and association 
efforts. The method of clustering looks to discover groupings within the data. The 
method of association attempts to determine a rule (or rules) that can be used to describe 
a large portion of the data. 
a. K-means 
The k-means clustering (k-means) algorithm, or Lloyd’s algorithm, divides the 
data space into k cells. To initialize the algorithm, k initial “means” are chosen. Once 
initialized, k-means consists of two iterative steps. In the assignment step, each point is 
assigned the cell that has the least squared Euclidean distance between the point and the 
mean. Once all the points have been assigned, the new means, called centroids, are 
updated. The observations are then sorted again and placed in the cell with the closest 
mean. The algorithm stops when observations are no longer being assigned to new cells. 
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b. Apriori Algorithm 
The apriori algorithm is an example of association rule learning. It is used to find 
frequent “item sets.” Since it was initially developed for datasets that contain a large 
number of transactions, it has been used within the field of healthcare for the detection of 
adverse drug reactions by creating association rules for the combinations of drugs on a 
specific subpopulation of patients (Harpaz et al., 2010). 
2.1.2.3 Reinforcement Learning Algorithms 
Reinforcement learning makes use of a small labeled dataset which includes 
supervisory data, and a larger unlabeled dataset with only input variables. This type of 
learning is based on the concept that the use of unlabeled data after training with labeled 
data can still provide incremental improvement in the results. This learning method is 
particularly valuable when the cost of labeling datasets makes labeling a full dataset 
prohibitive. This would be true in the development of algorithms to help review images 
for significant features or automatic image processing. Given a large number of images 
available, it would be costly to have a subject matter expert on the images review all 
available images. Instead, it is more likely that the subject matter expert would review a 
smaller sample of images examples to provide appropriate labels.  
This section included summaries of common algorithms used for supervised, 
unsupervised, and reinforcement ML. As the field is still developing, the total number 
will continue to grow through both the addition of completely new algorithms and 
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development of variants of existing methods. Table 2.2, below, summarizes both the 
methods, available algorithms, and the purposes for which they are typically utilized. If 
an algorithm has been used for more than one type of learning, it was entered in the 
section for which its use is most prevalent. 
Table 2.1. Common Machine Learning Algorithms 
 
 
Machine 
Learning  
Supervised Learning Unsupervised Learning Reinforcement Learning 
Learning 
Purpose 
Classification Regression Clustering Association Prediction Control 
Type 
▪ Logistic 
Regression 
(LR) 
▪ Linear 
Regression 
(LR) 
▪ Hidden 
Markov 
Models 
(HMN) 
▪ DCA 
▪ 
Temporal 
Difference 
▪ Criterion 
of 
Optimality 
▪ Support 
Vector 
Machines 
(SVM) 
▪ Non-linear 
Regression 
(NLR) 
▪ Neural 
Networks 
(NN) 
▪ Single 
Value 
Decompositi
on (SVD) 
▪ Tabular 
Temporal 
Difference  
▪ Brute 
Force 
▪ Discriminant 
Analysis (DA) 
▪ Ensemble 
Learning 
▪Gaussian 
Mixture 
▪ K-Means 
 
▪ Value 
Function 
▪ Naïve Bayes 
(NB) 
▪ Neural 
Networks 
(NN) 
▪ Principal 
Component 
Analysis 
(PCA) 
▪ Apriori 
 
▪Direct 
Policy 
Search 
▪ Nearest 
Neighbors 
(kNN) 
▪ Nonlinear 
regression  
▪ Single 
Value 
Decom 
-position 
(SVD) 
  
 
  
▪ Decision 
Trees (DT) 
▪ Decision 
Trees (DT) 
▪ 
Hierarchical 
  
 
  
    
▪ Self-
organizing 
maps 
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2.1.3 Open Software for Machine Learning 
There is a wide variety of open source software platforms readily available to 
assist researchers harness the power of machine learning algorithms. Open source 
software is accessible to the general public for use as is or maybe adapted for greater 
performance or a different application. Typically developed in a group, the software is 
free which makes the software attractive to individuals or teams without extensive 
financial assistance. 
With the growth of open source ML platforms readily available and the decision 
on which software to utilize becomes harder. Considerations should include the 
availability of a specific algorithm within a library or framework and the researchers 
comfort with coding in general or a specific program. Table 2.2 contains a brief list of 
popular ML libraries and their associated platforms or frameworks. A library contains a 
set of objects for a particular use. A framework, on the other hand, is a collection of 
libraries designed to support a methodology. Software is defined as containing support 
programs, the existence of a code library, and reliance on a scripting language. 
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Table 2.2. Available open Source Machine Learning Software 
 
ML Library Language Description Creator Established 
Accord.NET C# .NET ML framework with audio and 
image processing libraries (.NET, 2018) 
Cesar 
Souza 
2009 
Amazon ML   Guided platform built on proven, 
scalable ML technology which serves 
the parent company (free only with 
AWS) (AWS 2018) 
Amazon 2015 
Apache 
Mahout 
 Java, 
Scala 
Project which produces free 
implementations of ML algorithms for 
filtering, clustering, and classification 
(Mahout, 2017) 
Apache 
Software 
System 
2014 
Apache Singa  C++, 
Python,  
Java 
Flexible architecture for distributed 
training (Apache Incubator, n.d.) 
DB 
Systems 
Group 
2015 
H20  Java, 
Python, 
R 
Open-source ML Platform focused on 
enterprise service (H2O.ai, 2018) 
H2O.ai 2011 
Oryx 2  Java, 
Scala, 
Apache 
Hadoop 
Real-time large scale ML; packages for 
filtering, classification, regression, and 
clustering (Onyx 2, n.d.) 
 2014 
Scikit-learn, 
TensorFlow, 
Theno* 
Python 3 “most popular” ML libraries for use 
within python (Raschka, 2015) 
Various  2016 
Caret, 
randomForest, 
rpart* 
 R Open source platform for statistical 
programming and applied ML (R Core 
Team, 2012) 
University 
of 
Auckland 
1993 
Shogun C++, 
Java, 
Python, 
C#, 
Ruby, R, 
Lua, 
Octave, 
Matlab 
Open source ML library with range of 
ML methods (Shogun, n.d.) 
Soeren 
Sonnenburg 
and Gunnar 
Raetsch 
1999 
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2.2 Overview of Survey Methodology 
This paper is the synthesis of a formal, systematic literature review of published 
research concerning machine learning and diabetes mellitus within the past several years. 
The basis for the research was a protocol developed to explore the breadth and depth of 
current research on T2DM using the techniques of machine learning. The protocol is 
explained in detail in the following sub-sections. 
2.2.1 Research Focus 
In order to understand the focus and research completed on T2DM using machine 
learning techniques, this work investigates the following research questions. 
Question 1: What are the major T2DM research areas that are being 
actively pursued by the scientific community? 
Question 2: What ML techniques are commonly being implemented? 
Question 3: How is the effectiveness of machine learning research being 
assessed? 
In the course of the literature review, it was noted that one of the greatest 
limitations on the research involved the data used as a foundation for the work. Therefore 
one additional research question was added which focused on the suitability of current 
data and the limitations on researchers and results due to datasets. 
Question 4: What limitations exist that hamper the productivity of the 
current research efforts? 
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2.2.2 Repository Search Strategy 
The purpose of this research effort was to explore the current research for the T2DM 
using ML technology. The search was limited to articles as part of the PubMed database. 
This online archive contains 28 million citations for biomedical literature from a variety 
of sources to include MEDLNE, journals, and books (National Center for Biotechnology 
Information, n.d.). The strategy used to identify search terms for an automated search 
within PubMed consisted of identifying major search terms from the research questions, 
identifying alternative spellings and synonyms for major terms, and then determining the 
best search phase to use within the selected database. 
During a preliminary literature investigation, the author noted that T2DM is 
annotated with a variety of alternative phrases in published literature to include type II 
diabetes, type II diabetes mellitus, type 2 diabetes, type 2 diabetes mellitus, T2, and DM 
type 2. The inconsistent use of a reference term had the potential to remove relevant 
articles for a key search. The final search string selected for used in PubMed for this 
literature review was: 
“machine learning” AND (“diabetes” AND (“type II” OR “type 2” OR 
“T2DM” OR “T2” OR “T2D” OR “DM2”)) 
This search string resulted with 76 citations for review. Figure 2.1 provides an 
overview of the research methodology utilized for this paper. An initial search utilizing 
the aforementioned string was conducted to create the initial literature repository. 
Inclusion criteria were applied against abstracts of papers included in the initial 
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repository to form the base repository. The full papers were then examined with 
exclusion criteria to form the refined repository. The refined repository contained all 
relevant articles to the literature review. 
 
Figure 2.1. Research Methodology for Literature Review 
2.2.2.1 Search Documentation 
The title, author(s), journal title, year published, and title for the documents 
identified in PubMed using the chosen search string were stored in an Excel table 
designed as an initial repository for the remainder of the literature review. The list of 
articles was then evaluated using the inclusion criteria detailed in Section 2.2.2.2 against 
the information included in the published abstract. All papers that met this criteria were 
downloaded and the full papers were then reviewed using the exclusion criteria. Those 
papers were then examined for key pieces of information chosen for analysis using Table 
2.2. 
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Table 2.3. Literature Review Checklist 
 
Article Authors All authors listed on the publication 
Year Year published 
APA Reference APA reference  
Journal Title Journal Title 
Article Title Article Title 
Key Issue Concern or gap that prompted research 
Research Purpose Goal of research paper 
Model Dependent Variable Dependent variable for analysis 
Type of Learning Supervised, unsupervised, semi-supervised 
Machine Learning Purpose Various 
Machine Learning Algorithm(s) Various 
Dataset Methodology Traditional or Train/Validation 
Traditional Data Allocation Percentage for training/percentage for validation  or N/A 
Cross Validation Various 
Model Performance Metrics Various 
ML Software Software used for ML 
Country of Dataset Origin Various 
Dataset Name Various 
Data Time Frame Start Year - End Year 
Dataset Time (Years) Number of Years 
Data Issues Researcher recognized issues with data collection or format.    
Instances Number of subjects or cases included within the dataset.   
Instances Used in Model 
Development 
Number of subjects/cases used in analysis 
Instances (Dependent Variable) Number of subjects/cases used in analysis with T2DM 
# of Features Number of variables/features in the dataset 
# of Features used in Model 
Development 
Number of variables used in the modeling portion of the analysis 
# of Features in Model Number of variables included in the final model 
Types of features Types of variables/features included in the dataset 
Study Limitations Study limitations acknowledged by the author 
Benefits of Analysis Stated benefit of the analysis 
Recommendations for Future 
Work 
Recommendations for future work by the author 
Sources of Funding Various 
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2.2.2.2 Inclusion Criteria 
When reviewing abstracts, the author focused on the following considerations: 
Inclusion Criteria 1: Publications that describe research in which ML 
techniques are used to investigate a research 
question focused on the prevention, diagnosis, or 
management of T2DM. 
Inclusion Criteria 2: Documents published after 2012. 
2.2.2.3 Exclusion Criteria 
When reviewing published papers, the author focused on the following 
considerations: 
Exclusion Criteria 1: Identified article was published as a conference 
proceedings. 
Exclusion Criteria 2: Identified article was a literature review. 
Exclusion Criteria 3: Identified article was qualitative. 
Exclusion Criteria 4: Publications/reports for which only an abstract is 
available. 
Exclusion Criteria 5: Research that was not primarily focused on T2DM. 
Exclusion Criteria 6: Dataset must include data from human subjects 
Exclusion Criteria 7: Research methods did not include ML. 
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Exclusion Criteria 8: Method of medical diagnosis is not recognized by 
the American Medical Association 
2.3 Literature Survey Outcomes 
2.3.1 Summary of Articles Included 
This literature review limited the scope of the search of articles included within 
PubMed through March 22nd, 2018. Of the 76 documents included in the initial 
repository, only a total of 39 articles were included in the refined repository on which the 
rest of this paper is based. 36 articles were excluded from the refined repository, and 14 
articles were rejected for failure to meet the established inclusion criteria. Of these 
articles, 11 were published prior to 2013. Another 22 articles did not meet the exclusion 
criteria. The most prevalent reasons for exclusion of an article from the literature review 
was that the research did not focus of T2DM. 
Table 2.4. Impact Table of Inclusion and Exclusion Criteria 
 
Criteria Explanation 
Articles 
Impacted 
Inclusion 1 
Publications that describe research in which ML techniques 
are used to investigate a research question focused on the 
prevention, diagnosis, or management of T2DM. 
3 
Inclusion 2 Documents published after 2012. 11 
Exclusion 1 Identified article was published as a conference proceeding. 3 
Exclusion 2 Identified article was a literature review 0 
Exclusion 3 Identified article was purely qualitative. 1 
Exclusion 4 
Publications/reports for which only an abstract was available 
online. 
0 
Exclusion 5 Research not primarily focused on T2DM. 13 
Exclusion 6 Dataset must include data from human subjects. 3 
Exclusion 7 Research methods did not include ML. 1 
Exclusion 8 
Method of medical diagnosis not recognized by the American 
Medical Association. 
1 
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Figure 2.2 shows the growth within the research conducted over the given year 
period. In 2013, only four articles were published, but by 2017, 16 articles were 
published for the T2DM research using machine learning techniques. 
 
Figure 2.2. Annual Comparison of Published Articles on Type 2 Diabetes Mellitus and 
Machine Learning  
 
Of 39 published articles that met this review’s inclusion and exclusion criteria 
were published in 31 different journals. Table 2.4 lists all of the journals in which the 
papers were published. The journals with more than one paper published on the topic 
included Big Data, IEEE Journal of Biomedical and Health Informatics, Journal of 
Diabetes Science and Technology, and Medical Care. In looking at the authors, the 29 
papers had over 244 contributors. On average six authors were listed as contributors in 
each paper. What was surprising in looking at the authors was that only eight authors had 
published research papers on the intersection of T2DM and ML. Of those the highest 
number of published contributions within that window was three. Only two authors had 
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successive publications which were published in the same journal that was IEEE Journal 
of Biomedical and Health Informatics. 
Table 2.5. Summary of Journals with Publications on Type 2 Diabetes Mellitus and 
Machine Learning Between 2012 and 2018 
 
Journal Number of Articles 
Artificial Intelligence in Medicine 1 
Big Data 2 
BMC Nephrology 1 
BMJ Open 1 
Briefings in Bioinformatics 1 
Computational Biology and Chemistry 1 
Diabetes 1 
Diabetes Care 1 
Diabetes, Obesity and Metabolism 1 
Diabetologia 1 
Diabetology & Metabolic Syndrome 1 
Health Informatics Journal 1 
Health Informatics Research 1 
IEEE Journal of Biomedical and Health Informatics 3 
IEEE Transactions on Biomedical Engineering 1 
Information Sciences 1 
International Journal of Biostatistics 1 
International Journal of Medical Informatics 1 
Journal of American Medical Informatics Association  1 
Journal of Biomedical Informatics 1 
Journal of Clinical Epidemiology 1 
Journal of Diabetes Science and Technology 5 
Journal of Translational Medicine 1 
Medical Care 2 
Medical Decision Making: An International Journal of 
the Society for Medical Decision Making 
1 
Medical Physics 1 
NPJ Genomic Medicine 1 
Plos One 1 
Sao Paulo Medical Journal 1 
The Lancet: Diabetes & Endocrinology 1 
Translational Psychiatry 1 
Total 39 
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2.3.2 Major Topics Covered 
A key component of this research effort was determining areas of interest for 
medical research and narrowing down the most frequently used analytic approaches to 
tackle those issues. Before delving into the articles themselves, a simple keyword 
analysis was performed. While eight articles chose not to list key words, the other 31 
articles cited 112 key terms. After removing repeated and similar terms, the words were 
placed into one of two primary categories consisting of healthcare or analytics. Once 
placed into the categories, the words were again sorted by general topic areas. For 
healthcare, the important topics, outlined in Table 2.5, covered medical measurements, 
medical concerns, healthcare systems, and T2DM related issues. Determining the correct 
features in which to measure physical health and disease progression is a challenging and 
complex issue. First and foremost, choosing the best measurements comes from 
understanding the disease at the heart of the study. The medical measurement terms 
included within this bin were either general terms (phenotype and genotype) which 
indicated whether the research was focused on physical or genetic characteristics or was a 
unique or non-traditional indicator of T2DM. 
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Table 2.6. Healthcare words cited in published literature focused on Type 2 Diabetes 
Mellitus and Machine Learning  
 
Medical Measurements Medical Concerns Healthcare T2DM Related Issues 
anthropometric 
measurements 
disease progression healthcare diabetes mellitus type 2 
anthropometry early disease prediction high throughput diabetic kidney disease 
arterial markers high throughput primary care diabetic retinopathy 
biomarkers medication adherence privacy disease complex 
body mass index missing heritability 
 
disease progression 
continuous glucose 
monitoring 
noisy labels 
 
glycemic variability  
fats noninvasive treatment 
 
healthcare 
genotype patient centered medicine 
 
hypoglycemia prediction 
glomerular filtration rate patient similarity 
 
impaired glucose tolerance 
glycemic control population screening 
 
kidney failure 
glycemic variability privacy 
 
metabolic syndrome 
hypertriglyceridemic waist 
phenotype 
risk assessment 
 
microvascular complications 
optical coherence 
tomography 
risk classification 
 
pre-diabetic state 
phenotyping risk predictions 
 
renal insufficiency 
photoplethysmorgaphy screening  
  
prognostic tool 
   
protein 
   
protein-protein interaction 
   
serum creatinine 
   
SNPs 
  
  
triglycerides 
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Table 2.7. Analytic key words cited in published literature focused on Type 2 Diabetes 
Mellitus and Machine Learning  
 
Analytical Purpose Available Tools Machine Learning Methods of Analysis Analytical Concerns 
risk assessment big data analytics 
artificial neural 
networks 
big data analytics positive predictive value 
evidence based medicine cohort study boosting 
comparative 
effectiveness research 
selection bias 
medical informatics 
comparative 
effectiveness research 
classification 
contextual anomaly 
detection 
sensitivity 
predictive analytics data mining 
classification and 
regression tree 
data mining size constraints 
predictive models database research ensemble learning  interaction network 
time dependent 
confounding 
predictive models electronic health records FDSP 
inverse probability 
weighting  
predictor feature engineering feature learning 
joint image-region-map 
model  
propensity score machine learning Gini importance Kallikrein-Kinin system 
 
risk classification medical informatics predictive models 
marginal structural 
model  
risk predictions  modeling random forest 
Markov-Gibbs random 
field  
 
regulatory feature data 
random forest feature 
contribution method 
metric learning 
 
  
Semi-supervised 
clustering 
mixture of generalized 
linear effects  
  
super learning multivariate model 
 
  
supervised decision 
techniques 
non-negativity-
constrained 
autoendcoder 
 
  
supervised machine 
learning 
prediction 
 
  
support vector machine predictive models 
 
  
survival tree signal processing 
 
   
statistical learning 
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2.3.1.3 Insights on Current Type 2 Diabetes Mellitus Research 
The articles in this literature review focused on finding solutions on gaps between 
today’s medical capabilities and identified medical needs in the diagnosis and treatment 
of T2DM. As part of the introduction for published articles, the authors outlined the 
purpose of the research. Each cited a critical gap, explained implications of leaving this 
aspect of medical care at the status quo, and then proceeded to explain their research 
methodology. For the most part, the issues addressed by the researchers are not unique to 
T2DM, but if the gaps could be bridged for patients with T2DM the payoff would be 
more impactful due to the prevalence of the disease. While the solutions proposed by the 
researchers are important, the documentation of the gaps themselves provides valuable 
insight into the research areas that are seen significant enough to attract funding support, 
areas and for which current technological capabilities may potentially be able to solve. As 
a majority of the research was funded, the gaps identified were seen as significant to 
wider audiences than just the authors. The gaps generally fell into three categories. 
The first gap category included papers that looked at potential applications or uses 
for new medical knowledge. For example, Acciaroli et al. (2018) focused their research 
on how to best use glycemic variability indices to classify patients. An individual’s 
glucose levels fluctuate throughout the day based off food consumption and exercise. The 
glucose level increases after meals and decreases after cardiovascular events. Glycemic 
variability is the measure of change in glucose swings. Researchers discovered that some 
patients have greater glycemic variability than other patients. Another region of growth is 
the advancement of molecular technology. As aptly summarized by Leung et al. (2013) a 
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major challenge is synthesizing new knowledge so that it can impact clinical practice.  
The increased ability to measure patient characteristics at the molecular level provides 
more detailed information, but increased knowledge has not fully been translated into 
better medical practice. Continued research needs to be done to link more refined 
measurements to more precise care. 
The next bin includes research that attempts to address how best to decrease the 
time that a provider must spend on a single patient to identify the ailment and recommend 
treatment. Doctors must analyze a patient’s medical history and current laboratory results 
to narrow down possible ailments and associated treatment plans. Researchers are 
examining the medical diagnosis process to determine if they are possible efficiencies 
within the system. Efficiencies exist where technology can replace the human in the loop 
in assessing routine data collected to look for abnormalities. While the doctor’s opinion 
will remain central to the decision of the final treatment plan, automatic review of 
portions of a patient’s record potentially improves the speed of the decision making, or 
call a doctor’s attention to a critical component of the record. One area of growing 
interest is the application of machine learning technology as part of the medical image 
review process. Available medical imaging includes x-ray, computed tomography, 
magnetic resonance imaging, and ultrasound imaging. To assess a patient’s current 
physical health, a medical professional will need to review each image to look for signs 
of disease. If the initial image review is automated, doctors would only need to review 
files for which the images indicated risk of a particular disease. The change to the process 
would reduce the time an individual needs to spend reviewing multiple images. 
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EITanboly et al. (2017) focused research efforts to develop a computer-aided diagnostic 
system for optical coherence tomography images. By detecting retinal changes in T2DM 
diagnosed patients earlier in the development of the disease, the improved prediction 
model would provide patients additional time and awareness to make appropriate 
decisions that could either delay or prevent the onset of diabetic retinopathy, a 
complication associated with hyperglycemia. One common concern with articles that 
addressed automating medical tasks was ensuring that the process would perform better 
than a human’s performance on the same task. Automated processes that do not perform 
as effectively medical professionals could negatively affect patients and should not be 
implemented. 
Another gap between current medical capabilities and medical needs is the ability 
to assess a risk for individuals with regard to developing a disease because once having 
the disease an additional risk of developing specific complications associated with the 
disease. Current prediction methods do not capture all patients who will develop T2DM. 
However, given the advancements of analytics and medical measurements, there exists 
the possibility of refining prediction models to better identify individuals at risk. Also, 
technological advancements have broadened the available characteristics for medical 
professionals to better assess patient health by increasing the number of characteristics 
measured. Measurements that may be used as indicators are broken down into two 
distinct groups: genotypes and phenotypes. Genotypes are an individual’s heritable 
genetic identity. Phenotypes are observable characteristics that include physical 
appearance, development, and behavior. Researchers are working to link specific 
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genotypes and phenotypes to individual diseases. Allalou et al. (2016) noted that 20-50% 
of patients with gestational diabetes progress into T2DM within 5 years. The 
characteristics that make gestational diabetic patients more likely to become T2DM are 
not well documented. By finding the characteristics common to patients who progress 
from gestational diabetes to T2DM, clinics would be able to better treat mothers during 
and immediately following pregnancy. Li et al. (2016) noted that using anthropometric 
measurements, human body measurements, to predict T2DM remains controversial. Their 
work was unique in that it offered to reexamine the use of non-invasive measurements as 
indicators. The benefit of noninvasive measurements is that they are less expensive to 
obtain and could potentially be used to screen portions of the populations that are not 
routinely able to access healthcare. 
Anderson et al. (2016) explored how to best use existing EHR data to gain new 
knowledge about the progression of T2DM. Li et al. (2016) attempted to use limited EHR 
data to evaluate patient risk for T2DM in order to better protect patient privacy. Farran et 
al. (2013) noted that the medical community needed an effective way to stratify patients 
by classifying potential risks of developing complications over time. Advances in the 
development of better methods for assessing the patient risk allow for the medical system 
to focus prevention and treatment efforts on patients with the greatest level of risk. It also 
creates the potential for patients to be aware earlier of their risk so that if properly 
motivated they can make alterations to their behaviors to lower their risks. 
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2.3.2 Insights on Medical Data for Research 
The medical datasets used as a basis for the research came from a variety of 
sources. Each dataset had its own limitations due to the structure and completeness of the 
available information. The following section provides a review of the data sources used, 
the types of variables used within the research, and the associated limitations. Analysis of 
existing data resources provides a foundation which can be leveraged to recommend 
changes to how data is current collected and stored within the medical system. 
2.3.2.1 Data Sources 
The articles in this literature review utilized data from four primary sources: 
electronic health records, national health studies, completed research efforts, or data 
collected for the purposes of the specific research paper. The first three sources of 
information provide data at potentially reduced cost to researchers, but research utilizing 
this type of data may be limited in that researchers may have to adjust the scope of their 
research effort to conform to the data at hand. 
Ethical and security concerns have informed the construction of a detailed 
approval process for the use of medical data. A critical detail in the construction and use 
of medical data is ensuring that the data is used in a manner consistent with the way the 
data was initially collected or approved secondary uses. Most medical data is collected 
with the intent to assess a patient’s health and inform treatment decisions. The data 
collected for this type of use, also termed as the original use, may contain a patient’s 
family history, laboratory test results, records of procedures, financial information, 
prescribed medications, and clinical notes on issues such as treatment compliance. Any 
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other use of medical data obtained in this manner is termed as the secondary use. This 
term reflects the use of any data for non-clinical applications. There is considerable 
debate about the extent to which an individual’s medical information can and should be 
used for research purposes. In order to ensure that medical data will be used within the 
secondary use guidelines of the controlling institution and in a manner that protects 
patient information, the majority of data used for medical research is considered 
restricted access. Researchers will need to obtain approval for their research plans 
through both their institution’s institutional review board (IRB) and receive an additional 
IRB approval from the organization that owns the data repository. 
Assuming that the researcher chooses to use an existing dataset there are a variety 
of different data repositories available through both public and private agencies. Choice 
of repository depends on the research question. In comparison to using electronic health 
records, the use of data from a study or trial provides concentrated data about a specific 
type of patient.  Studies allow for the aggregation of interesting cases. Casanova et al. 
(2006) chose to use the Jackson Heart Study from the University of Mississippi Medical 
Center to uncover potential predictors of T2DM in African Americans. Hertroijos et al. 
(2017) elected to use data repositories from two Dutch Diabetes Care networks to 
develop glycemic trajectories for patients recently diagnosed with T2DM. The inclusion 
of a second, similar repository allowed the team to validate the model developed using 
the initial repository. By using data from a specific study, the researchers can focus their 
efforts on highlighting unique aspects related to a subpopulation. In some instances, 
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studies allow researchers to study the effectiveness of treatment protocol since the 
patients included within the study receive standardized care. 
In comparison, the electronic health record (EHR) system aggregates individual 
patient treatment data for a larger population. The medical repository may be defined by 
medical facilities within a geographic location or, more likely, by agreements between 
large health providers. The establishment of an EHR system has created a more 
standardized, readily accessible repository of medical information on a large sample of 
patients. Researchers have recognized that use of data compiled as part of an EHR could 
support clinical research by providing longitudinal treatment data for a robust patient 
population. These records have the potential to allow researchers to evaluate treatment 
outcomes and develop screening criteria for known health risks. The transition from 
paper to electronic records made the aggregation of medical data easier. Each EHR is 
unique to the controlling medical system and may include important information like a 
patient’s medical history, diagnoses, current medications, immunizations, and laboratory 
reports. Lack of standardization of what medical data must be included within an EHR 
would limit aggregation at the national and international level and causes challenges for 
how to externally validate developed models with region EHR data. In addition, 
researchers have recognized that use of data compiled as part of an EHR could support 
clinical research by providing longitudinal treatment data for a robust patient population. 
These records have the potential to allow researchers to evaluate treatment outcomes and 
develop screening criteria for known health risks. 
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Researchers continue to explore existing medical databases to find new novel 
indicators for unique sub-populations and develop greater knowledge of non-invasive 
indicators. The growth of electronic data bases, better methods for the measurement of 
known characteristics, increased knowledge of genetics, and the increased availability of 
data analysis tools capable of handing the scale of medical data have contributed 
improvement in this area. 
2.3.2.2 Medical Dataset Variable Categories 
The availability of the data used in the majority of the research efforts was 
dependent on the data collected and stored in an existing data repository. The majority of 
the variables within the datasets fell into nine general categories. The following 
summarized types provides a general overview of the types of data that may be included 
for that category for a given study. 
a. Demographic. This type of variable includes information such as a patient’s age, 
ethnicity, gender, time to diagnosis, and source of medical insurance. Most of the 
variables included within this type are nominal data types such a gender or ethnicity. 
b. Clinical laboratory tests. These variables includes outcomes for tests performed on 
samples of blood, urine, or other tissues take from the patient. The laboratory tests are 
performed with the intent to diagnose a disease or to monitor the patient for changes 
in their health conditions. 
c. Prescribed medications. Patients under the care of a medical provider for a health 
condition may be prescribed drugs to control physical reactions. For example a 
patient may be diagnosed medication to control blood pressure. Information 
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contained within this section should then include the type, frequency, and quantity of 
each prescribed drug. 
d. Vital signs. As part of an initial screening when meeting with a medical professional 
at a care clinic, a patient’s vital signs are recorded. Variables annotated within 
medical repositories may include a patient’s height, weight, blood pressure, or resting 
heart rate. These variables provide the medical staff important information about a 
patient’s health particularly when observations are conducted over a period of time. 
e. Genomic Data. Identifiable variations in an individual’s genes can provide medical 
professionals with important information that can impact medical care decisions. 
While still not common practice to gather genotype data for all patients, this 
collection and analysis of this type of data is growing. 
f. Anthropometric measurements. This type of measurement is used to assess the size 
and shape of the human body. Common measurements may include waist 
circumference, waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), and body 
mass index (BMI). 
g. Diagnosis codes. The U.S. healthcare system uses the International Classification of 
Disease (ICD) codes to annotate a patient’s disease and heath conditions when the 
patient is seen by a medical provider (National Center for Health Statistics, 2018). 
The ICD system as a whole is a comprehensive tally of health conditions that 
standardizes entries in patient records. First adopted in 1893, the ICD allowed 
researchers to assess health trends across time and space. The codes are published in 
two different manuals for separate purposes. ICD-10-CM is used for outpatient 
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coding and contains over 68,000 codes. While ICD-10-PCS contains the procedural 
classification system for use in an inpatient setting. Finally ICD-10-PCS contains 
over 87,000 codes. T2DM had 86 distinct codes. Table 2.8 contains a sampling of the 
codes to illustrate the details regarding a patient that can be gained from the ICD 
code. 
Table 2.8. Classification Codes for Diabetes Mellitus (National Center for Health 
Statistics & Centers for Medicare and Medicaid Services, 2018) 
 
ICD 
Code 
Description 
E11621 Type 2 diabetes mellitus with foot ulcer 
E11630 Type 2 diabetes mellitus with periodontal disease 
E11641 Type 2 diabetes mellitus with hypoglycemia with coma 
E11649 Type 2 diabetes mellitus with hypoglycemia without coma 
E1165 Type 2 diabetes mellitus with hyperglycemia 
E1169 Type 2 diabetes mellitus with other specified complication 
E118 Type 2 diabetes mellitus with unspecified complications 
E119 Type 2 diabetes mellitus without complications 
E1110 Type 2 diabetes mellitus with ketoacidosis without coma 
E1111 Type 2 diabetes mellitus with ketoacidosis with coma 
E1122 Type 2 diabetes mellitus with diabetic chronic kidney disease 
E1129 Type 2 diabetes mellitus with other diabetic kidney complication 
E11311 
Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular 
edema 
 
h. Specialized tests. Depending on the medical issue at hand, medical providers have 
additional medical tests which may provide information about a particular aspect of a 
patient’s health. Variables pertinent to this category include information obtained from 
tests like an echocardiogram, a sonogram of the heart, or electromyography, a test to 
analyze nerve and tissue electrical activity. 
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i. Medical Images. Pictures of certain structures within the body may provide additional 
information about a disease. Common medical images that are used for diagnosis are x-
rays, computed tomography scams, magnetic resonance images ultrasounds, and nuclear 
medicine imaging. Those images are reviewed by medical specialists trained to look for 
abnormalities. 
2.3.2.3 Insights on Training and Validation 
Prior to using the dataset, the researchers must develop a data plan to describe 
how the available data will be used to train, validate, and test the model developed using 
machine learning. There are two commonly used methods for how to use available data 
to train and validate model performance. Traditionally, the available dataset is separated 
into three sections and training dataset is used to develop the model. The data is then 
provided to the machine learning algorithm as a set of examples from which parameters 
are identified. The validation dataset is used to adjust the parameters used for a classifier. 
This dataset can also be used for feature selection. The test set is held in reserve to judge 
the performance of the model. However, this method only works when there is a large 
volume of data. The second method, the development of model parameters through the 
use of cross validation, may allow the researcher meet both the test and validation 
requirements without losing modeling or testing capability. In general the data set will be 
divided into small, equal sections. The data sections will then be allocated into training 
and validation test sets. These tests will be used to develop the model. Once completed, 
the sections will be re-allocated to form a new training and validation test sets. The 
process will continue until either all possible ways to divide the original sample into 
 54 
training and validation sets is complete (exhaustive cross validation) or until a pre-
determined number of runs is complete (non-exhaustive cross validation). 
Within this literature review the preponderance of the researchers chose to use k-
fold validation by dividing the training dataset into k subsections. The model is then built 
using k-1 sections. Once the model is complete the model is then tested using the 
remaining section and the researcher annotates the model performance. The process is 
then repeated until each section has been held in reserve as the validation set. The overall 
model performance is the average of the model performance when tested using the 
section held in reserve. 
2.3.2.4 Insights on Limitations Due to Dataset/Structure 
Within each article, the researchers annotated the limitations of their work due 
stemming from the available data. The primarily limitations were due to the size of the 
available data set, frequency of missing values, class imbalance, large dimensionality, 
and limited variable types. All of the papers selected to be part of this literature review 
cited missing entries as a limitation in performing the analysis. Researchers had three 
options for how to deal with missing data. First, the researcher could choose to remove 
all cases for which there was missing data. Farran et al. (2013) only used patients with 
complete data for the variables within the model. From over 270,000 patients, termed 
“hospital visitors,” the number considered in the model was 10,632. This option, although 
valid, removed a significant portion of the available data from the analysis. Han et al. 
(2017) also chose to delete vacant data. As a result, the sample size shrunk from 9,562 to 
7,913. Secondly, the researcher could choose to approximate the missing data based on 
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other data entries. Lastly, the researcher could choose to impute the data. Before opting 
for this method, the researcher must determine why the data is missing. Is the missing 
data related to other available information about the subject or is the missing data 
dependent on the value? One possible reason for missing data is that the patient chose to 
censor particular information such as a family history of a disease. The second most 
prevalent issue that researchers needed to address was how to deal with class imbalance. 
This particular issue occurs when there is a large difference between the size of groups 
with or without a feature. For example, there may be 200 entries of patients that screened 
for T2DM, but only 5 percent of the patients showed large glycemic variability. Datasets 
that link output variables to input variables are particularly valuable in the development 
of risk models. 
2.3.3 Recent Machine Learning Algorithms Used for Type 2 Diabetes Mellitus 
ML is a method which automates model building based on the idea that systems 
can learn from data to identify patters and make informed recommendations. In this 
context ML is used to improve performance in T2DM prevention, diagnosis, and 
management. Choice of the best type of ML to use was dependent on both the available 
data and the research questions. In most cases, the research questions attempted to answer 
how best to predict health risk for patients. The dataset chosen to support the analysis 
included the known classification of the patient which made the data amenable to use 
supervised learning. The research questions that used genetic information as possible 
predictor variables applied unsupervised methods to determine which features were most 
important. 
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The preponderance of the research used supervised ML for the purposes of 
classification and prediction. Acciaroli et al. (2018) used supervised ML to build 
prediction models with the capability to distinguish between three classes of individuates: 
healthy people, patients with impaired glucose tolerance, and patients with T2DM. The 
researchers chose to use logistic regression build with 5 fold cross validation since the 
size of the dataset was too small for the traditional division of the dataset into a training, 
validation, and test set. Contrarily, Allalou et al. (2016) used ML to develop a 
metabolomics signature for the prediction of patient progression from gestational diabetes 
to T2DM. Using feature selection, their team was selected the top 22 variables out of 182 
known variables to develop an accurate prediction model. 
Anderson et al. (2015) used unsupervised ML to explore relationships within the 
dataset. The end result of their work was the development of a prediction model for the 
progression of pre-diabetes into T2DM using variables found within EHRs. Finally, 
Argwal et al. (2016) applied a reinforcement ML technique in an effort to examine an 
alternative method to manual labeling to create training sets. The research team correctly 
surmised that labeling a dataset for use with machine learning was prohibitive due to both 
cost and availability of medical specialist to review the requisite number of files. 
2.3.2 Software Utilized by Research Teams 
Researchers working at the intersection of T2DM most often use open software. 
The two packages used the most often are R and the Waikato Environment for 
Knowledge Analysis (WEKA). Developed by Bell Laboratories, R is a free software 
package that is capable of working on a variety of platforms to include Windows and 
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MacOS. The frequent use of R can be attributed to its ability to handle large datasets, its 
graphical capabilities, and the thought that went into the development of its programming 
language. Additionally, ready-made functions for ML algorithms to include neural 
networks, deep learning, recursive partitioning, random forests, regularized and shrinkage 
methods, and support vector machines are available for download. Table 2.9 includes a 
small sample of over 150 available R ML packages. Even though the table is not 
comprehensive, it hints at the breadth of what exists. 
Table 2.9. Examples of existing ML packages for R (Hothorn, 2018) 
R Package Purpose Authors 
randomForest 
Classification and regression based on a forest of 
trees using random inputs 
Leo Breiman, Adele Cutler, 
Andy Liaw, Matthew Wiener 
rpart 
predictive models by indirect classification and 
bagging for classification 
Andrea Peters, Torseten 
Hothorn, Brian D. Ripley, 
Terry Therneau, Beth Atkinson 
tree classification and regression trees Brian Ripley 
nnet 
software for feed-forward neural networks with a 
single hidden layer and for multinomial log-linear 
models 
Brian Ripley, William 
Venables 
ROCR 
flexible tool for creating cutoff-parameterized 2D 
performance curves 
Tobias Sing, Oliver Sander, 
Niko Beerenwinkel, Thomas 
Lengauer 
caret 
training and plotting classification and regression 
models 
Max Kuhn 
svmpath 
computes the regularization path for the two-class 
SVM classifier 
Trevor Hastie 
kernLAB 
Kernel-based ML for classification, regression, 
clustering, novelty detection, quantile regression, 
and dimensionality reduction 
Alexandros Karatzoglou, Alex 
Smola, Kurt Hornik 
glmpath 
a path-following algorithm for L1 regularized 
generalized linear models and Cox proportional 
hazards model 
Mee Young Park, Trevor Hasite 
CoxBoost 
routines for fitting Cox models by likelihood 
based boosting for a single endpoint or in the 
presence of competing risks 
Harold Binder 
BayesTree 
implementation of the Bayesian Additive 
Regression Tree 
Hugh Chipman, Rober 
McCulloch 
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Like R, WEKA is a free licensed software that is used for data analysis. Written in Java, 
the program has a variety of tools for data pre-processing, classification, regression, 
clustering, association rules, and visualization (WEKA, n.d.). 
2.4 Further Research Insights and Common Concerns 
At the end of their papers, research teams highlighted their concerns regarding the 
findings and the potential applications of the work. One prevalent concern expressed was 
the need to limit negative consequences to the patient when employing machine learning 
findings. The researchers were particularly concerned when the final result of the analysis 
was intended to replace a human within the analysis portion of diagnosis and treatment 
decisions. There was a common understanding that the final model needed to perform at 
least as well as medical professionals before the model should be used in clinical 
practice. Another concern expressed by researchers was whether the work would have 
meaningful impact. Some researchers considered whether the available prediction model 
would provide meaningful warnings to patients with enough time for the patient to 
change their behavior to avoid undesirable consequences. 
The results of the research included within this literature review aptly illustrated the 
positive impact that the integration of supervised ML into medical research can have on 
the identification of important variables for the purposes of classification and prediction 
models for T2DM applications. Continued advancements using ML will depend on 
fostering a small community of researchers that consistently explore the use of ML for 
T2DM application, the development of improved medical datasets to support the 
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research, and the cost to assess the predictive value of an indicator against the cost to take 
the measurement and store the data. 
Of the 266 authors who contributed to the literature included in this study, only a 
small subset had published more than one paper involving ML for T2DM applications. 
This may indicate that there needs to be greater support, both financially and 
intellectually, to encourage more analysts to pursue research in this area. The creation of 
a community of practice for the application of ML for DM. The group will be able to 
facilitate changes to medical database construction to support future research efforts. 
Furthermore, the community of practice will be able to initiate discussions with the 
medical community to solicit input from subject matter experts on proposed research 
questions and methodologies. The engagement will also provide researchers to share their 
findings and potential influence changes to the medical system. 
To produce the most benefit, datasets needs to be complete and comparable. A large 
number of missing data entries within large data repositories can create variation in the 
final predictive models. If cases with missing data are deleted, the available data for 
analysis is significantly smaller than the initial data set. Placing values on improving 
completeness of electronic health records will improve the resultant models. In addition, 
the limited availability of research databases has restricted researchers from verifying 
their findings or those researchers within a reasonable timeframe and also limits their 
ability to compare the results of single analytic method with more than one dataset. This 
could be especially important in the ability to compare the results of research utilizing 
electronic health records. 
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Analysis conducted in isolation may result in recommendations that cannot be applied 
in practice due to practical considerations. Future work that seeks to find best variables to 
use for prediction of T2DM should consider selecting multiple sets of variables for 
various scenarios. When comparing prediction models that rely on the availability of 
select pieces of data to make a prediction, it is imperative that researchers need to 
consider the portion of patients which are likely to have the variables in their datasets and 
the cost of those tests.  
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CHAPTER THREE 
DEVELOPMENT OF PERFORMANCE LOSS FUNCTIONS FOR 
HEALTHCARE APPLICATIONS 
3.1 Introduction 
Relatively recent advances in both medical knowledge and increased 
technological capability to measure changes within the human body have made the role 
of a healthcare provider increasingly difficult.  Doctors are expected to digest excessive 
amounts of data and, from that data, develop actionable recommendations in a timely 
fashion. This global “expectation” of healthcare providers creates a demand for increased 
involvement of other specialties within the scientific community in the development of 
better methodologies for transforming data into information and then using the resultant 
information to develop optimal treatment plans. The Precision Medicine Initiative (PMI) 
outlines a goal of tailoring medical care for the individual patient. For this effort to be 
successful, it is incumbent upon research teams to think critically about the problem at 
hand, determine what aspect of patient treatment their field could provide assistance in 
improving, and start an open dialogue with the medical community. This paper seeks to 
establish an informative exchange as to how quality engineering methodologies can be 
applied to treatment protocol selection by examining how to adapt the quality loss 
function for use within the healthcare domain. In support of a larger effort to develop 
improved metrics for health assessments and patient’s physical performance this article 
develops the concept of reference interval-based performance functions. 
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3.1.1 Research Motivation and Scope 
The rise of the financial cost of healthcare in the United States has intensified the 
desire to find efficiencies within the medical system to lower overall costs and, at the 
same time, improve the quality of medical care for patients. The phrase healthcare costs 
encompasses all funding related to the management of the complex healthcare system as 
well as the costs stemming from the lack of productivity of the ailing portion of the 
population. Non-optimal treatment plans, ineffective treatment, or lack of care can lead to 
longer patient recovery time, multiple cycles of treatment, loss of life, or the inability of 
the patient to recover to their pre-ailment physical condition.   
This chapter examines how the adaptation of an existing analytical methodology 
within quality engineering could facilitate the establishment of better decision tools for 
healthcare providers. Improved decision tools that combine laboratory results, available 
treatment options for the ailment, and associated treatment risks would assist medical 
professionals in the selection of the best treatment option for the patient.  
The advances made during past century in medical knowledge and practice have 
made a medical professional’s role increasingly difficult. Doctors are expected to digest 
vast amounts of data and, from that data, develop actionable recommendations in a timely 
fashion. Based on an assessment of the number of medical articles published in the 20 
major clinical journals in 1992, researchers estimated that doctors would need to read 17 
articles a day to keep up with advances in medicine (Davidof et. al, 1995). Since the 
publication of this research effort, the number of medical articles published per month 
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has continued to increase. The continued growth had made staying abreast of the most 
recent advancements even more difficult for practitioners. For this reason, it is important 
to develop improved decision tools for medical professionals to harness the available 
information. The involvement of other disciplines will serve to innovate current processes 
and, if successful, improve the quality of patient care through decreased diagnosis time 
and improved treatment efficacy. The importance of involving other parts of the scientific 
community is best highlighted by the establishment of PMI. The initiative’s research 
platform outlines the vision of tailoring medical care to the individual (Ashley, 2015). 
The multidisciplinary research effort leverages medical databases to find better 
techniques for both diagnosis and treatment informed by individual patient characteristics. 
For PMI to be successful multidisciplinary research, teams must think critically about the 
problems at hand, determine what aspect of the problem their respective academic fields 
can assist in solving, and then start an open and productive dialogue with other teams 
working on the same problem and practitioners. This paper seeks to establish a 
productive discussion centered the application of quality engineering methodologies to 
treatment selection within healthcare. Existing analytical tools refined within the field of 
quality engineering for manufacturing applications have potential to improve healthcare 
system efficiency. In particular, the adaptation of the quality loss function (QLF) for use 
within the medical field would provide a means of mapping a measured physical 
characteristic to either physical performance loss or an increased risk of future health 
complications. The technique could allow providers to assess the value of a treatment 
protocol on a patient’s overall health prior to selecting the best treatment. 
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Before applying the manufacturing quality methodologies to the healthcare field, 
researchers will need to adjust developed techniques to account for differences in the 
initial problem construction between a manufacturing application and a medical 
application. This paper provides a brief review of QLFs and their development for use 
within the manufacturing sector. After outlining the unique aspects of medical quality 
characteristics, the author proposes a new methodology for assessing performance of an 
individual based on measurable physical characteristics. Lastly, insights for the potential 
use of performance functions for both univariate and bivariate healthcare assessments are 
discussed. 
3.1.2. Manufacturing Loss Functions 
In the manufacturing sector, quality engineers are often tasked to develop and 
monitor a process whose output needs to adhere to a pre-identified specification value for 
a select measured quality characteristic with minimum variance. The desired value is a 
single number commonly referred to as the “target” or “target value.” The examined item 
is only usable by the customer if its measured characteristic meets the pre-identified 
requirement. If an item’s measurement exceeds the specification limits, the product must 
be scrapped or reworked. If the item does not meet the specification requirement, the 
manufacturer incurs a financial loss related to that item since the entity is not able to sell 
the item. Suppose that a company manufactures nails to be used for wood frame 
construction of residential homes. If the nail manufacturing process is flawless, the 
measurable characteristics of each nail produced on the assembly line are the predefined 
targets. In this case, the manufacturer incurs no financial penalty related to production 
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defects. In reality, production lines are not perfect and sources of variance exist within 
the process. Few nails produced in the factory are exactly the target length of 1.45 inches 
long. The consumer base, however, does not need nails that are exactly 1.45 inches long. 
As long as the nails are within 0.05 inches of the target’s desired length, they can still be 
used safely for frame construction. Any nails that do not fall within the 0.05 tolerance 
window must be scrapped. Quality engineers work diligently to ensure that the 
manufacturing process produces nails with the smallest ratio of defective items to usable 
items. Their job, in essence, is to reduce the loss to the manufacturer. The quality 
engineer mathematically relates the cost of defective items to process performance using 
the target value and process variance. This methodology will be described in greater 
detail in Section 2. The relationship between the measured characteristic and the cost 
enables the manufacturer to identify strategic points within the production process for 
investment to reduce process variability and improve desired target achievement. 
Like the manufacturing sector, the healthcare industry strives to improve the 
effectiveness of treatments through both target acquisition and variability reduction. 
Variability in patient response to treatments has the potential to incur additional expense 
on the part of the patient, the treating medical organization, society at large, or a 
combination thereof. The purpose of this paper is to examine how QLFs could be used 
within the healthcare community to relate an analyte’s measurement and associated 
healthcare costs. An analyte is a substance that is analyzed by finding the measurements 
of its chemical subcomponents (Merriam-Webster, 2017). By relating the measured value 
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of physiological characteristics with costs patients and medical professionals will be 
better able to assess the value of a treatment protocol. 
3.2 Quality Loss Functions 
3.2.1 Development and Application in Manufacturing  
Loss functions are a mapping of an event to an associated cost. Traditionally loss 
has been defined from the viewpoint of a manufacturer and, as such, occurred when the 
item produced was unable to provide value to the manufacturer without additional 
investment. Using the example discussed in the introduction, let us consider again the 
case of a manufacturer who produces nails for wood frame construction. The target value 
for the nail’s length is 1.45 inches. Natural variability in the assembly process affects 
production and the end result is that no two nails produced are exactly the same length. 
As long as the nail’s measured length is within a specified tolerance of the target, in this 
case  0.05 inches, the nail can still be used safely for frame assembly by the customer 
and the nail maintains value to manufacturer. If a nail exceeds the predetermined 
tolerance limit the item would be scrapped and the value of the nail to the manufacturer 
would decrease. A nail that measures less than 1.39 inches or more than 1.51 inches 
could not be used by a consumer for the intended purpose. A traditional step loss function 
relates the nail length to the manufacturer’s cost, L(y). Other practical scenarios for loss 
functions may include the additional possibility of reworking an item in addition to that 
of scrapping the item when the tolerance is exceeded.  
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3.2.2 Traditional Step Loss Functions in Manufacturing 
Traditional step loss functions (Taguchi et al., 2004) vary by the type of quality 
characteristic chosen: nominal-the-best type (n-type), smaller-the-better type (s-type), and 
larger-the-better type (l-type). The three types of characteristics are explained in more 
detail below. 
3.2.2.1 Step Loss Functions: Nominal-the Best Type Quality Characteristic 
For nominal-the-best type (n-type) quality characteristics the manufacturer 
accepts all items whose measurement of a chosen characteristic lies within the pre-
determined upper and lower specification limits. The specification limits are defined by 
the allowable tolerance, Δ, from a desired target value, τ. Loss is incurred by the 
manufacturer only when a tolerance limit is exceeded. The step loss function for an n-
type quality characteristic can be written as: 
 
L(y) is the loss associated with y, the measured value of the desired quality 
characteristic. The cost for scrapping or reworking the product is A, a constant cost. The 
lower specification limit, LSL, is the lowest value that a characteristic can be without the 
item being scrapped or reworked. The upper specification limit, USL, is the largest value 
that a quality characteristic can be without the product having to be scrapped or 
reworked. Figure 3.1 illustrates a step loss function for an n-type quality characteristic. 
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Figure 3.1 Traditional Step Loss Function: Nominal-the-Best Type Quality Characteristic 
 
The light grey area illustrates the additional cost that a manufacturer incurs from 
scrapping or reworking a product. As can be seen, the loss value is uniform when the 
measurement exceeds the specification limits. As long as the measurement of the 
characteristic is within the tolerance window the product’s value to the manufacturer is 
not affected by either the absolute distance between the measurement and the desired 
target or by the absolute distance between the measurement and the closest specification 
limit. 
3.2.2.2 Step Loss Function: Smaller-the-Better Quality Characteristic 
For smaller-the-better type (s-type) characteristics, the company strives to 
manufacture items whose measured characteristic is as small as possible. Traditionally 
the target value for an s-type characteristic is set to zero. A practical example of an s-type 
characteristic could be the sound created by a lawnmower. In this case, the manufacturer 
desires the noise volume for engine to be as small as possible. If the sound emitted by the 
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machine exceeds the hearing safety threshold or, more likely, exceeds the threshold for 
which consumers are willing to purchase, the product will need to be scrapped or 
reworked before being sold. The traditional step loss function for an s-type quality 
characteristic is expressed mathematically as: 
 
 
The loss to the manufacturer, denoted by A, is incurred by the manufacturer only when 
the measurement of the characteristic exceeds the tolerance window. Figure 3.2 illustrates 
a traditional step loss function for an s-type quality characteristic. 
 
Figure 3.2 Traditional Step Loss Function: Smaller-the-Better Type Quality 
Characteristic. 
The light grey area illustrates the additional cost that a manufacturer incurs from 
scrapping or reworking a product. As can be seen, the loss value is uniform when the 
measurement exceeds the upper specification limit. As long as the measurement is less 
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than the USL the product’s value to the manufacturer is not affected by the absolute 
distance between the measurement and the desired target or by the absolute distance 
between the measurement and the upper specification limit.  
3.2.2.3. Step Loss Function: Larger-the-Better Type Quality Characteristic 
For the case of a larger-the-better type (l-type) quality characteristic, the 
manufacturer desires to produce products with the largest possible measurement for the 
chosen quality characteristic. Practical examples of an l-type characteristic could include 
a product’s useful lifespan or the amount of resistance an exercise band could endure 
before snapping. The traditional loss step function for an l-type quality characteristic may 
be expressed mathematically as: 
 
As seen in Figure 3.3, the manufacturer incurs a loss when the measured 
characteristic is less than the established specification limit. 
 
Figure 3.3. Traditional Step Loss Function: Larger-the-Better Type Quality Characteristic 
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There are two notable shortcomings to the traditional step loss function. First, the 
manufacturer cannot use a known value of the loss to determine the measured 
characteristic’s value. The uniform formulation results in an uncountable number of 
different measurements which could result in the same loss. The manufacturer cannot use 
loss to determine how the process should to be tweaked to obtain better results in the 
future. Secondly, the value of the loss, L(y), only takes into account manufacturer’s 
financial loss. The loss to the customer is ignored by the traditional step function. When a 
product fails to match expectation of the customer, the value of the product decreases in 
the eyes of the customer. A company advertises a product with specific characteristics 
and the customer chooses to purchase the product based on the advertised characteristics. 
The difference between reality and expectation could create frustration in the consumer. 
While the manufacturer does not incur an immediate loss when the item does not meet 
the target but remains within the specification limits, the deviation from the target value 
has the potential for future losses due to recalls, returns or warranties. 
3.2.3  Development and Description of Quality Loss Functions 
Taguchi (Taguchi et al., 2004) believed that any deviation of a measured quality 
characteristic from a desired target value results in loss. He articulated a more 
comprehensive value of the loss by adding the customer’s perceived loss (the difference 
between the expected value and observed value) to the manufacturer’s loss. Deviation 
from a characteristic’s target value, even if the measurement remains within the accepted 
tolerance window, can result in a loss of goodwill from the customer due to the variance 
in quality. Taguichi’s quality loss function (QLF) incorporates both the viewpoint of the 
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manufacturer and the customer. The loss function increases in value as the amount of 
deviation from the target increases. Inclusion of the customer’s loss provides recognition 
that not all products produced within specification limits are equal. In his work, Taguchi 
looked at the best way to calculate the value of loss for three different types of quality 
characteristics: nominal-the-best (n-type), smaller-the-better (s-type), and larger-the-
better (l-type). This methodology is explained in more detail below. 
3.2.3.1 Quality Loss Function: Nominal-the-Best Type Quality Characteristic 
For n-type of quality characteristics, the closer the measurement of the quality 
characteristic to the desired target the smaller the summative loss to the consumer and 
manufacturer. Taguchi opted to use the quadratic function to represent the approximate 
loss between the specification limits. A function to estimate the loss is necessary since 
true relationship between measured value and the resultant loss is unknown when the 
measurement lies within the tolerance window. The mathematical representation of the 
loss function for an n-type characteristic can be written as: 
 
The approximate loss is calculated by multiplying the loss coefficient, also known 
as the proportionality constant and denoted by k, by the square of the difference between 
the measurement of the characteristic and the desired target value. If the value of the 
characteristic exceeds either the lower or upper specification limit, the loss occurred is a 
constant value of A. As can be seen in Figure 4, the QLF accounts for the loss between 
the specification limits (customer’s loss) in addition to the loss that occurs when the 
specification limits are exceeded (manufacturer’s loss). Whether the deviation is to the 
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left or to the right of the target value does not impact the loss calculation because of 
symmetry. The value of k is chosen by the analyst to relate the measured characteristic’s 
numerical value to the loss incurred at that measurement by the customer. As such, the 
value is unique for each problem. As stated earlier, the true relationship between the 
measured value and the customer’s value of loss is unknown. The curve merely estimates 
how the loss changes within the tolerance window. For manufacturing applications with 
assumed symmetric loss above and below the desired target, the constant k relates the 
loss associated with the specification limit with the distance of the limit from the target 
value. The mathematical form of a loss coefficient for a symmetric n-type characteristic 
can be expressed as: 
 
The constant c is the loss associated at a specification limit and d is the absolute 
distance between the specification limit and the desired target value of the characteristic’s 
measurement. If the loss incurred is not the same at the upper and lower specification 
limits or the target value is not in the center of the tolerance window, there should be 
different values of k calculated for the customer’s estimated loss if the measured value is 
below the target and if the measured value is above the target. 
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Figure 3.4. Quality Loss Function: Nominal-the-Best Type Characteristic 
3.2.3.2 Quality Loss Function: Smaller-the-Better Type Characteristic 
For the s-type quality characteristic, it is desirable that the measured value of the 
characteristic be as small as possible. Traditionally the target value for an s-type 
characteristic is set to zero. The quality loss function imposes a penalty for any deviation 
of the measured reading above zero (the readings cannot be negative). Once the deviation 
surpasses the upper specification limit the loss reaches a maximum value of A, the loss to 
the manufacturer. The mathematical formulation for the quality loss function for an s-
type quality characteristic can be as:  
 
The loss between the target (zero) and the specification limit is calculated by 
multiplying the loss coefficient, k, by the square of the measured value of the selected 
quality characteristic. As shown in Figure 3.5, the loss increases as the difference 
between the measured quality characteristic and the desired target grows. 
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Figure 3.5. Quality Loss Function: Smaller-the-Better Type Quality Characteristic. 
 
Practical examples of characteristics which could be considered s-type include 
noise levels, the weight of an item, and the breaking distance of a car. Manufactures 
desire to produce products in which identified s-type characteristics as small as possible. 
The measurement must, however, always be positive.  
3.2.3.3 Quality Loss Function: Larger the Better Type Quality Characteristic 
For the case of an l-type quality characteristic, the manufacture’s goal is to 
maximize the measurement of the quality characteristic, y. Like the traditional step loss 
function, the manufacturer’s loss is denoted by the constant A and is incurred by the 
manufacturer when the measurement of quality characteristic, y, is less than the 
specification limit. The quality loss function takes into account the loss to the consumer 
when the quality characteristic deviates from the desired target, but is still within the 
acceptable tolerance window. The QLF imposes a penalty for all values of y that are less 
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than the target, but more than the specification limit. The quality loss function for an l-
type characteristic is defined as: 
 
The loss estimate is calculated by multiplying the loss coefficient, k, by the 
reciprocal of the square of the value of the measured characteristic. Practical examples of 
l-type quality characteristics in manufacturing include a product’s useful life, reliability 
of component parts, or the strength of a component material. As can be seen in Figure 
3.6, the customer’s loss grows as the distance between the measured characteristic and 
the target grows. 
 
Figure 3.6. Quality Loss Function: Larger-the-Better Type Quality Characteristic 
The quality loss function proposed by Taguchi provides two distinct advantages 
over the traditional step loss function. First, in using the traditional step function the 
analyst is forced to accept the assumption that all products whose measured characteristic 
is within the tolerance window have the same value to the customer. Only the loss of the 
manufacturer is taken into account and the voice of the customer is lost. The quality loss 
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function allows for the inclusion of the voice of the customer. In addition, the traditional 
step loss function does not provide gradated differences in loss related to the measured 
value. The loss of value to the customer due to the measurement’s deviance from the 
target when the measurement with within the tolerance window is not included in the 
overall loss estimate. In comparison, Taguchi’s methodology allows for the calculation of 
the total loss which incorporates both the loss to the manufacturer and the loss to the 
customer.  
Figure 3.7 provides a visual means for which to compare the differences of the 
two methodologies. The picture shows measurements (a-d) for a single, measured 
characteristic of four products (A-D), the target value for the characteristic ( , and the 
upper and lower specification limits ( , ). As can be seen in the illustration, 
three of the measurements span a large portion of the tolerance window and one 
measurements sits to the right of the upper tolerance. If using a traditional step loss 
function, the loss values for products A, B, and C would all be zero. Product D would be 
the only product with a valued loss of A, the manufacturer’s loss. Only using the quality 
loss function can differences between the products be articulated to the manufacturer 
using the estimated loss value. Given the differences in measurements, one should expect 
that the customer would perceive a difference in product performance when using 
product A versus product C. The figure shows that there is relatively the same amount of 
distance between the measurements of a and b, and the measurements of c and d. 
Common sense would dictate that the loss incurred by product would be closer for two 
products whose measurements are relatively close. Using the traditional step function to 
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value loss, the loss value for the product C would be closer to loss value for the products 
A and B than product D. 
 
Figure 3.7. Illustrative Diagram: Measurements Relative to Specification Limits. 
 
Since the true value of the loss to a customer is not measurable, Taguchi developed 
a reasonable methodology to estimate loss utilizing the quadratic function. The quality 
loss function, while not perfect, was an improvement upon the traditional step method for 
loss valuation. 
3.3 Motivation to Alter Manufacturing Loss Functions for Future Healthcare 
Application 
3.3.1 Uniqueness of Healthcare Characteristics 
Like manufacturing, the healthcare industry relies on the use of physical 
measurements to assess a product. In order to determine the proper diagnosis and 
treatment plan for a patient, medical professionals use qualitative and quantitative data to 
form and validate hypotheses about the patient’s health. Qualitative information is 
collected as medical professionals observe the patient during the initial screening and 
subsequent meetings. Based on the information provided during the screening and 
knowing possible ailments which could presumably cause the identified reaction or 
ailment, the medical professional may then order select laboratory tests to help confirm 
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the suspected cause. Once the sample is analyzed, the laboratory provides the resulting 
measurement and the associated tolerance window to the medical professional 
responsible for the patient. Almost 80% of medical decisions made by doctors are 
influenced by information from laboratory reports (Katayev, 2010). To assess the 
measurement’s significance, the measurement the medical professional uses the provided 
the reference interval, decision limit, or the reference change value to assess whether the 
measured physiological characteristic is considered to be within a normal range. The 
differences between these measurements will be discussed more in depth in Section 3.2. 
The assessment about the physical characteristic provides information to the doctor to 
narrow down possible causes for the ailment. 
A key to improving both the speed and quality of diagnosis and effectively 
choosing an appropriate treatment protocol is the development of a deeper understanding 
of important measurable characteristics in the human body. The knowledge regarding 
healthcare quality characteristics has been limited by four distinct challenges. First, 
medical knowledge is still a growing field. As an example, deoxyribonucleic acid, DNA, 
profiling was not developed until 1984. Today DNA is used to test for an individual’s 
susceptibility to known hereditary diseases. Within the span of 30 years, the improved 
test expanded the breadth of the medical community’s capability drastically. Medical 
professionals are still learning about the building blocks the human body and their 
importance to peak functioning. Secondly, researchers continue to develop and refine 
techniques to measure specific physical indicators. As the testing process improves the 
amount of information that a doctor can glean from a patient’s sample will continue to 
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grow. Furthermore, the increased medical data repositories and computational capability 
provided by modern systems will allow medical research teams to identify physiological 
differences between subpopulations which can either indicate a smaller tolerance window 
for a measurable physical characteristic or might indicate the selection of a specific 
treatment protocol. Normal ranges for known characteristics potentially may be refined 
so that inter-population variability will no longer mask ailments. Some tolerance 
windows for specific physical characteristics have been established for each gender. 
Continued research focused on the identification of important sub-groups and associated 
reference ranges is needed to narrow current reference ranges. Wide tolerance windows 
do not help medical professionals efficiently treat patients since they provide little 
information. Lastly, medical professionals are forced to primarily rely on univariate 
analysis to support multivariate decisions. Many of the references available, to include 
reference intervals, are compiled while holding all other factors stable. For example, 
doctors are not able to provide a reference interval for characteristic a given that 
characteristic b is not within the normal range. Additional research needs to be conducted 
so that medical professionals are better able to understand how to treat patients with 
multiple ailments using on or more approved drugs. As medical knowledge grows, 
technology improves, and subpopulations are identified medical professionals will be 
able to better use the results from laboratory measurements to diagnose and treat patients. 
Specifically, the ability to understand the significance of a single value in light of a 
patient’s personal history will allow doctors to possible diagnose patients sooner or to 
treat a patient more efficiently. Over time, continued research on healthcare quality 
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characteristics will enhance our understanding of the human body and how it reacts when 
stressed.  
In comparison to quality characteristics within the manufacturing sector, there are 
two distinct facts make healthcare characteristics unique. First, the target for a healthcare 
characteristic is defined as a range rather than a point value. The optimal level of glucose 
in the blood stream for a specific individual is not empirically known. Diligent medical 
research teams have been able to specify a range within which the glucose reading for 
95% healthy population would fall. Reference intervals (RIs) for select quality 
characteristics are established through well-documented studies and will be explained in 
more detail in Section 3.1.2. RIs are currently the most prevalent metric used to assess a 
patient’s health. Unlike manufacturing where engineers compare a measurement to a 
point target, doctors compare the laboratory result to a target range. The use of an 
acceptable range aligns with the concept that each human is unique and the realization 
that human understanding of medical science is limited. Secondly, a naturally occurring 
inter-variability between the physical qualities of people and possible intra-variability 
between successive measurements of a single patient. Differences between successive 
measurement can be due to error in measurement technique or biological changes (in a 
single patient) or biologic differences (between patients) (Ricos et al., 2004). In 
healthcare, the biologic differences have the potential to impact the choice and 
effectiveness of treatment plans. The following paragraphs provide a brief summary of 
the different comparison metrics that are used by providers to understand laboratory 
results. 
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3.3.2 Healthcare Measurement References 
There are three different numeric values which medical professionals may use to 
assess the significance of a patient’s laboratory result. The comparison references are 
used to determine if the sample’s measure is atypical. The three numeric values are 
discussed in more detail in sections 3.3.2.1 to 3.3.2.3. 
3.3.2.1 Reference Intervals 
Reference intervals (RI) are the range within which 95% of the values of the 
population from which the sample was taken are estimated to fall. In the case of medical 
RIs, the reference group from which samples were taken was limited to selection from a 
pre-screened healthy sub-population. This type of numeric reference is the most widely 
used yardstick used to help determine a patient’s health. When test results for an 
individual’s laboratory assessment are sent back each measure will be paired with the 
appropriate reference interval.  
RIs can be published both by the manufacturer of the equipment used to perform 
the test and by independent laboratories that employ the equipment. Before processing 
analyte samples, it is recommended that laboratories establish a laboratory specific 
reference interval or verify existing reference intervals from another facility are 
applicable to the serviced population (Clinical Laboratory Standards Institute, 2008). It is 
important to note that the RI for a given characteristic may vary between locations. 
Variance between the published reference intervals for similar reference populations at 
different laboratories can be attributed to the use of different types of test equipment, the 
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types of chemicals used in the analysis, or technician technique (American Association 
for Clinical Chemistry, 2017).  
Recent advancements in technology and published methodologies for determining 
and verifying intervals have improved the quality of the intervals over the past few 
decades. Often cited and referenced, EP28-A3c: Defining, Establishing, and Verifying 
Reference Intervals in the Clinical Laboratory offers the most comprehensive 
examination of laboratory protocols which ensure usefulness and reliability of reference 
intervals (Clinical Laboratory Standards Institute, 2008). The focus on standardization 
has helped to reduce the variability between RIs from different locations. Differences in 
reference intervals between laboratories and medical facilities have the potential to 
induce additional confusion into the decision-making process (Plebani, 2016). The 
following paragraph will briefly describe the process for establishing an RI. First, the 
laboratory must fully document its proposed methodology to include criteria for the 
reference sample population. Next, at least 120 reference individuals from a reference 
population must be used to form the reference sample group (Clinical Laboratory 
Standards Institute, 2008). The reference sample group is screened to ensure that they 
meet the minimum health standards outlined by the documented protocol. In a numerical 
study using National Health and Nutrition Examination Survey (NHANES) data, Horn et 
al. (2013) was able to show that inclusion of unhealthy subjects could increase the width 
of the RI by as much as 30 percent. A wider RI can result in an increased number of 
individuals who are not appropriately diagnosed. The reference sample group then 
provides the necessary samples. The RI is found by including the central 95% of the 
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values found within a sample. The lowest and highest 2.5% of samples are excluded. 
While separate methodologies for creating reference intervals for parametric and 
nonparametric data are included in EP28-A3c, the guide recommends the use of the 
nonparametric methodology for simplicity (Clinical Laboratory Standards Institute, 
2008). 
Accurate reference ranges are needed by the medical community for patient care 
and to interpret data from vaccine trials (Kibaya et al., 2008). The accuracy of a reference 
interval have the potential to impact treatment decisions for patients. As highlighted by 
Brewster et al. (2007), patients can be misdiagnosed when inappropriate reference limits 
are used. The team analyzed serum creatine kinase (CK) from ethnically diverse sample 
to validate the applicability of the published reference interval. Their findings indicated 
that specific ethnic subgroups had naturally higher CK level activity than the general 
population. If the RI established for the general population was used for diagnosis, the 
patient’s laboratory readings would block the patient from participation in statin therapy. 
This study illustrated that RIs had the potential to impact the availability of treatment 
options for patients.  In order for a RI to be useful, the sample reference population must 
be reflective of the population for which the RI will be used. If the patient population is 
not adequately represented in the sample used to establish the reference interval, the 
resultant limits can lead to a suboptimal decision on whether to start or continue 
treatment. 
Past studies, like the one by Brewster et al. (2017) bring into question the 
applicability of common reference intervals to all patients. While it has been 
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acknowledged that the quality of RIs is better than at any point in history there is still 
ample room for improvement. Establishing quality RIs is hampered by the availability of 
adequate sample reference groups and by a limited understanding of which factors impact 
the levels of a substance within the human body. It has been noted that establishment of 
RIs for the pediatric population is difficult due to ethical considerations of sampling 
healthy patients. In addition healthy reference sample group for the geriatric population is 
difficult due to the high percentage of that population who do not meet the minimum 
health requirements to provide usable sample (Ceriotti, 2012). A recent National Health 
and Nutrition Examination Survey (NHANES) study showed only one out of ten subjects 
in the 70-80 age range could meet the requirements to be part of the reference sample 
group (Horn & Pesca., 2003). In addition to the complications in gathering data from 
subpopulations due to ethical concerns and health issues, the lack of understanding of 
what factors can affect measurements hinders the identification of appropriate 
subpopulations which could allow for narrowed RIs. As pointed out by Ceriotti only 47 
out of the 296 analyte reference intervals provided in the Tietz textbook included a 
separate RI for each gender (Ceriotti, 2017). This statement suggests that while gender 
does influence the levels of 47 analytes, not all analyte levels are influenced by gender. In 
summary, reference intervals provide a range in which a healthy individual could expect 
the reading to fall. Wide RIs hinders prompt diagnosis by masking abnormal values. The 
identification of subpopulations with potentially narrower RIs in comparison to the 
general RI may have a profound impact. Of all the researched limits for medicine, RIs are 
the most widely documented and researched. 
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3.3.2.2 Decision Limits 
Initially termed “discrimination value” by Sunderman, decision limits are used to 
mark the difference between the “healthy” and “diseased” population (Sunderman, 1975). 
While reference intervals focus on describing a physiological state of a healthy person, 
decision limits were created to help medical professionals determine the risk of disease 
(Ceriotti, 2008). The two conditions which affect the identification of decision limits are 
the clinical question for which the lab was ordered and the patient category (Ceriotti, 
2008). There are currently three different methods used to establish decision limits: 
Bayesian, epidemiological, and physiopathological. The Bayesian approach uses 
knowledge of the diagnostic test, distribution for the analyte in a healthy population, 
distribution for the analyte in an unhealthy population, and the cost of misdiagnosis to 
determine an appropriate decision limit for the clinical question. The epidemiological 
approach is based evidence from population studies. The limits are determined by 
consensus. The last approach, physiopathological, is based on clinical experience. To 
date, only eight analytes have universally accepted decision limits. Those analytes are 
total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, 
apolipoprotein A-I, apolipoprotein B, and glycated hemoglobin (Ceriotti, 2017).  
Standards continued to be refined and are updated as new information becomes 
available. For example, in 1997, an International Expert Committee recommended 
changes to criteria used to diagnose diabetes (Kahn, 2003). Specifically, the panel 
recommended that the fasting plasma glucose level that distinguished between those with 
diabetes and those without be lowered. The recommended change reflected the 
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knowledge gained from examination of data that clearly showed diabetic retinopathy, a 
diabetes complication that affects the eyes and can result in blindness, occurred 
frequently at a lower reading of fasting plasma glucose. The lower threshold for fasting 
plasma glucose will directly influence the number of people who are diagnosed with 
diabetes. The change could potentially result in less people loosing eyesight since they 
are more aware of the importance of proper control of blood sugar. 
3.3.2.3 Reference Change Values 
Reference change values are the difference in an individual’s analyte 
measurement over a period of time. A reference value may be used to monitor individuals 
who have been diagnosed with either an acute or a chronic condition. The utilization of 
reference change value increases a provider’s sensitivity to an individual’s pathologic 
changes in comparison to the use of reference interval. If an individual is taking 
medication to alter the level of an analyte within his or her body, comparison of a 
laboratory measurement to a target range value may or may not show that the medication 
was having the intended affect. Comparison of an individual’s successive lab results has 
the potential to illuminate physical change that might not be apparent because the 
patient’s natural variability falls within the bounds of the population variability. The use 
of the reference change value is limited to instances when successive readings of the 
same analyte are taken from one individual. 
3.3.3 Need Unmet by the Quality Loss Functions in the field of Healthcare 
Quality loss functions are used within the manufacturing application area to 
determine where limits should be set in order to minimize the loss to society. In 
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transferring the concept of loss functions to a healthcare setting it is important discuss 
two important aspects of loss functions: the purpose of the measurement and the meaning 
of the measured value. Prior to use, there must be agreement on the purpose of the loss 
valuation within healthcare. The purpose of the loss value for manufacturing serves as 
motivation to improve the process for long term gains to society as a whole. The quality 
loss function maps an event or measurement to a cost. When establishing a summative 
loss function for use within healthcare, it is important to keep in mind that the value will 
help medical professionals compare the impact of treatment protocol options. The 
measurement of a select physical characteristic maps to a valuation of health. Unlike 
manufacturing there only two perspectives need to be included, the use of an adaption of 
the loss function within healthcare will need to take into account three perspectives: the 
provider, the patient, and society at large. Loss functions allow the user to clearly see 
what will happen if a quality characteristic does not meet the target. For example, use of a 
loss function in healthcare could provide insight into the meaning of a laboratory test 
does not fall within the allowable bounds. A loss function would allow for health 
providers quantize a patient’s physical performance based on the measured characteristic. 
Readings outside a specified tolerance window would indicate health implications, the 
possible need for further tests, or the need for immediate treatment. The second 
influential decision use of loss functions within healthcare is the meaning of the 
measured characteristic. When loss functions used within the manufacturing sector, the 
manufacturer specifies both the target value and the limits for the product. The target 
value is a point target. The product performs best when the measured characteristic is at 
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the target value. The limits delineate the lowest and highest measurement within which 
the product can still be used for its intended purpose. In healthcare, the loss function 
would need to be adapted for use with a target interval. Medical knowledge has not 
advanced to the point where the best value of an analyst for an individual is known. At 
this juncture, there is only general consensus that a healthy value of a measured analyte 
exists within a specified range. The limits for the loss function could be based either on 
decision limits or the reference interval. The following two sections propose univariate 
and bivariate loss functions for use within healthcare. The performance function is an 
adaptations of the loss functions with a target interval for use within the medical field.  
3.4 Proposed Univariate Performance Functions 
3.4.1 Applications of Univariate Performance Functions 
Performance functions provide a means of mapping a patient’s physical 
performance outcome given a measured physical characteristic. A clinician could 
reference a performance diagram to make an assessment of how to further investigate, 
diagnose, or treat the patient. Readings outside the specified tolerance limits would 
indicate possible health risks. 
3.4.2 Healthcare: Nominal-the-Best Type Characteristic 
As explained earlier, an n-type characteristic for a quality loss function consists of 
a target value with established upper and lower specification limit. An n-type 
characteristic for a performance function would consist of a target range and with upper 
and lower specification limits. If the patient’s measurement falls within the target range, 
the patient’s measurement would be considered optimal. A patient’s value for the 
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measured characteristic may however fall above or below the specified target range and 
indicate possible associated health risks. If performance functions are adapted by the 
medical community, the following three physical characteristics would be designated as 
n-type measurements. 
a. Heart Rate: Heart rates typically are between the ranges of 60 to 100 beats per 
minute(bpm) (American Heart Association, 2018). The rate measurement for an 
individual may vary based on a large number of factors to include gender, fitness, 
current emotional state, and the individual’s position while the reading was being 
taken (sitting, standing, or lying down). Some issues that can be indicated by heart 
rate are rhythm disorders include tachycardia (heart rate exceeding 100 bpm), 
bradycardia (too low heart rate), pre-mature contraction, and Adam-Stokes 
disease (very fast and steady). 
b. Ferritin: A protein found in in reticuloendothelial cells, ferritin stores iron and 
releases it to the rest of the body in a controlled fashion. The amount of iron can 
be measured by radioimmunoassay. Typical values for adults by gender are 20 to 
200 nanograms per milliliter (ng/mL) for men and 20 to 120 ng/mL for women 
(US National Library of Medicine, 2018). A test result that is less than the 
established normal range could indicate chronic iron deficiency. A slight increase 
above the normal level could indicate renal disease. Levels above the normal 
range could be an indication that the patient has acute or chronic hepatic disease, 
iron overload, leukemia, or an acute or chronic infection. 
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c. Vitamin D: This substance plays a role in the control of calcium and phosphate 
levels within the human body. The amount of Vitamin D is measured through a 
blood test. The normal range of range is between 20 and 40 ng/mL (Mayo Clinic, 
2018). A lower than normal level can be due to the lack of exposure to sunlight, 
insufficient diet, or liver or kidney diseases. Low levels of Vitamin D have also 
been linked to greater risk for cardio vascular disease. The use of certain 
medications such a phenytoin, an anti-epileptic drug, can also result in a lower 
reading of Vitamin D. If Vitamin D is too high, a patient could experience adverse 
symptoms which could include nausea or kidney stones. 
d. Thyroid Simulating Hormone (TSH): Produced by the pituitary gland, this hormone 
signals the thyroid to generate and release triiodothyronine (T3) and thyroxine 
(T4) in to the blood steam. T3 and T4 help to control the body’s metabolism. To 
test for the substance, the patient provides a blood sample. The normal range for 
TSH in an adult is from .4 to 4.0 milli-international units per liter (Mayo Clinic, 
2018). If TSH is below this range, the measurement could mean that the thyroid is 
not producing enough thyroid hormone and possible hypothyroidism. If the TSH 
is too high, the measurement could indicate that the thyroid is too active and 
possible hyperthyroidism. 
3.4.2.1 Healthcare: Step Function for Nominal-the-Best Type Characteristic 
For an application in healthcare, the traditional step loss function is renamed as a 
“performance” function. The function provides a numeric estimate of how well the body 
is performing based on the measured physical characteristic. Performance values close to 
 92 
zero are considered optimal. A higher performance value indicates decreased 
performance of the body and associated increased risk of future health complications. 
Figure 8 graphically illustrates the proposed performance function for an n-type 
characteristic. The horizontal axis is broken down into three distinct zones. Each zone is 
indicative of the performance that may be achieved with the given characteristic 
measurement. Zone 1 coincides with the specified target interval and should align with 
the established reference interval for measured substance. As can be seen, the 
performance loss within zone 1 is zero. As the measured value deviates outside zone 1, 
the recommended target interval, the individual experienced decreased performance or 
increased future health complications. 
 
Figure 3.8. Performance Step Function for Nominal-the-Best Type Characteristic. 
The performance loss function would be unique to each physical attribute measured. 
Some health characteristics are known to have a greater impact on an individual’s 
physical performance or are associated with higher risk for long term health 
complications. The mapping of values outside of the established tolerance window would 
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result in a larger value of performance loss. Variations of the performance function could 
include more zones to communicate known risks with set measurements outside the 
tolerance window. Other physical characteristics might exhibit asymmetric performance 
degradation. Careful analysis will need to be conducted for each health characteristic to 
determine the most appropriate number of zones, to verify symmetry of performance, and 
determine the “magnitude” of the estimated performance loss and increased risk. The 
mathematical form of the performance step function for an n-type characteristic would 
be:  
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Like the traditional step loss function, the performance function does not offer a 
good estimate of performance degradation in the middle of a zone. The advantage of this 
method is that it is easy to calculate performance loss and increased risk with a 
quantitative measurement.  
3.4.2.2 Healthcare: Performance Function for Nominal-the-Best Type Characteristic 
In order to make the performance function more sensitive to changes in the 
measured physical characteristic, the step function is replaced with a smooth continuous 
function. Figure 3.9 provides an illustrative example of a loss function for an n-type 
characteristic with symmetric loss outside of zone 1. Like the step function shown in 
Figure 3.8, zone 1 is the accepted tolerance window for a normal measurement. As the 
measurement increases or decreases from the boundary of zone 1, the performance loss 
grows.   
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Figure 3.9. Performance Function for a Nominal-the-Best Type Characteristic. 
The mathematical form of the performance function for an n-type characteristic 
would be as follows:  
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By using the quadratic function to model the decreased performance, the loss 
would be increased by an amount proportionate to the absolute value of the deviation of 
the measurement from the specified target. Since performance loss would most likely be 
different if the patient’s test result is less than or more than the target, asymmetric 
performance loss modeling is a future research area. 
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3.4.3 Healthcare: Smaller-the-Better Type Quality Characteristic 
Next let us consider a performance function for an s-type characteristic. S-type 
quality characteristics have an upper specification limit with an ideal target at zero. 
Below are three examples of in which s-type quality characteristics can be found in the 
health domain. 
a. Blood Glucose Levels: Doctors monitor the average level of blood glucose over a 
window of two to three months utilizing a glycohemoglobin test. The test has a 
variety of names to include A1c, glycated hemoglobin, glycosylated hemoglobin, 
hemoglobin, and HbA1C. The test examines the average sugar levels over time 
within the blood stream. The results are given as a single value (percentage form), 
and are interpreted along a range. The higher the number, the higher the average 
blood glucose level over the time window. A normal test result is considered any 
value below 5.7 percent (Mayo Clinic, 2018). Prediabetes is present with an A1c 
result between 5.7 and 6.4 percent. A patient is considered diabetic with an A1c 
greater than 6.4 percent. 
b. Cancer Antigen 125 (CA 125): CA 125 is a membrane-bound protein on the surface 
of cells and is released into blood. The test is used to monitor the status of cancer 
before, during, and after treatment. High levels of the protein have been linked 
with ovarian cancer, pelvic inflammatory disease, pancreatitis, and the first 
trimester of pregnancy. Sample measurements reading below 46 units per 
milliliter (U/ml) are considered normal (Mayo Clinic, 2018) 
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c. Antimitochondria Antibodies (AMA): In an autoimmune response, the body’s 
immune system will attack healthy cells, tissues, and organs. An AMA test 
measures the amount of antibodies in the blood stream. The normal range for 
AMA is less than 1.0 units. 
In healthcare s-type characteristics, it is desirable that the measurement reading 
from a laboratory test be as small as possible. 
3.4.3.1 Healthcare: Step Function for Smaller-the-Better Type Characteristic 
A performance function for an s-type characteristic estimates the growing 
performance loss as the measured characteristic deviates from the desired target range. 
The target range and boundaries for the zones are based on established reference intervals 
and decision limits. Like the performance function proposed for the n-type characteristic, 
the performance loss is due to mounting medical complications associated with the 
measured characteristic and increased risk for future health complications. Once the 
deviation surpasses an upper specification limit the loss value is set at a constant L. 
Figure 3.10 illustrates an s-type medical characteristic which spans three zones of health 
risk. 
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Figure 3.10. Performance Step Function for a Smaller-the-Better Type Characteristic.  
The mathematical form the performance step function for the s-type characteristic 
would be as follows: 
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The performance step function maps the value of a physical measurement to 
performance loss. The drawback of using a step function is that it is not sensitive to 
changes in a patient’s measurement when the measurement remains within the same 
zone. As long as the measurement of the characteristic does not leave a zone, the 
performance loss will be the same for all measurements within the zone. The next section 
will propose an alternative to the s-type performance step function that allows for more 
sensitive means of articulating the performance degradation (health risk) of the patient. 
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3.4.3.2 Healthcare: Performance Function for Smaller-the-Better Type 
Characteristic 
 
In this section, we will look at altering the s-type performance function to be more 
sensitive to changes in the health measurement. Figure 11 illustrates the s-type 
characteristic with three levels of risk. Zone 1 represents the low risk area and is defined 
as the normal range for the measured characteristic. Within this range, a patient’s 
measurement falls within the published reference interval. As the patient’s reading 
increases above the published range, the patient’s risk for additional health complications 
increases. In zone 2, the increasing loss line is illustrative of the physical performance 
loss experienced by the patient. Once a patient’s reading reaches zone 3, the patient is at 
high risk for additional health complications. 
 
Figure 3.11. Performance Function for a Smaller-the-Better Type Characteristic 
The mathematical form of the performance function for an s-type medical 
characteristic would be as follows:  
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3.4.4 Healthcare: Larger-the-Better Type Characteristic 
The last type of health characteristic to be defined is the l-type medical 
characteristic. In this case, the patient’s performance peaks when the measured value is as 
large as possible. L-type characteristics have a lower specification limit with an ideal 
target at infinity. Below are three examples of l-type characteristics found in the medical 
domain. 
a. High-density lipoproteins (HDL): Lipoproteins help move lipids, fat molecules, 
around the body. HDL, one of the five major types of lipoproteins, helps to 
remove fat molecules from cells to the liver. A lipid panel is used to determine the 
amount of HDL in the body. A healthy amount of HDL is determined to be 
greater than 60 mg/dL. Patients with less than 40 mg/dL are considered to be at 
high risk for heart disease(Mayo Clinic, 2018). Patients with at least 60 mg/dL are 
not considered to be at risk for heart disease. 
b. Vo2 Max: A practical example of a larger the better type quality characteristic in 
the healthcare field is the lung capacity of a patient measured as Vo2 max. The 
test determines cardiovascular and respiratory fitness. The greater the test score 
achieved by the patient indicates a greater level of fitness. 
c. Strength: Another quality characteristic of the larger-the-better type could include 
muscular strength. There is no limit on the amount of strength that a person 
should have. A lower bound exists so that a person can perform “daily” tasks.  
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3.4.4.1 Healthcare: Step Function for Larger-the-Better Type Characteristic 
A performance function for an l-type characteristic needs to be able to estimate 
the growing performance loss and increased health risk as the measurement deviates to 
the left of the target range. The target range and boundaries for the zones would be based 
off the reference intervals and established decision limits. Like the performance function 
proposed for the n-type characteristic, the zones reflect a varying level of performance 
loss due to mounting medical complications associated with the measured characteristic. 
Once the deviation surpasses a lower specification limit, the loss value is set at a constant 
L. Figure 3.12 shows an example of a step performance chart for an l-type medical 
characteristic. The example shows an increased risk to the patient’s health and a loss of 
physical performance with a lower reading of the medical characteristic. 
 
Figure 3.12. Performance Step Function: Larger-the-Better Characteristic.  
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The mathematical form of the performance step function for an l-type 
characteristic would be as follows:  
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As stated earlier, the performance step function is a good starting point for 
articulating physical performance of a patient based on a measurement. Like step 
functions used within manufacturing, the step loss function is not sensitive to changes in 
a characteristics measurement if the measurement remains within a defined window. For 
example at the low end of zone 2, the patient’s situation is more precarious than at the 
high end of zone 2 because of the greater probability of moving into zone 3. Using the 
step function, the loss value does not adequately convey that risk to the medical 
professional. The next section will propose an alternative that allows for more sensitive 
means of articulating the performance degradation (health risk) of the patient. 
3.4.4.2 Healthcare: Performance Function for Larger-the-Better Type 
Characteristic 
 
The step function discussed earlier is not sensitive changes in the measured 
physical characteristic within a zone’s boundaries. By altering the form of the 
performance function from a step function to a continuous function, the provider may 
better associate relationship between the measured characteristic and the increased health 
risk to the patient. Figure 3.13 illustrates the performance loss of an l-type medical 
characteristic across three levels of risk. Zone 1 is the low risk area and encompasses the 
characteristic’s published reference interval. Within this range a patient’s measurement 
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falls within the published “normal” ranges. As the patient’s reading decreases below the 
published “normal” range, the patient has an increased risk for additional health 
complications. In zone 2, the line is illustrative of the physical loss experienced by the 
patient. Once a patient’s measurement crosses into zone 3, the patient is considered high 
risk for a decreased physical performance. 
 
Figure 3.13. Performance Function for Larger-the-Better Type Characteristic.  
The mathematical form of the performance function for an l-type medical 
characteristic would be as follows: 
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The above illustrations are merely starting points for further research in this area. 
The most important aspect of this conceptual work is the mapping of a physical 
measurement to associated health risk and the consideration for how the loss 
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measurement could be used by medical professionals. The potential value in this work is 
that it provides a way to articulate the trade space of risk within the medical field.  
3.5 Proposed Bivariate Performance Functions 
3.5.1 Applications of Bivariate Performance Functions 
Both the traditional step loss function and the quality loss function described in 
Section 4 examine performance loss for a single quality characteristic. Given that there 
are possible trade-offs between the different types of characteristics, better insights might 
be obtained from looking at the region of interest for two loss characteristics and the 
resultant mapping of the measurements to a performance valuation. Since the body is a 
complex system, it would be more appropriate to assess treatment options based on sets 
of analyte values instead of in isolation. The use of bivariate performance functions might 
aid medical professionals in evaluating treatment options for multiple symptoms. 
Bivariate performance loss functions potentially may provide an avenue for treating 
medical conditions affecting one physical measurement characteristic using treatments 
whose side effects are known to affect another measurable physical characteristic. With 
the performance loss function, it would be possible to estimate the total performance loss 
before the medication is prescribed. For example, select medicines used to relieve high 
blood pressure can affect the glucose level in the blood stream. In the case of individuals 
with borderline A1c readings, it would be prudent to assess whether using the blood 
pressure medication would push the patient’s A1c past a decision limit. However, use of 
the medication might be useful if it did not push the total performance loss to an 
unacceptably high level. This research is particularly important given the rise of patients 
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diagnosed with multiple ailments and prescribed multiple drugs. The following sections 
lead the reader through investigations of three bivariate cases. These conceptual 
illustrations allow the reader to ponder the possibility of the impact of bivariate 
performance functions. 
3.5.2 Investigation of Two Nominal Type Characteristics 
The use of bivariate performance functions would help medical professionals 
effectively assess the impact of a treatment on more than one physical characteristics. 
Figure 3.14 illustrates the region of interest for two n-type characteristics, A and B. 
Ideally, the patient’s lab results would fall within the recommended reference intervals, 
the area between the LSL1 and USL1. The area in which both characteristics’ 
measurements are within the “normal” reference interval is named the ideal conformance 
region. This region is illustrated by the light grey square in the center of Figure 3.14. If 
either of the patient’s lab result measurements for characteristic A or B exceeds the 
associated LSL1 and USL1 the patient’s performance moves from the ideal conformance 
region into the acceptable conformance region. The acceptable conformance region is 
denoted by a darker shade of grey than the ideal conformance region. Within this area, 
the patient is at an increased risk for medical complications. Decision limits are 
illustrated in this instance as LSL2 and USL2. As stated earlier a decision limit is a 
universally accepted boundary for a specific analyte between “diseased” and “not 
diseased.” While only a few decision limits currently exist, it is expected that more 
decision limits will be defined in the coming years. As either of the patient’s lab result 
measurements for characteristic A or B exceeds the associated LSL2 and USL2 the patient 
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moves into the non-acceptable conformance region. Within this region, the patient will 
experience health complications. The diagram provides a method of visualizing increased 
risk to the patient or decreased performance for multiple characteristics. Treating the 
medical issue as a multivariate problem is both more realistic and safer for the patient.   
 
 
Figure 3.14. Conformance Region for Two Nominal Type Medical Characteristics. 
Figure 3.14 illustrates a bivariate performance step function for two n-type 
characteristics. For this example, both n-type characteristics are symmetric. Like the 
performance step function described for the univariate case, loss is only incurred after the 
characteristic’s measurement exceeds the first set of specification limits. For this 
example, the first set of specification limits is the upper and lower founds for the 
reference interval. The number of specification limits will depend on the number decision 
limits associated with the analyte.  
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Figure 3.15. Bivariate Step Function for Two Nominal-the-Best Type Characteristics. 
Figure 3.15 illustrates a performance function for two, symmetric n-type 
characteristics. Like the performance step function, the value of the performance function 
is zero if the reference intervals are not exceeded for either of the measured 
characteristics. Once either characteristic exceeds the upper or lower bound of the 
reference interval, the performance function takes on a value. The value of the 
performance loss is the distance from the plane connecting the axis for the values of 
characteristic B and characteristic A to the surface curve.  
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Figure 3.16. Bivariate Performance Function for Two Nominal-the-Best Type 
Characteristics.  
3.5.3 Investigation of a Nominal-the-Best Type & a Smaller-the-Better Type 
Characteristic 
Figure 3.16 illustrates the region of interest of an n-type characteristic, A, and an 
s-type characteristic, B. Ideally, the patient’s lab results would fall within the 
recommended reference intervals which are bounded in the illustration by LSL1 and USL1. 
This region is illustrated by the light grey rectangle in the center of the diagram. As the 
patient’s measured characteristics exceed the reference interval limits, the patient moves 
into the acceptable conformance region, the next darker area. If the patient’s values 
exceed the next set of limits, LSL2 or USL2, for either characteristic, the patient moves 
into the “non-acceptable” conformance region. Within this area, the patient has a 
diagnosed health complication.  
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Figure 3.17. Conformance Region for a Nominal-the-Best Type & a Smaller-the-Better 
Type Characteristic. 
Figure 3.17 below illustrates the performance function created by an n-type 
characteristic, A, and an s-type characteristic, B. Ideally, the patient’s lab results would 
fall within the recommended reference intervals, the ideal conformance region bounded 
by LSL1 and USL1 for each characteristic. Within the ideal conformance region, the 
performance loss is zero. As the measurement for the n-type deviates above or below the 
target interval and as the measurement of the s-type characteristic gets larger, the value of 
the performance function increases. While the patient’s values remain between the 
reference interval and the decision limit values, the patient is considered to be within the 
acceptable conformance region. Once the one of the patient’s lab results indicate that a 
decision limit has been passed the patient moves into the non-acceptable conformance 
region. The figure illustrates that the value of the performance increases between the 
established limits. The goal of medical professionals is to treat a patient so that the 
overall performance function is minimized. 
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Figure 3.18. Bivariate Performance Function for a Nominal-the-Best Type & a Smaller-
the-Better Characteristic.  
3.5.4 Investigation of a Nominal-the-Best Type & a Larger-the-Better Type 
Characteristic 
Figure 3.18 illustrates the region of interest for the interaction of an n-type 
characteristic, A, and an l-type characteristic, B. In the ideal conformance region, both 
measured characteristics are within the established “normal” region. This region is 
illustrated by the light grey rectangle in the center of the diagram. As either of values for 
characteristic A or B passes the first set of specification limits, the interaction between the 
characteristics enters the acceptable conformance region. The next set of specification 
limits, as shown on the diagram with a subscript 2, is associated decision limits with the 
measured characteristic. As either of values for characteristic A or B passes the second set 
of specification limits, the interaction between the characteristics enters the non-
acceptable conformance region 
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Figure 3.19. Conformance Region for a Smaller-the-Better Type & a Larger-the-Better 
Type Characteristic.  
Figure 3.20 below illustrates the performance function created by an l-type 
characteristic, A, and an s-type characteristic, B. Ideally, the patient’s lab results would 
fall within the recommended reference intervals, the ideal conformance region bounded 
by LSL1 for characteristic A and USL1 for characteristic B. Within the ideal conformance 
region, the performance loss is zero. As the measurement for the l-type characteristic gets 
smaller than LSL1 or the measurement for the s-type characteristic increased above USL1, 
the value of the performance function increases and the patient enters the acceptable 
conformance region. While the patient’s values remain between the reference interval and 
the decision limit values, the patient is considered to be within the acceptable 
conformance region. Once one of the patient’s lab results indicate that a decision limit 
has been passed the patient moves into the non-acceptable conformance region. The goal 
of medical professionals is to treat a patient so that the overall performance function is 
minimized. 
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Figure 3.20. Bivariate Performance Function Conformance Region for a Smaller-the-
Better Type & a Larger the Better Type Characteristic.  
3.6 Conclusion 
With the involvement of a diverse and innovative team that spans the entire 
scientific community, the promise of precision medicine has the best chance of becoming 
a reality. The purpose of this initiative is to assist medical professionals to more 
accurately predict the best prevention measures and treatment strategies for a specific 
disease for an identified group of people. While traditionally involved in solving 
manufacturing problems, quality engineers have a critical role to play in the development 
of precision medicine. The purpose of this paper was to initiate a dialogue about how to 
apply existing quality engineering methodologies to healthcare. Specifically, this paper 
looked at how to adapt the concept of quality loss functions first developed by Taguchi 
for use in valuing performance loss and increased risk for future medical complications 
given biometric measurements. The proposed performance function provides medical 
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professionals with a quantitative means of relating changes to physical measurements to 
an individual’s overall health. As stated earlier, the most important step in adapting 
traditional quality engineering methodologies for use within healthcare is in identifying 
the defining the differences in the problem construction between manufacturing and 
healthcare. Each identified difference presents an opportunity for the quality engineer to 
either validate the universality of the methodology or to suggest an alternate methodology.  
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CHAPTER FOUR 
DECISION MAKING IN HEALTHCARE USING ROBUST DESIGN WITH 
CONDITIONS-BASED SELECTION OF REGRESSION ESTIMATORS 
 
This chapter has been published in Quality and Reliability Engineering International and 
should be cited as:  
 
Pegues, K. K., Boylan, G. L., & Cho, B. R. (2017). Decision making in health care using 
robust parameter design with conditions‐based selection of regression estimators. 
Quality and Reliability Engineering International, 33(8), 2151-2169. 
The foundation for the aforementioned publication was the joint work with Boylan, G. 
(2013). 
Boylan, G. (2013). Robust Parameter Design in Complex Engineering Systems. (Doctoral 
dissertation). Retrieved from Tiger Prints, Clemson University. 
4.1 Introduction 
 
4.1.1 Research Motivation and Scope 
 
Robust Parameter Design (RPD) is an engineering philosophy and statistical 
method used to determine the optimum conditions that bring the mean process 
performance towards the desired outcome target with minimum process variability. 
While the RPD methodology has been applied mainly in the manufacturing sector, we 
believe that this methodology has the potential for greater impact within the healthcare 
domain. Since tackling RPD problems for healthcare sector is a multistage effort, the 
purpose of this paper is to provide clarification on estimator selection when high 
variability and asymmetry dominate healthcare process outputs. In particular, a variety of 
alternative regression approaches are examined via experimental analysis and simulation 
to determine which methods produce the best solutions. 
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This chapter provides readers a clear, conditions-based approach for the 
application of RPD when the conditions of either asymmetry or a high degree of process 
variability cannot be ruled out. This work is an extension of previous efforts to examine 
situations in which the parameters needed for ordinary least regression (OLS) fail to hold. 
Data analysis can illuminate intrinsic process conditions that should inform selection of 
the regression estimation method. In a parallel paper Boylan and Cho (2012) examined 
distributional characteristics in the context of the four sample moments and investigated 
how variations in those moments affect the normal probability plot, focusing on the 
presence of skewness and kurtosis in the data under study. In that instance, residual-based 
assumptions supporting the use of OLS regression were assumed to hold to facilitate 
comparisons between the estimators considered. The paper also examined how the 
validity of assumptions associated with underlying populations impacts the resultant 
statistical analysis of the data. Many of the statistical procedures commonly utilized 
within quality engineering literature are based upon the assumption of normality. The 
assumption of normality, although helpful for tractability, may not reflect reality for 
healthcare applications. As the research community develops a deeper knowledge of 
medical conditions and underlying causes, a parallel effort within the engineering 
community should focus on developing better methodologies for dealing with non-
normal distributions and asymmetry. The ramifications of utilizing faulty analysis can 
include increased cost to the organization, physical harm to the patient, or a combination 
thereof. Given that asymmetry naturally exists in situations involving smaller-the-better 
(s-type) and larger-the-better (l-type) healthcare quality characteristics, the use of a 
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normal distribution for modeling healthcare outcomes may not be appropriate when 
asymmetrical effects become amplified and are coupled with elevated degrees of process 
variability. A variety of alternative approaches to regression estimation exists and is 
documented in both statistics and regression-based literature. This chapter explores the 
performance of existing regression estimation techniques under varying process 
conditions with the aims of creating renewed interest in alternative approaches. To 
simulate asymmetric conditions, a skew normal distribution is integrated into the 
research. This distribution, also known as an asymmetric Gaussian curve, generalizes the 
normal distribution to allow for non-zero skewness. 
The combination of experimental investigations and simulation allow us to 
evaluate which regression approach performs best in terms of producing the best results 
under examined conditions. A sequence for implementing this approach is portrayed in 
Figure 4.1. Monte Carlo simulation and numerical case studies are used in Section 4.3 to 
provide clarification as to which estimators should be considered in Phase Ib. In Section 
4.2, a proposed healthcare specific methodology is developed using the skew normal 
distribution as the basis for modeling system attributes. In Section 4.3, the numerical 
demonstration provided is composed a case study with Monte Carlo simulation. Finally, 
in Section 4.4, the results are analyzed. 
4.1.2 Robust Parameter Design: Development and Application 
 
Although many researchers endorse the philosophical arguments behind 
Taguchi’s (1986, 1987) original version of RPD methods his mathematical approaches 
have generated criticism. The differing viewpoints of the research community regarding 
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the validity of Taguchi’s assumptions, the varying assessments as to the effectiveness of 
the approach, and the associated analytical methods are thoroughly documented by many 
researchers, including include Box (1988) and Tsui (1992). A review of the RPD 
literature since 1980 reveals that a majority of the work focused on alternative 
optimization techniques. The degree to which a response surface yields a “good fit” is 
contingent the correct identification of the prevailing conditions of the sampled data and 
the appropriateness of the method used to develop the fitted model. Researchers, by 
proceeding forward into the optimization phase of research, are endorsing that that the 
parameter estimates are sufficient for use, that estimates are obtained using appropriate 
estimators, and that prevalent conditions within the data support the chosen parameter 
estimator technique. 
 
Figure 4.1. Methodology process map for healthcare applications. 
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A review of statistics-based literature highlights the variety of existing regression 
estimation methods. The volume of literature focused on alternative estimation 
approaches quantitatively demonstrates the need for better results than those found with 
OLS. Many of these alternatives were developed to overcome issues associated with 
outliers, contaminated data, non-normality in the responses and/or residuals, and 
heteroscedasticity. The spectrum of estimation methodologies includes data 
transformations, generalized linear models (GLM), the weighted least squares (WLS), and 
an assortment of various resistant and robust regression techniques to include least 
trimmed squares (TLS), least absolute deviation (LAD), M-estimation, M-M estimation, 
and S-estimation. A selection of these methods will be discussed in greater detail in 
Section 4.3.3. 
To overcome non-normality of a data sample, researchers applied transformations 
on the response (Y) or utilized GLMs. As Ryan (2009) observed, the drawback is that the 
use of transformations can induce change in both the distribution of data about the 
regression line and the vertical spacing of the observed values. Since the need to 
transform data may stem from a few influential observations, researchers are urged to use 
caution as they proceed. GLMs, another approach for dealing with non-normality, have 
received considerable attention as a practical alternative to transformations (Myers et al., 
2002, Myers et al., 1997). The critical aspect of GLMs is the use of a smooth monotonic 
link function  from any distribution within the exponential family. In a 
sense,  acts like a transformation and link functions transform  rather than  
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itself. Therefore,  transforms the systematic part of a model without altering the 
distribution of the associated random variation. 
Published papers have aimed to determine the limitations of estimation 
approaches and performed limited comparisons between alternatives. Several research 
efforts examined the performance differences between select estimation approaches 
(Koutrouvelis et al., 2000; Bera et al, 2002). Other research efforts investigated robust 
estimators (Muhlbauer et al., 2009; Hamada et al., 1997). These works focused primarily 
on statistical measures (relative efficiencies, breakdowns, and robustness) to establish the 
superiority of one method relative to other methods. Interestingly, whereas GLMs have 
seen attention in the RPD literature, comparatively few RPD-specific efforts have 
explored the various resistant regression methods as viable alternatives for determining 
optimal solutions. Among those that have, the process conditions examined focus 
predominantly on outliers, non-normal (but symmetric) response distributions, and 
unbalanced data sets. Table 4.1 summarizes several of the more contemporary research 
efforts found in the RPD literature, which are addressed in some detail in the following 
paragraphs. 
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Table 4.1. Summary of works examining estimator selection in RPD problems. 
 
Researchers  Year Conditions Examined 
Regression Estimators 
Compared 
Simpson & 
Montgomery34 
1998 Outliers under normality 
OLS, M, most-B robust, LTS, S, 
M-M, various versions of 
Generalized M 
Lee & Nelder35 2003 
Non-constant variance and non-
identity (Gaussian) link 
functions 
GLM 
Cho & Park36 2005 Unbalanced datasets OLS vs. WLS 
Ch’ng et al.37 2005 
Non-normal responses and 
outliers 
OLS vs. M-M  
Robinson et al.38 2006 
non-normal (gamma) and 
batch-to-batch variation 
(random block design) 
GLMM  
(gamma with log link) 
Lee et al.39 2007 
Outliers, non-normal symmetric 
distributions 
OLS vs. M-M 
Goethals & Cho40 2011 
Heteroscedastic conditions and 
unbalanced data 
OLS vs. WLS  
 
Regarding GLMs, Lee and Nelder (2003) examined their use as a generalization 
of data transformation and RSM approaches that allowed for “arbitrary variance and link 
functions.” In a more recent effort, Robinson et al. (2006) examined generalized linear 
mixed models (GLMM) in an RPD context to address the non-normality encountered with 
a resistivity quality characteristic by using the known distribution for the response 
(Gamma) combined with a log link. While the results in each of these works clearly 
demonstrated the potential benefits of utilizing GLMs, they were not necessarily 
comparative studies.  
The remaining works shown in Table 2.1 pertain to more direct comparisons 
between traditional and robust regression approaches. Simpson and Montgomery (1998) 
examined alternative regression techniques when dealing with outliers within normally-
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distributed data. However, this study focused more on statistical estimator performance 
measures such as efficiency, consistency, and breakdown points rather than optimal RPD 
solutions obtained through application. Cho and Park (2005) considered RPD solutions in 
the case of unbalanced data and proposed the integration of a WLS approach. The 
proposed weighting scheme was based upon the quantity of observations at each design 
point and value at the design point is inversely proportional to the variance associated 
with the response surface functions obtained for the process parameters. In the interest of 
finding better optimal settings in dual-response surface optimization problems when non-
normal conditions and/or outliers exist, Ch’ng et al. (2005) compared OLS to the M-M 
robust estimation technique developed by Yohai (1987). In the examination of estimators 
in RPD involving contaminated data, Lee et al. (2007) also included a comparison of the 
OLS method to the M-M regression technique. It is worth noting that the non-normal 
conditions examined in both of these cases focused on symmetric distributions. Goethals 
and Cho (2011) extended the work of Cho and Park (2005) to the optimal process target 
problem. Their work considered heteroscedastic conditions in addition to the unbalanced 
data case. 
 
4.2 Potential Applications of RPD in Healthcare Environments 
In an ideal world, medical treatment for a particular issue will have a beneficial 
impact on patients. For each instance, a patient would discover a problem, would then be 
diagnosed, a treatment plan outlined, and the patient is cured of the initial recognized 
ailment. This simplified scenario is not today’s reality. Healthcare is a complicated, 
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complex system in which a large number of factors to include a patient’s health, current 
intuitional knowledge regarding  complaints, resource allocation, provider skill, the 
limitation of known developed protocols as well as other factors which play a role in final 
outcomes. The combination of compelling emotional medical narratives and the 
increasing costs of healthcare has spurred governmental agencies, public and private 
business ventures, and research and development teams for both industry and academia to 
focus on decreasing the cost (emotional and financial) of healthcare to society at large. 
As written, the “cost of healthcare” denotes the sum total cost of healthcare for both 
treated and untreated diseases and preventive measures for all aspects of health.  
With a common goal of improving healthcare, powerful stakeholders for the US 
healthcare system are seeking efficiencies that will improve care and reduce overall costs. 
Another change to the United States’ medical system has been brought about by 
technological advances of the computer age. Medical records are in the process of being 
digitized and the large swaths of data for medical procedures and vital statistics are 
available for research. The large data repositories by controlled agencies such as the 
National Institute of Health have enabled research teams to start dissecting complicated 
issues such as cancer treatment and diabetes management. Research teams are also 
working to improve other aspects of healthcare from operating room efficiency to 
prosthetic development. At regional and local levels, management teams are working to 
make hospital systems operate more efficiently. These parallel, and for most cases, 
unlinked efforts improve healthcare in small ways on a daily basis. Small changes 
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improve lives, but the question of how healthcare policies, both nationally and locally, 
should be established so that each patient has the optimum chance of recovery remains. 
To the best of our knowledge, it is believed that one of existing methodologies 
that could significantly impact patient recovery is design of experiments (DOE). The 
application of DOE is not new in the healthcare industry and its professional workforce 
has long understood important roles of carefully-designed experiments. The most widely-
used DOE tools are perhaps full factorial designs and fractional factorial designs with 
several factors, each at two discrete levels, in order to study the effects of main factors 
and interactions between those factors on the response variable of interest. When the 
number of levels becomes more than two, the number of experimental runs required 
considerable increases; thus, it becomes less feasible from the perspective of costs 
incurred and resources available to complete the whole experiment. In addition, when 
those two-level factorial designs are used, one of the fundamental assumptions is that the 
effects between the two levels are linear. The advancement of precision medicine relies 
on the adoption of evidence-based practices and process validation. Both linear and 
quadratic effects of factors and interactions are often inherent within healthcare data. 
Capturing those effects can be effectively done by the central composite design and 
obtaining optimum conditions through the RPD process. 
The methodology for RPD is broken down into two phases. The first phase 
includes the identification of the primary quality characteristic, influential control factors, 
possibly noise factors, and the experimental region of interest. Control factors are those 
that affect outcomes. In the case of a healthcare system, they include the amount of drug 
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that a patient is provided or the existence of known, and genetic traits of a patient. Noise 
factors are those factors that may not be controllable or very costly, if they can be 
controlled, from the point of view of the system. For a healthcare example, those could be 
a patient’s diagnosis, the patient’s satisfaction with the benefits provided by his or her 
insurance company, or the length of the patient’s trip to the hospital. The idea is to find 
optimum conditions for the control factors for which changes along the range of noise 
factor values affect healthcare outcomes as little as possible. While in this phase, 
observations are collected in a replicated design framework and data analysis is 
performed. The outcome of this phase is an approved model for the quality characteristics 
of interest. These models are then used to determine optimum conditions which allow the 
system to reach close to a specified target with minimum variance. 
A comprehensive literature review shows that the RPD concept has not been 
applied rigorously in healthcare environments. Some potential applications of RPD for 
healthcare decision making are outlined below. 
Patient Adherence to Treatment Plans: It has been estimated that less than 60% of 
prescribed treatment plans are followed by patients. Why, if the patient has sought out 
medical advice, is the final treatment plan not being followed? Possible factors could 
include the treatment costs, insurance benefits, medical severity, social factors, and risk 
of being admitted. RPD could help doctors determine optimal conditions, or 
hospital/insurance policies, which would achieve a target adherence rate with minimum 
variability. 
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a. Incentive for Preventative Treatments. RPD could potentially provide insights on 
how to increase the use of preventive care services made available through 
insurance programs, community wellness programs, or direct government 
funding. What services or incentives need to be offered to reduce the impact of 
uncontrollable factors on the use of preventive care?  
b. Gauging Risk. RPD could provide an avenue to make assessments on the amount of 
risk (variance) that stakeholders are willing to take on. If the quality characteristic 
being studied is the effectiveness of a treatment, then being on target means that 
the patient is being effectively treated. As it is further away from the target, 
greater costs will be incurred by the healthcare system. Also, a smaller variability 
implies a less risk that the health industry is willing to take on. 
c. Improved Resource Allocation. During the first phase of RPD, stakeholders gain a 
better understanding of specific control factors that influence the quality 
characteristic of interest. By exploring the interactions, stakeholders will have a 
better idea of how to allocate scare resources to improve the overall quality of 
healthcare.  
4.3 Proposed RPD Modeling and Optimization Procedures 
4.3.1 Experimentation and Analysis 
Consider a situation in which we need to obtain the optimal conditions for which a 
patient can safely undergo surgery without further compromising health. A clinician 
might be interested in determining the range for a patient’s body composition, resting 
heart rate, and possible other mitigating factors that must be met prior to commencing the 
 125 
procedure. To that end, consider a replication-based experiment conducted with the intent 
to find optimal factor settings, x=( that achieve the desired target outcome, 
with the least variability. In this case, the quality characteristic of interest, Y, is suspected 
to be influenced by a set of control factors or x. The research team will define an 
experiment region which is bounded by the minimum and maximum values for each of 
the control factors. The experiment consists of m x n trails where m is the number of 
replications for each specified design point, n. For each design point, the values of the 
control variables are set to predetermined levels. Let  denote the jth response at the qth 
design point, where q = 1, …, n and j = 1, …, m. The tabular layout of a replication-based 
design of experiment is depicted in Table 2.2. 
 
Table 4.0.1 Design of Experiment 
Design 
Point 
 Replications y  s 
  
1  
  Control 
  factor  
  settings 
y11………y1j…….y1m 1y  s1 1  
                               
q yq1………yqj......... yqm qy  sq q  
                               
n yn1………ynj………ynm ny  sn n  
 
Parameter estimates for the data are found through analysis of the data collected 
at each design point. The estimates include both sample mean, , and standard deviation, 
s. If the distribution is suspected to be non-normal, the sample skewness, γ, can also be 
calculated to account for the asymmetry in the responses. Parameter estimates at each 
design point for a sample are found using the following equations: 
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(1) 
The next step is to develop response surface functions for the select parameters of 
interest that are valid throughout the experimental region. To start, a comprehensive data 
analysis of the sample responses and the residuals, the difference between the model and 
the sampled responses, is conducted to verify assumptions regarding the underlying 
distribution. The analysis of the responses should include an investigation of normality 
and variability. The analysis of the residuals should include verification of the 
assumptions of normality, homoscedasticity, and independence. Investigators have the 
option to use graphical methods, numerical methods, and formal normality tests. Two 
approaches are briefly explained in parts (i) and (ii) below: 
(i) Assessment of Normality and Variability. To assess normality in a set of 
responses, the three most common tests are the Kolmogorov-Smirnov test, the 
Anderson-Darling test, and the Shapiro-Wilk test. Generally, due to a variety of 
reasons including experimental costs, the sample sizes obtained in RPD 
experimentation typically small. Thus, for the Shapiro-Wilk test using the W 
statistic given by  where  may 
be a reasonable choice for testing  and . The 
term p is defined as the number of observations sorted in ascending order,  is the 
largest integer that is less than or equal to p/2, and s denotes the sample standard 
deviation. For a given significance level , tables are then used to reference the 
coefficients a, and the critical values W. If W* > W, then insufficient evidence 
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exists to reject the assumption of normality. One drawback to objective tests is that 
if the normal assumption is rejected, the test provides no additional information 
regarding the underlying distribution of the data. As discussed by Boylan and Cho 
(2012), graphical measures, such as normal probability plots, may be useful tools 
to overcome this shortfall and to provide more salient information about the data. 
For example, normal probability plots often illustrate whether the distribution is 
symmetric or asymmetric, the degree of positive or negative skewness, the degree 
of variability, and the degree of kurtosis.  
Determining whether a process is highly variable is a more subjective assessment. 
According to Willinger et al.(2004), high variability may be loosely defined as a 
phenomenon by which a set of observations assumes values that vary over orders of 
magnitude, with most taking closely grouped values, a few assuming extreme values that 
deviate considerably from the first group with non-negligible probabilities, and 
intermediate observations occurring with appreciable frequencies. In general, a trademark 
of highly variable data is that the sample standard deviation is quite large. This result 
implies a “largely uninformative” sample mean that does not adequately describe the 
location of the bulk of the observed values. Using this concept, we classify a highly 
variable process as one in which the range of variability in the responses is noticeably 
large and where one or more of the responses lies more than three standard deviations 
(+/– 3) from the mean response. 
(ii) Residual analysis. As with the responses, normality in the residuals may also 
be examined using graphical measures such as the normal probability plot. Additional 
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complementary, objective methods are provided by the Kolmogorov-Smirnov or the 
Shapiro-Wilk tests. To investigate independence, the Durbin-Watson test is usually 
sufficient to detect a lack of randomness in the residuals. Should remediation be 
necessary, two possible options are the addition of predictor variables or use 
transformations in the variables to eliminate interdependencies. Finally, 
heteroscedasticity, or non-constant variance, is often investigated graphically using a plot 
of the residuals against the fitted values, as well as objectively using either the Brown-
Forsythe test, which is more robust to departures from normality in the data, or the 
Breusch-Pagan (B-P) test. The B-P test assumes independence and normality among the 
residuals. The test also assumes a relationship for the error variance among the k 
regression coefficients and k-1 predictor variables that in the form 
. As can be seen, the error variance fluctuates up 
or down with x, based on the sign of the associated coefficients. Constant error variance 
corresponds to the instance where constrained coefficients in response function equal 0, 
the alternative hypotheses  versus : not all  are tested 
using the statistic, , in which Nm denotes the total 
number of experimental observations, SSR* is the regression sum of squares obtained by 
regressing the squared residuals, and SSE is the error sum of squares obtained for the full 
regression model. If  then we reject H0 and conclude that sufficient 
evidence exists to support non-constant variance. In processes with high variability or 
asymmetry in the responses, the assumption of constant variance in the residuals would 
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most likely not hold. This situation would necessitate the use of remedial measures, as 
outlined in Section 4.3.3. 
4.3.2 Modeling Symmetry and Asymmetry 
In traditional RPD applications, asymmetric conditions typically observed in the 
univariate s- and l-type problems are often modeled via a normal distribution. Ideally, it 
would be preferable to use a distributional model capable of supporting both the 
symmetry usually assumed in the n-type model, as well as the asymmetry of the s-, l-, and 
certain n-type models. This would become particularly important if extending the 
problem to the multi-response case. Although some common distributions, such as the 
gamma, Weibull, and unbounded Johnson distributions, can effectively portray processes 
with innate skewness, these distributions present challenges in modeling normality when 
small skewness exists. 
Due to an inherent relationship to the normal distribution, the skew normal (SN) 
distribution provides a suitable alternative for modeling both symmetric and asymmetric 
situations. First introduced by O’Hagan and Leonhard (1976) and addressed more 
recently by Azzalini (1985), Azzalini and Dalla-Valle (1996), and Arellano-Valle et al. 
(2004), the skew normal distribution extends the normal distribution by incorporating a 
third parameter, , as a shape parameter to account for non-zero skewness. The 
probability density function for the skew normal relative to the normal distribution is 
given by: 
     | 2 ,f x x x x     , 
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where ϕ(x) and Φ(αx) correspond to the probability density and cumulative distribution 
functions of the normal distribution, respectively. Recall that the normal probability 
density function for some random variable Z with parameters  and 2 can be rewritten in 
terms of the standard normal density function 
2
22
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We can easily extend this by adding location () and scale () parameters to the density 
function, using the transformation x→(x-ξ)/ω. This yields:  
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(3) 
When  = 0, the skew normal distribution reduces to the normal, making normality a 
special case of the SNdistribution. From Azzalini (1985), the mean and standard 
deviation of a SN() distribution are given by: 
            
  ˆ  = 2E y                                                                                    (4) 
 2 21 2s    
                                                                                     (5) 
Where δ = . The SN distribution is a relatively new distribution compared 
to the more commonly observed family of continuous distributions. Since it derives from 
the normal distribution which remains widely used for n-type characteristics, its extension 
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to s- and l-type characteristics, as well as certain instances of n-type characteristics, may 
help to overcome many  modeling complexities encountered in asymmetric situations. 
As Goethals and Cho (2012) showed, modeling system properties with the skew 
normal distribution can be achieved by initially calculating estimates for the first three 
sample moments (mean, standard deviation, and skewness) for the qth design point. In 
Table 2, the sample mean  and standard deviation sq then correspond to the location 
(q) and scale (q) parameters at the qth design point. Thereafter,  and sq estimates are 
used to derive estimates for the skew normal process mean and standard deviation by 
applying them to Equations (4) and (5) as follows: 
( ) q
ˆ  = 2q SN q qy s                                                                             (6) 
 2 2( ) 1 2q SN q qs s                                                                           (7)  
Here, the parameter q is estimated using the sample skew. In short, using an alternative 
formulation for sample skew provided by Azzalini (1985), an estimate for q can be 
derived as follows: 
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where the sign of  determines the sign of q. For the purposes of simulation, the 
estimate for q may then be used to estimate the shape parameter directly by rearranging 
the previously stated relationship in the following way: 
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This step is necessary within the R environment as the shape parameter and sample skew 
are scaled differently in the context of the skew normal distribution. As Equations (6) and 
(7) suggest, the estimates for the process mean and standard deviation are influenced by 
the inclusion of the sample skew. By using this methodology, we ensure that inherent 
process skewness is accounted for in the final response surface estimates, and that actual 
process characteristics are more accurately represented. 
4.3.3 Selecting an Appropriate Regression Estimator 
Prior to completing a comprehensive analysis, a research team needs to evaluate 
regression estimation methods and decide on which one to implement. For many groups, 
OLS is chosen due to familiarly as well its ubiquity in past research efforts. To obtain an 
optimal RPD solution, we advocate that teams instead match the regression estimation 
method with the inherent underlying conditions of the dataset. Table 2.3 below lists the 
ten methods selected for analysis. In the subsequent paragraphs, a brief synopsis of each 
alternative method is provided. 
Table 4.0.2. Regression Estimators examined as potential RPD alternatives.  
 Methods for Determining Regression 
Estimator 
Base Case OLS  
Alternatives  
for  
Comparison 
1) GLM (gamma or inverse Gaussian model) 
2) OLS (SN) 
3) WLS ( y and s) 
4) WLS (median and MAD) 
5) Least trimmed squares (LTS) 
6) S-estimation 
7) Least absolute deviation (LAD) 
8) M-M estimation  
9) M-estimation (Huber Proposal 2) 
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In early research, Kutner et al. (2003) stated that asymmetry and high variability 
would likely bring about non-constant variance. If this is the case, then OLS standard 
errors are potentially inaccurate and statistical inferences based on the results could be 
potentially misleading. Thus, an alternative method may provide a better estimate for the 
regression coefficient. 
The first alternative approach considered is that of the generalized linear model 
(GLM). The GLM is the conventional regression approach for data sets exhibiting non-
normality. When applying the GLM method, a practitioner needs to specify the linear 
predictors’ distribution and select an appropriate link function, g(∙). For the purposes of 
this research effort, the GLM method utilizes a gamma or an inverse Gaussian. These 
distributions are suitable for modeling varying degrees of asymmetry. Link functions 
transform the expected value of the response to the linear predictor and assume the form 
. By using GLMs, the selection of the link 
function is distinct from the distributional assumption. Although a wide variety of link 
functions exist, this research is limited to those listed in Table 2.4. 
Table 4.3. Applicable link functions for the gamma and inverse Gaussian distributions. 
Link Function i = g(i) Gamma 
Inverse 
Gaussian 
Identity i       X            X 
Log logei       X            X 
Inverse i-1       X*            X 
Inverse-square i-2             X* 
* denotes the default link used by the glm()function in R. 
 
Process conditions influence the selection of both the distribution and link 
functions. Individual distributions have recommended link functions that typically 
produce preferable mathematical and numerical properties. Given a suspected 
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distribution, practitioners should be cautioned to take the underlying process conditions 
for a particular set of data into consideration prior to using the traditionally associated 
link functions. For example, in many applications, the gamma distribution is paired with 
the inverse link. Consider a case in which the response y increases somewhat linearly 
with control factor . If the variance appears to increase with the square of the mean, 
then the gamma distribution could be paired with the identity link. When choosing the 
appropriate link response, researchers should select the GLM model that results in the 
lowest Akaike information criterion value, or in other words, the smallest residual 
deviance. This recommendation is based on the fact that the response deviance is 
similarly scaled for models created with the GLM method. 
When dealing with asymmetric conditions, two factors bear considerable 
importance. First, depending on the degree of variability and skew, the mean will shift 
away from the central tendency of the distribution. Secondly, the standard deviation may 
not accurately describe the dispersion in the distribution as it tends to be significantly 
affected by the “play” in the skewed or long tail of the distribution. When the data 
contains outliers, the effects would worsen. For these reasons, an alternative method of 
weighted least squares (WLS) is also examined in this paper. The WLS method was 
among the first to tackle how to perform analysis taking residuals into account. The 
method of WLS, developed by Aitken in 1935, alters the value placed on data dependent 
on the deviance of the residual. If the residual of the qth point is relatively small, then it is 
assigned a relatively large weight. On the other hand, if the qth residual is large, the 
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impact of the outlier will be reduced utilizing a smaller associated weight. The WLS is 
described with the following equation:  
2
ˆ
1
Minimize




n
q q
q
w
                                                                    (8) 
where  denotes the residual associated with the qth design point given by .  
The term yq refers to the sample mean if there are multiple replications per design point. 
For cases in which the data is assumed symmetric, the mean is typically the “starting 
point” or the value what has the greatest probability of occurring. However, in cases 
where asymmetry is suspected, the two options for alternate “starting points” are median 
and median absolute deviation (MAD). To illustrate this point, consider the comparison of 
probability densities for samples drawn from a skew normal distribution and a normal 
distribution with the same mean shown in Figure 2.2. For the sample with a normal 
distribution, the mean value corresponds to the peak in the density function. For the 
sample with this particular skew normal distribution, however, the mean lies to the right 
of the preponderance of probabilities. Therefore, in this case, the mean does not have the 
greatest likelihood of occurrence. However, an alternate measure, the median, occurs 
close to the peak of the distribution. This example illustrates that while the mean 
certainly defines the population’s central tendency for any distribution, the mean does not 
necessarily correspond to greatest likelihood if asymmetry is present. 
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Figure 4.1. Comparison of normal and skew normal densities with the same sample 
mean.  
Based on the conditions of asymmetry and variance examined in this paper, the 
weights for the WLS method are determined in a manner similar to that used by Goethals 
and Cho (2011). That is, observations possessing less variance receive greater weight. 
Denoting  as the vector of residuals,  in the general form of the 
standard regression model in which Y is the vector of responses, X is the 
design matrix, and β is the vector of estimated regression coefficients, in the case of non-
constant error variances, we may rewrite the  covariance matrix as:  
1
2
( ) 0 0
0 ( ) 0
( )
0 0 ( )n
Var
Var
Var
Var



 
 
 
 
 
 
ε
 
Since  for each of n components of  the variance of the qth component 
is equal to the expected value of the squared error of the qth component, or 
.  In practice, a vector of squared residuals is used to estimate the error 
variance. By regressing the squared residuals against the predictors in X, the fitted values 
of the resultant variance vector, φ, establish the n design point weights, wq. As the 
weights as inversely proportional to the error variance with the value of the weight, the 
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relationship is defined as . Articulating the weights in this manner reduces the 
effects of high variability exerted by large residuals. If the error variance is large, then the 
associated weight would be comparatively small. Utilizing this method, the WLS 
estimator can be written as . To ensure minimal model error, the 
procedure introduced by Goethals and Cho (2011) uses an iterative approach to reweight 
the model parameters using subsequent estimation of the error variance. For this method, 
the algorithm either stops once either convergence is achieved or when the difference 
between the standard error for each of the estimated coefficients in is quite small 
relative to the standard errors obtained in the previous iteration. 
The remaining regression alternatives listed in Table 2.3, alternatives 5-9, consist 
of variants of robust regression methods. These methods were developed to address the 
disproportional influence of outliers on the response surface functions. The term “robust” 
describes an estimator’s ability to overcome an outlier’s leverage on the generated 
estimate. Often, outlying responses are classified as anomalies or annotated as potentially 
contaminated. In the healthcare field, it is often hard to conclusively classify an outlier as 
an exception or an indicator of great importance. Robust estimators are particularly 
intriguing because they mitigate the leverage of extreme observations without 
discounting them altogether. The underlying methods for robust regression approaches 
are designed so that violations of supporting assumptions have little impact on the 
regression results. The four robust regression approaches analyzed for this study are S, 
LAD, M-M, and M estimations. 
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It could be argued that the simplest alternative for estimating robust regression 
coefficients the LAD. The introduction of the OLS method supplanted its use and interest 
in the method waned. A resurgence of in the use of LAD started when Karst (1958) 
suggested its suitability for use with data sets containing outliers in comparison to OLS. 
The LAD method minimizes the sum of the absolute values of the residuals, or errors 
between points generated by the regression function and corresponding data points: 
ˆ
1
Minimize
n
q
q




                                                                    (9) 
Although the LAD method proved more robust than OLS, significant outliers can 
still influence the resultant model. This particular shortcoming has motivated increased 
research in the search for more robust approaches. 
One of the earlier efforts was made by Huber (1973) who introduced the M-
estimation for regression. Mathematically, the method focuses on the residuals and takes 
the following form: 
ˆ
1
Minimize log
n
q
q
n s
s



 
 
 

                                                           (10) 
where  = some symmetric function with a unique minimum at 0. If we presume s is 
known and set then the maximum likelihood estimator of the regression 
coefficients β solves the non-linear system of equations , where   
represents Huber’s bounded monotone   function. After some modification, this 
becomes , where  is selected for consistency at normality 
and the embedded tier-one estimates for location and scale are obtained using Huber’s 
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Proposal 2 estimators, which result from solving the following equations simultaneously 
for  and 50 
2
1 1
0      and       
n n
q q
q q
y y 
  
  
    
    
   
 
 
This method has proven to be a viable and efficient estimator that is robust to outliers in 
the response variable. However, it was also found to lack resistivity to outliers. 
Rousseeuw (1984) proposed the least trimmed squares (LTS) method to overcome 
efficiency shortcomings with a previous method (least median of squares (LMS)). The 
objective in this approach involves minimizing the sum of squared residuals over a 
subset, q, of the complete set of n points:  
2
ˆ :
1
Minimize
q
q q n
q




                                                                  
(11) 
In short, the residuals are squared and then sorted in ascending order. Of the n residuals 
in the full set, the (n – q) largest are “trimmed” so that only the residuals from the 
remaining q points are included in the regression. Thus, the (n – q) largest points which 
are not used do not influence the fit. The result is a fit that retains the resistivity 
properties of the LMS method, and it is known to be more efficient. 
Both the LMS and LTS methods involve the minimization of a robust measure of 
the scatter of the residuals. Introduced by Rousseeuw and Yohai (1984) as a means for 
performing robust regression in time series analysis, these methods find a plane or 
hyperplane that minimizes the scale s by obtaining the solution to: 
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                                                           (12) 
In this context, p corresponds to the k-1 predictors and  is typically denoted by the 
integral of Tukey’s bisquare function given by 
6 4 23 3 | | 1
( )
1 | | 1
u u u u
u
u

   
 
 , 
and c0=1.548 and  = 0.5 are selected for consistency at the normal distribution. This 
method is highly resistant to leverage points, robust to outliers in the response, and is 
often more efficient than the LTS method. 
Yohai (1987) proposed the M-M estimator as an improved alternative that 
essentially blended earlier methods in order to retain the robustness, while gaining the 
efficiency of M-estimation. The M-M method proceeds in three stages. The first involves 
an initial estimation of regression coefficients. In the second, a highly robust and resistant 
S-estimate is computed that minimizes an M-estimate of the scale of the residuals. In the 
final stage, the estimated scale is then held constant, while a nearby M-estimate of the 
regression coefficients is determined. 
4.4 Integrating the Estimators into the RPD Framework 
Pursuant to the selection of a regression estimation approach based upon inherent 
process conditions, fitted response surface functions are then developed for the process 
location and scale. For the purposes of comparison, this is done for each of the alternative 
regression methods outlined in Section 2.3.3, using full second-order polynomial model. 
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Thus, the general form of the estimated response functions with k –1 predictor variables 
is expressed as:  
Location:                                                          (13) 
 Scale:                                                            (14) 
 
1 11 12 1
2 22 2T
1 2 1
/ 2 / 2
/ 2
ˆ ˆ=  , ,   
.
where and
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k
k
k kk
X X X
sym
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1×k k ×kk ×1
X b B
, 
where (and ), (and ), and (and ), reflect the estimates of the 
intercept, first-order, and second-order coefficients of the response surface functions for 
the location and scale, respectively. In addition, the terms and  correspond to the 
residual error for the location and scale deviation, respectively. In order to investigate the 
performance of the fitted functions at estimating a response, a mean squared error (MSE)-
based optimization scheme is used on either a spherical region of interest such that 
, where  is the radius of the sphere, or a cubic region bounded by (-1, 1). Using 
this approach as a framework, each of the models delineated in Table 2.3 are evaluated 
on the RPD solution they produce. 
4.4 Numerical Demonstration via Simulation 
In this section, we examine a case using commonly-applied experimental data sets 
as bases for Monte Carlo simulation. The overarching purpose of the simulation is to 
determine the degree to which underlying process asymmetry and variability (and, 
consequently, non-constant variance) affect estimator performance in the context of RPD 
solutions, which should ultimately serve as a guideline for engineers and healthcare 
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professionals as to which estimators tend to perform best under a particular set of 
conditions. 
This numerical study involves approximately normally-distributed data with 
moderately low variability in which all of the base assumptions concerning the data hold. 
An initial examination is intended to verify expectations regarding conventional 
approaches when assumed conditions hold. Subsequently, through experimentation, the 
impacts of increasing variability on estimator performance are examined. We examine 
four scenarios derived from combinations of high/low asymmetry with high/low 
variability to determine the effects on estimator selection. Within each case study, initial 
results are obtained from the base data and observations are then drawn to assess 
estimator performance. Thereafter, 1,000 iterations of each simulation scenario are 
conducted to facilitate performance trend analysis and assessments regarding estimator 
performance under the evaluated conditions. Simulations were developed in the statistical 
computing environment R version 2.14.1 (2012) which is open source software. For the 
purpose of estimator comparison, each simulation involves several key settings that are 
applied to each estimation model: 
1) Using the actual experimental data, simulated data are derived using the 
skew normal approach. 
2) Full second-order response surface functions are developed for the location 
(mean or median) and scale (standard deviation or MAD) response surface 
functions. 
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3) Optimization results are obtained for each estimation model using the MSE-
based optimization scheme developed by Cho (1994) and Lin and Tu (1995). 
Pursuant to (3) above, estimation approaches are then evaluated based on the optimal 
solutions they generate in terms of deviation from the established process target and 
variability in the result. 
4.4.1 Case Study: Investigating the Effects of Variability on Estimator Performance 
In this experiment, adapted from Phillips et al. (1995) and Shin et al.(2011), 
normally-distributed n-type quality characteristic is of interest. The control factors, X1, 
X2, and X3 are known to influence the outcome Y with the desired target value  = 57.5. 
Using the original data obtained from Shin et al.(2011) and the procedure delineated in 
Section 2.3.2, five replicates were generated at each design point. The experimental 
framework displayed in Table 2.5 is a central composite design (CCD) comprised of 
eight factorial points, six axial points, and six center points, with the calculations for the 
mean, standard deviation, and skewness at each design point. 
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Table 4.4. Experimental framework for Case Study A 
 Coded Units       Metal Removal Rate  
(mm3/min)  Cut Speed Cut Feed Cut Depth  Observed Responses (simulated) 
Run X1 X2 X3 Y1 Y2 Y3  Y4 Y5 Y  s   
1 -1 -1 -1 44.6 52.5 57.4  52.4 57.8 53.2 3.82 0.19 
2 1 -1 -1 63.9 60.3 64.7  65.8 67.5 62.9 3.51 -0.77 
3 -1 1 -1 45.6 51.5 45.4  62.0 52.8 53.4 3.67 -0.24 
4 1 1 -1 67.1 64.5 61.6  58.6 55.5 62.6 3.24 -0.32 
5 -1 -1 1 59.4 55.6 51.4  57.7 59.5 57.3 3.10 -0.11 
6 1 -1 1 67.6 64.6 64.3  71.8 67.4 67.9 4.31 -0.21 
7 -1 1 1 65.5 60.8 60.5  57.2 55.6 59.8 4.47 0.46 
8 1 1 1 67.4 66.5 71.8  68.2 72.0 67.8 3.21 -0.85 
9 -1.682 0 0 58.2 56.1 61.3  65.0 47.3 59.1 4.73 -1.13 
10 1.682 0 0 69.5 63.2 59.3  73.0 61.0 65.9 4.46 0.73 
11 0 -1.682 0 63.2 60.4 59.0  61.0 65.8 60 3.55 -0.16 
12 0 1.682 0 59.5 62.6 61.7  57.3 59.9 60.7 3.10 -0.17 
13 0 0 -1.682 51.7 66.3 57.2  61.9 64.4 57.4 4.29 -1.13 
14 0 0 1.682 65.3 66.1 61.4  72.5 64.2 63.2 5.04 1.32 
15 0 0 0 60.3 56.5 64.1  61.1 60.5 59.2 3.87 -0.03 
16 0 0 0 59.2 66.9 56.7  62.7 57.8 60.4 3.74 -1.18 
17 0 0 0 58.5 59.0 61.2  56.4 57.2 59.1 3.95 -0.08 
18 0 0 0 62.4 53.0 59.6  64.0 56.6 60.6 3.71 0.22 
19 0 0 0 64.8 63.3 60.9  54.9 66.3 60.8 4.00 0.64 
20 0 0 0 53.4 60.5 60.9  64.7 59.9 58.9 3.92 -0.51 
 
 
4.4.1.1 Preliminary Data Analysis 
The initial graphical analysis of the responses suggests approximate symmetry and 
moderately low variability exist.  Applying the Shapiro-Wilk test yields  =0.958 vs. 
0.951, and since , insufficient evidence exists to reject normality. 
Notwithstanding, the non-zero values in the γ column of Table 2.5 coupled with the few 
responses in Figure 2.3(a) that deviate from the reference line suggest that some 
asymmetry is, in fact, present. In terms of process variability, Figure 4.3(b) shows the 
deviations between the observations and the mean response to be quite small, and well 
within the 3 threshold defined in Section 4.3.1.  
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                                                                 (a)                                   (b) 
Figure 4.2. Assessing a) normality and b) variability in the responses. 
 
After performing a preliminary regression for a full second-order model for the mean 
response using the OLS approach, a graphical analysis of the residuals (Figure 2.4) 
suggests that the assumptions of normality and independence hold, but that non-constant 
variance may exist.  Yet, application of the Breusch-Pagan (B-P) hypothesis test yields 
=16.1 <  (.95,9)=16.9 which suggests constant variance and thus disputes the 
deduction suggested by the plot in Figure 4(c). It is often the case with smaller sample 
sizes that the objective test results fail to capture the presence of non-constant variance.   
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                                           (a)                                    (b)                                     (c) 
Figure 4.3. Investigation of a) normality, b) independence, and c) variance in the 
residuals. 
After performing a second-order regression for all 100 experimental observations, 
reiterating the Breusch-Pagan test yields , which is clearly less than 
(.95,9)=.1691 and reinforces the initial test results. The revised residual plots shown in 
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Figure 5 are based on the full complement of 100 observations and illustrate the validity 
of the basic residual assumptions in this case.  
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Figure 4.4. Residual analysis based on all 100 observations in the metal cutting study.  
 
Taken together, the results of the data analysis suggest that the experimental data 
meet all requisite provisions for the application of OLS regression. This implies that OLS 
would be the best approach given that this method is known to produce the best linear 
unbiased estimates for the process location and scale, or dispersion, when these 
conditions hold. 
4.4.1.2 Results Based on Original Experimental Data 
We first performed a single run of the experiment to motivate the discussion on 
conditions-based estimator selection. Additionally, the run demonstrates the benefits of 
using the skew normal distribution to model system properties. The OLS method using 
traditional tier-one estimators under the assumption of zero skewness is also applied. The 
results in Figure 2.6 show the optimal operating conditions  obtained 
under each regression model using the MSE-based optimization scheme, the associated 
optimal process mean and standard deviation, and the resulting target bias and MSE. For 
the GLM approach, the Gaussian-identity (default) distribution-link combination was 
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used, which essentially mirrors the OLS counterpart and is appropriate when traditional 
assumptions hold. From the results in Table 4.6, a single run of the experiment suggests 
two things: first, accounting for even low degrees of asymmetry can produce better RPD 
solutions than the traditional approach to OLS estimation; and second, OLS regression 
(under the SN approach) is still suitable, although the use of the median-based WLS 
method can achieve superior results. However, recognizing that these solutions are 
estimates, it is therefore quite likely that subsequent implementations of the experiment 
could yield different sets of optimal coordinates. 
Table 4.5. Regression and optimization results of a single run with five simulated 
observations. 
 
OLS 
(Traditional) 
OLS 
(SN) 
WLS 
Mean/s 
WLS 
Median/MAD LTS S LAD MM 
Huber 
Prop 2 GLM 
x1 -0.380 -1.682 -0.071 -0.515 0.056 0.023 -0.215 0.101 -1.682 -1.682 
x2 -1.682 -1.682 1.682 -1.682 -1.682 -1.682 1.682 -1.682 -1.682 -1.682 
x3 -0.170 1.014 -1.682 1.682 -1.682 -1.682 -1.682 -1.682 1.155 1.014 
ˆ ( *) x  57.172 57.615 58.825 57.540 57.466 57.490 58.430 57.459 57.586 57.615 
bias 0.328 0.115 1.325 0.040 0.034 0.010 0.930 0.041 0.086 0.115 
ˆ ( *) x  2.649 2.086 2.733 0.449 2.369 2.169 2.563 2.928 2.064 2.086 
MSE 7.127 4.365 9.225 0.203 5.612 4.703 7.431 8.575 4.266 4.365 
Moreover, the objective is to examine trends to develop a better sense of how the 
estimators perform on average, which cannot be achieved via a single run. Accordingly, 
we conducted 1,000 iterations of the simulation, generating fresh random data based on 
the original experiment at each iterate. At the end of each simulation run, the MSE and 
target bias were recorded for the optimal RPD solutions and then averaged across all 
iterations to observe trends. Table 4.7 contains the simulation results, along with the 
proportion of iterations in which a particular estimation approach yielded the smallest 
MSE and bias.  
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Table 4.6. Simulation results under low variability conditions. 
  
OLS 
(Traditiona
l) 
OLS 
(SN) 
WLS 
Mean/
s 
WLS 
Median/MA
D LTS S LAD MM 
Hube
r 
Prop 
2 GLM 
Avg MSE 4.029 3.250 3.349 2.379 2.636 2.593 3.359 3.205 3.292 3.250 
% Best 
MSE 4.90% 
3.50
% 5.10% 30.30% 
20.70
% 
20.50
% 
9.20
% 
5.50
% 
1.90
% 
3.50
% 
Avg Bias 0.300 0.266 0.260 0.243 0.205 0.200 0.220 0.220 0.259 0.266 
% Best 
Bias 7.20% 
4.80
% 6.70% 19.50% 
23.10
% 
19.90
% 
9.70
% 
7.70
% 
3.90
% 
4.80
% 
Noting that all nine of the alternative estimation approaches outperformed the 
traditional OLS approach in Table 4.7, it is clear that despite approximate 
symmetry/normality in the process data, there is enough inherent skewness to affect the 
optimization results. In the most basic sense, this is illustrated by comparing the first two 
columns in Table 4.7 (OLS-Traditional vs. OLS-SN), which suggests that by accounting 
for even slight levels of non-zero skewness, better RPD results can be obtained. Beyond 
this, the fact that median-based approaches (WLS, MAD, LTS, and S estimations) yielded 
better results in terms of both average performance and consistency suggests that these 
methods are preferable when any degree of asymmetry exists. The main reason that the 
WLS procedure produced better results on average is most likely from the result of down-
weighting those observations with higher variability, thus demonstrating the viability of 
using that method to exert greater control over sources of process variation. 
4.4.1.3 Investigating the Effects of High Variability Conditions 
To examine the effects of variability, we incorporated a simple modification to 
the simulation that would induce a greater degree of variability in the process. Whereas 
before we used the sample standard deviation(s) in Table 4.5 to generate normal random 
variates in the base scenario, in this instance we randomly sampled an integer from a 
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range of 2 to 5 at each design point to serve as a factor that would then be multiplied by 
the original values for s. Hence, the variability at each design point would be increased 
by a factor of anywhere from 2 to 5 times. 
The idea here is that simply multiplying the s vector by a single common factor 
would not have any impact on the results other than to scale them by that factor. That is, 
there would certainly be more variability in the responses, but the proportional change in 
each design point would be the same and would negate any real effects on the results as 
the underlying conditions regarding base assumptions would still hold. Thus, our 
objective is to inject variability not only horizontally within each design point, but also 
vertically across the vector of sample standard deviations. This would challenge system 
performance and very likely upend the underlying assumptions of response variability 
and heteroscedasticity. As the plots in Figure 4.6 show, this is precisely what occurs, as 
several observations exceed the 3threshold (Figure 4.6a), and the variability trends 
coupled with the Breusch-Pagan results in Figure 4.6b clearly suggest non-constant 
variance in the residuals. As noted previously, the presence of such conditions inhibits 
the use of OLS and suggests the need for either remedial measures or alternative 
estimation approaches.   
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Figure 4.5. Analysis of responses (a) and residuals (b) under high-variability conditions.  
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To establish performance trends among the estimators, we performed 1,000 
iterations of the high-variability scenario. In this instance, the GLM approach is modified 
to account for differences in the data. Specifically, further analysis of the residual data for 
response surface functions for both the mean and variation suggested the need to consider 
either a gamma or inverse Gaussian distribution to correct for non-constant variance. 
After preliminary modeling using the various distribution- link function combinations in 
the GLM approach, it is determined that the gamma-identity and inverse Gaussian-log 
combinations would produce the best fit for the mean and standard deviation response 
surface functions, respectively. Results for the MSE and bias were then averaged across 
all 1,000 iterations, and performance proportions were calculated to produce the results 
shown in Table 4.7. 
Table 4.7. Simulation results under high variability conditions.  
 
OLS 
(Traditiona
l) 
OLS 
(SN) 
WLS 
Mean/
s 
WLS 
Median/MA
D LTS S LAD MM 
Hube
r 
Prop 
2 GLM 
Avg MSE 35.604 
30.39
8 
28.26
1 20.194 19.714 20.277 
32.28
4 
28.51
4 
31.25
3 3.643 
% Best 
MSE 4.90% 
3.70
% 7.30% 18.30% 
17.40
% 
16.10
% 
8.60
% 
5.60
% 
3.40
% 
16.00
% 
Avg Bias 2.225 2.079 2.087 1.790 1.579 1.694 2.089 2.037 2.112 0.166 
% Best 
Bias 5.20% 
2.80
% 6.40% 15.10% 
15.90
% 
14.40
% 
8.10
% 
4.90
% 
3.50
% 
24.80
% 
 
The results in Table 4.7 draw several insights. First, all nine of the alternatives 
once again produced a better result than the traditional OLS method, reinforcing the 
benefit of using the skew normal approach for modeling process asymmetry. Second, it is 
clear that the increased variation induces a change in estimator performance such that the 
GLM method using the gamma-identity and inverse Gaussian-log combinations 
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outperforms all others on average, both in terms of the resulting MSE and target bias. 
While the next-best performers (LTS, WLS (median/MAD), and S-estimation methods) 
performed relatively well, they all achieved an average MSE nearly six times larger than 
the GLM method. 
Although differences in the generated data can be a contributing factor, the 
reasons behind these results can also be attributed to the increased likelihood of extreme 
observations in either tail. And if an extreme observation from one tail is not counter-
balanced by an extreme point from the other, then the resulting sample could very well 
appear skewed, despite being generated from a normal distribution. Obviously, when the 
data are approximately normal, the mean and the median will have nearly the same value. 
However, as the data become skewed due to the occasion of one or more extreme 
observations, mean-based estimators deteriorate in their ability to provide the best 
estimate of central tendency due to the influenced of outlying data points. Similarly, the 
standard deviation no longer provides the best measure of the true dispersion in the 
distribution. The median and the MAD, on the other hand, retain their properties and are 
resistant to extreme observations, thereby making them preferable when such conditions 
exist. In addition to this, high variability typically will also induce non-constant variance, 
which invariably results in suboptimal solutions if OLS regression is applied. As the plots 
in Table 2.8 show, this is precisely what is occurring in this scenario, and serves to 
explain why the robust and GLM approaches perform well.  
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4.5 Summary of Findings 
The numerical results in several key insights for solving the RPD problem in 
asymmetric and highly variable conditions, which are summarized in (i)-(iii) below: 
(i) Most importantly, the simulation results across all scenarios clearly demonstrate 
that as process variability increases, alternative approaches to the traditional OLS method 
are not only necessary, but preferable. When coupled with asymmetric conditions, the 
effects become even more pronounced, particularly when the levels of both conditions 
are high. The key question is why. As previously discussed, once elevated degrees of 
variability and inherent asymmetry shift the data from assumed normality, the 
performance of traditional approaches to estimation suffers as a result of the influence 
exerted by extreme observations from the long tail of the skewed distribution. The 
alternative methods examined (namely the GLM, S-, LTS, and WLS (median/MAD)) tend 
to overcome those influences most effectively. As the results have shown, the GLM 
approach tended to perform very well, if not best, in all of the examined scenarios. But it 
is important to recognize that this is predicated on the identification of the right 
distribution-link combination, which is data-dependent and so constitutes another 
required step in the application of that particular method. However, viable alternatives to 
this are the WLS (median/MAD), LTS, and S-estimation methods, which also performed 
markedly better than traditional OLS and WLS approaches in high variability and high 
asymmetry-high variability situations. Thus, in view of the aims of this paper, the 
pressing question for healthcare professionals is which approach to use and when. Based 
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on the analysis of the presented results, the answer is depicted in Figure 4.7, which shows 
the modification to Phase 1b of the original process map from Figure 4.1. 
Two additional points should be made. First, some might suggest that high 
variability should not pose an issue, as it could be overcome by simply increasing the 
sample size required for estimation. Added replication at each experimental design point 
could ameliorate potential issues and would be preferred. However, this is often not 
feasible due to time and cost constraints, as well as other limitations on resources 
required for experimentation. Second, the results obtained in the numerical example show 
performance trends rather than definitive conclusions as to the certainty of one 
estimator’s performance versus another’s. What they demonstrate is that when elevated 
degrees of process variability and asymmetry exist, estimator selection matters in terms 
of achieving the best RPD solutions. This echoes the importance of a detailed analysis in 
the early stages of experimentation to ascertain the degree to which such underlying 
conditions exist in the data, which in turn will influence the selection of the most 
appropriate estimation approach to use for response surface modeling and optimization. 
(ii) The use of the skew normal distribution facilitates more accurate modeling of the 
inherent distributional properties associated with a particular set of data and, based on the 
results of the numerical example, can produce better RPD results in terms of minimal 
bias and variability. Most notably, because normality is a special case, the skew normal 
can very easily capture both symmetric and asymmetric properties, thereby accounting 
for the presence of either in process outputs. Thus, by using the first three moments to 
replicate experimental observations in the numerical example, we were able to more 
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accurately portray process characteristics. This is important, as elevated variability and 
asymmetry are, in reality, quite probable in many healthcare and medical processes. 
Hence, the use of the skew normal distribution provides the capability to model either 
situation simultaneously, thereby allowing for a more accurate accounting of innate 
system properties. 
(iii) The ease and explicitness associated with the OLS approach has helped to 
solidify its position as the basis for regression estimation for more than two hundred 
years; and it continues to see the preponderance of use throughout the literature and in 
applied statistics texts.  Moreover, what tend to steer engineers away from considering 
realistic process conditions (i.e., asymmetry) and many alternative estimation methods 
are the computational complexities associated with them. But with today’s high-speed 
computing power and myriad readily-available software platforms such as R, the 
computational complexity of alternative estimation methods should no longer be avoided. 
As our results show, these methods can make a significant difference in the quality of the 
results achieved when certain conditions exist. But the reality is that these conditions 
actually exist more in practice than otherwise; and when they do, the necessary 
assumptions that underpin OLS regression no longer hold. If used in spite of this reality, 
the OLS method may likely yield suboptimal solutions. 
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iii.  Development of Response Surface Designs for Process Location and Scale
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High – Low S-estimation
High – High
GLM with distribution-link combos
Mean: Gamma – Inverse
Variation: Gamma - Identity
1) Distrib.-link combos may be data-dependent
2) S-estimation can be a suitable alternative, as it 
achieves the lowest MSE and Bias most often
Approved Models for Quality Characteristics
Analysis of Responses:
- Process highly variable?
- Inherent asymmetry exist?
Development/analysis of 
preliminary estimators 
and 2nd order models
Residual Analysis:
- i.i.d. N(0,2)?
- Constant variance?
OLS is suitable
Can also use Huber Proposal 2 or GLM 
(with Gaussian-Identity link function) to good effect
If more direct control over variability sources is 
required/desired: use WLS (median/MAD)
i. Data Analysis using graphical inference supported by statistical hypothesis testing
ii. Conditions-based selection of regression estimation approach
Alternative Approach Required
per following guidelines
No
Yes
Yes
No
 
Figure 4.6. Conditions-based selection guidelines for regression estimation in asymmetric 
and/or high-variability process conditions.  
4.6 Conclusion 
High variability and asymmetry are conditions that occur quite often across a 
broad range of healthcare applications and it is believed that it should be given special 
consideration in the experimental process regarding the selection of appropriate 
approaches to response surface estimation. To that end, the focus of this paper has been 
to examine various alternatives to OLS regression in the RPD framework when such 
conditions prevail. The results and analysis demonstrate that, as process conditions 
evolve (i.e., variability and/or asymmetry increase), the estimator selection process 
should evolve, as well, to achieve the best solutions possible. In particular, the results 
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have shown that the GLM, S-, LTS, and median-based WLS methods tend to yield better 
RPD solutions. While such methods are fairly well-known in statistical circles, their use 
by healthcare professionals in robust parameter design applications is comparatively rare, 
as noted by Haenkamp et. al (2009):  
“The majority of past [robust parameter design] research has traditionally 
been carried out by statisticians targeting an audience with good insights on 
statistics. When, instead, targeting engineers with less statistical knowledge 
as the major audience, clearly other demands are put on guidelines and 
tools.” 
One such demand is a clearer understanding of which tools to use and when. The 
methodology and analysis offered in this paper should help to answer this need by 
providing healthcare professionals with some clarification as to which estimation 
approaches will tend to provide the best RPD solution when certain conditions exist. The 
analysis in this paper is based upon controlled experimentation, the replication of 
observations made on a specified quality characteristic of interest under highly variable 
and asymmetric conditions, and the implementation of the skew normal distribution to 
effectively model both symmetric and asymmetric instances. Future research may expand 
the investigation to include additional conditions, as well as processes that involve 
multiple quality characteristics of interest. Furthermore, the development of skew 
normal-based link functions for use with GLM approaches would also add benefit. In the 
end, proper accounting for the inherent conditions in the data will allow healthcare 
professionals to more accurately model the processes they endeavor to optimize, which 
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will invariably translate to better RPD solutions and more reliable recommendations to 
decision makers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 158 
APPENDICES 
 
A. Summary Table of Stated Healthcare Concerns and Associated Research 
Focus 
APA Reference Healthcare Concern Research Focus 
Acciaroli et al., 
2018 
How to use glycemic variability indices 
to classify subjects remains 
controversial 
[1] Assess feasibility of using a 
glycemic variability index to 
distinguish between healthy individuals 
and those with impaired glucose 
tolerance (IGT) or T2DM 
[2]Assess feasibility of using a 
glycemic variability index to 
distinguish between  individuals with 
IGT versus T2DM 
Agarwal et al., 
2016 
[1] ML approaches to electronic 
phenotyping are limited by the scarcity 
of training datasets 
[2] Manual creation of training sets for 
ML approaches is time intensive 
Investigate an alternative method to 
manual labeling to create training sets 
for statistical models of phenotypes 
Allalou et al., 2016 [1] Gestational diabetes (GDM) affects 
3-14% of pregnancies 
[2] 20-50% of women with GDM will 
develop T2DM within 5 years 
[3] Prediction of progression from 
GDM to T2DM critical for individual 
risk stratification 
Develop a metabolomics signature to 
predict patient progression from 
gestational diabetes mellitus to T2DM 
Anderson et al., 
2016 
25% of T2DM are undiagnosed due to 
inadequate screening 
Assess whether electronic health record 
phenotyping could improve T2DM 
screening compared to conventional 
models 
Anderson et al., 
2016 
Providing more detailed insights on 
factors that drive progression to DM 
would be valuable in characterizing and 
intervening on at-risk patients 
Develop a prediction model ensemble 
for progress to prediabetes or T2DM 
using variables found within electronic 
health records 
Basu et al., 2017 It is unclear how to best individualize 
glycemic targets 
Identify characteristics of patients at 
high cardiovascular risk with decreased 
or increased mortality risk from 
glycemic therapy 
Basu et al., 2017 There exists substantial mis-estimation 
of risks of diabetes complications using 
existing equations (RECODe) 
Develop updated risk equations for 
complications of T2DM (RECODe) 
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APA Reference Healthcare Concern Research Focus 
Cao et al., 2017 Molecular basis for the comorbidity of 
schizophrenia and T2DM is not 
completely understood 
Determine molecular commonality 
between schizophrenia and glycemic 
markets of T2DM (identify a polygenic 
schizophrenia signature and explore its 
impact on T2DM 
Casanova et al., 
2016 
Prediction for incident diabetes is based 
on limited variables 
[1] Investigate relative performance of 
machine learning method such as RF 
for detecting diabetes  in a high 
dimensional setting 
[2] Uncover potential predictors of 
diabetes 
Chen et al., 2015 Performance of the recommended 
glomerular filtration rate (GFR)- 
estimating equations in T2DM 
population is inferior to the nondiabetic 
population; important for drug dosing 
Develop new GFR-predicting models 
for use in Chinese patients with T2DM  
Dagliati et al., 2017 ML algorithms can be embedded into 
data mining pipelines to extract 
knowledge from data 
Predict the onset of retinopathy, 
neuropathy, or nephropathy at different 
time scenarios 
Dong et al., 2017 Missing heritability is still a big 
problem for Genome-wide association 
studies ; susceptibility loci identified by 
GWAS only account for a limited 
proportion of the observed heritability 
of diseases 
Development of more powerful 
methods to predict novel risk SNPs 
from the large amount of SNP data and 
regulatory features  
EITanboly et al., 
2017 
Detecting early retinal changes in 
T2DM to give patients a chance to 
delay further complications is absent so 
far  
Diagnosis of diabetic retinopathy (DR) 
using optical coherence tomography 
(OCT) images for T2DM patients 
Farran et al., 2013 Efficient preventative strategies are 
needed to control risk factors for 
T2DM;  use knowledge to on 
individual population or at population 
level to identify groups of high-risk 
patients  
Build classification models and risk 
assessment tools for diabetes, 
hypertension and comorbidity using 
ML algorithms on data from Kuwait  
Han et al., 2017 Need a system or process to stratify 
individuals according to disease risk for 
clinical disease prevention  
Develop a risk stratification model of 
clinical disease to be used for 
interventions  
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APA Reference Healthcare Concern Research Focus 
Hertroijs et al., 
2017 
Iplementation of precision medicine 
based solely on genomics has proven to 
be difficult for certain diseases; 
phenotyping approach to precision 
medicine is only sparsely adopted in 
evidence-based guidelines for diabetes 
treatment  
[1] Identify subgroups of people with 
newly diagnosed T2DM with distinct 
glycemic trajectories 
[2] Predict trajectory membership using 
patient characteristics 
[3] Validate findings in different cohort 
of patients with T2DM 
Kagawa et al., 
2017 
Existing phenotyping algorithms are 
not sufficiently accurate for screening 
and identifying clinical research 
subjects 
Distinguish T2DM patients based on 
electronic health records; propose new 
metric to evaluate practicality of 
algorithms 
Kim et al., 2017 Need to find markers for end-stage 
renal disease;  because diabetic patients 
are likely to develop ESRD it is 
imperative to discover which elements 
of diabetic patient's medical problems 
lead to ESRD 
Discover frequently appearing medical 
complications at various levels of 
kidney functions for two different 
subpopulations defined by ethnicity 
Lee et al., 2016 No study has assessed the predictive 
power of phenotypes based on 
individual anthropometric 
measurements  
Assess the association between the HW 
phenotype and T2DM in Korean adults 
Lee et al., 2014 Prediction of type 2 diabetes using a 
combination of anthropometric 
measures remains a controversial issue  
Predict the fasting plasma glucose 
status that is used in the diagnosis of 
type 2 diabetes by a combination of 
various measures of Korean adults  
Leung et al., 2013 Diabetic kidney disease is rising in 
parallel to the growing epidemic of 
T2DM / rapid advancement of 
molecular tech, large datasets 
containing many genotypes and 
phenotypes;  challenge is in 
synthesizing discoveries and translating 
them to clinical practice  
Explore computation tools with a 
comprehensive data base on T2DM 
Li et al., 2016 Growing risk to patient population with 
the use of Electronic health records; 
need to reconcile the preservation of 
patient privacy and the need to have 
sufficient data for modeling and 
decision making 
Develop two adaptive distributed 
privacy preserving algorithms based on 
a distributed ensemble strategy  
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APA Reference Healthcare Concern Research Focus 
Lo-Ciganic et al., 
2015 
Little empirical evidence to support 
medication adherence threshold levels 
as a predictor of health outcomes  
Apply ML to examine how adherence 
to oral hypoglycemic medications is 
associated by avoidance of 
hospitalization; identify adherence 
thresholds for optimal discrimination of 
hospitalization risk 
Lopez et al., 2017 Need to definitively link single 
nucleotide polymorphisms to disease 
development 
Identify relevant SNPs to T2DM and 
build a decision support-tool for risk 
prediction 
McCoy et al., 2017 Individualized diabetes management 
would benefit from prospectively 
identifying well-controlled patients at 
risk of losing glycemic control 
Identify patters of H1bA1c change 
among patients with stable controlled 
diabetes  
Moreno et al., 2017 Develop noninvasive method to test for 
T2DM  
Screen for the presence of T2DM by 
means of the signal obtained by a pulse 
oximeter 
Neugebauer et al, 
2013 
Clinical trials are unlikely to be 
launched for many comparative 
effectiveness research questions 
Adaptation of a data adaptive 
estimation approach called Super 
Learning avoids reliance on arbitrary 
parametric assumptions in CER 
Neugebauer et al., 
2016 
Contribute to the understanding of 
potential consequences of the choice of 
estimation for propensity scores in real 
world comparative effectiveness 
analysis 
Use EHR data to evaluate the effects of 
four adaptive treatment intensification 
strategies (bias from incorrect 
parametric model specification)  
Olivera et al., 2017 T2DM is a chronic disease associated 
with a wide range of serious health 
complications 
Develop and validate predicative 
models for detecting undiagnosed 
diabetes  
Ozery-Flato et al., 
2016 
Development of a tool that could 
automatically evaluate a patient's 
response to treatment, identify patients 
who are most likely experiencing 
problems, and focus physicians' 
attention on those patients who require 
it most would be extremely valuable 
New approach for detection and 
analyzing patients with expected 
responses to antidiabetic drugs 
Ozery-Flato et al., 
2013 
Only limited information is available 
on the predictors ofT2DM in the group 
of patients already diagnosed with 
metabolic syndrome 
Investigate the predictive value of 
different biomarkers for the incidence 
of T2DM in patients with metabolic 
syndrome  
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APA Reference Healthcare Concern Research Focus 
Peddinti et al., 
2017 
 Predictive biomarkers are needed to 
allow physicians to identify and 
monitor individuals at high risk for 
T2DM 
Systematically evaluate the predictive 
power of comprehensive metabolomics 
profiles to predict T2DM 
Pedersen et al., 
2016 
 Not all patients undergoing weight-
loss surgery experience diabetic 
remission, but the mechanistic insights 
that cause the heterogeneous therapy 
results are not understood.  
 Combine clinical and genomic factors 
using heuristic methods to identify 
patients who may have a low likelihood 
in responding to bariatric surgery for 
improved glycemic control  
Pimentel et al., 
2016 
Current methods of treating T2DM are 
inadequate therefore it is important to 
focus on prevention of the disease 
Propose a new approach for T2DM 
based on EHR without using invasive 
techniques 
Pazavian et al., 
2015 
Interventions can only be cost effective 
when the target population has a high 
likelihood of developing diabetes at the 
baseline 
Develop a population-level risk 
prediction model for type 2 diabetes 
that can be used with health insurance 
claims or other readily available data 
 
Pamezankhani et 
al., 2016 
Most ML classified work well when the 
class distribution is evenly distributed, 
but class imbalance is prevalent in 
medical datasets 
Evaluate the impact of synthetic 
minority oversampling technique 
(SMOTE) on the performance of 
probabilistic neutral network, naïve 
Bayes (NB), and decision tree (DT) 
classifiers for predicting diabetes  
Sudharsan et al., 
2015 
Minimizing the occurrence of 
hypoglycemia is a challenging task 
since T2DM patients typically check on 
1-2 self-monitored blood glucose levels 
per day  
Develop a probabilistic model to 
predict an hypoglycemic event within 
the next 24 hours  
Vyas et al., 2016 The number of revealed protein-protein 
interactions is limited compared to the 
available protein sequences of different 
organisms 
Develop a model for discriminating 
disease proteins from non-disease 
proteins for T2DM 
Zheng et al., 2017 Existing expert based identification 
algorithms often have a low recall rate 
and could miss valuable samples  
Propose a data informed framework for 
identifying subjects with and without 
T2DM from EHR via feature 
engineering and machine learning 
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B. Summary Table of Machine Learning Techniques and Selected Dataset 
APA 
Reference 
Machine 
Learning 
Algorithms 
Model 
Performance 
Metrics 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset 
Name or 
Source 
Dataset 
Time 
Frame 
Acciaroli et 
al., 2018 
logistic 
regression 
accuracy, F1 
score, 
precision, 
recall 
 
 
  Finland Botnia Study 
Group 
  
Agarwal et 
al., 2016 
L1 penalized 
logistic 
regression 
accuracy, 
against rule-
based 
definitions, 
positive 
predictive 
value 
 
 
 
XPRESS United 
States 
Standford 
Children's 
Health and 
Stanford 
Healthcare 
January 
1994 - 
June 2013 
Allalou et 
al., 2016 
decision 
tree, J48 
decision 
tree, Naïve 
Bayes, 
logistic 
regression 
accuracy, area 
under the 
curve, F-score 
precision , 
specificity, 
sensitivity 
R-studio, 
Waikato 
Environmen
t for 
Knowledge 
Analysis 
workbench 
United 
States 
Study of 
Women, Infant 
Feeding, and 
Type 2 
Diabetes 
Mellitus After 
GDM 
Pregnancy 
(SWIFT) 
 
2008-
2014 
Anderson et 
al., 2016 
logistic 
regression, 
random 
forest 
accuracy, area 
under the 
curve, positive 
predictive 
value, negative 
predictive 
values, 
sensitivity, 
specificity 
 
 
R United 
States 
Practice 
Fusion 
Diabetes 
Classification  
2009-
2012 
Anderson et 
al., 2016 
Bayesian 
posterior  
area under the 
curve  
Reverse 
Engineering 
and Forward 
Simulation 
(REFS) 
United 
States 
Humedica 
Electronic 
Health 
Records 
2007-
2012 
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APA 
Reference 
Machine 
Learning 
Algorithms 
Model 
Performance 
Metrics 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset 
Name or 
Source 
Dataset 
Time 
Frame 
Basu et al., 
2017 
gradient 
forest, 
decision tree  
  R United 
States 
and 
Canada 
Action to 
Control 
Cardiovascular 
Risk in 
Diabetes 
(ACCORD) 
2001-
2009 
Basu et al., 
2017 
elastic net 
regularizatio
n to inform 
the Cox 
Hazards 
Model 
  R United 
States 
and 
Canada 
[1] Action to 
Control 
Cardiovascular 
Risk in 
Diabetes 
(ACCORD) 
[2]Diabetes 
Prevention 
Program 
Outcomes 
Study [3] 
Action for 
Health in 
Diabetes 
 
[1] 2001-
2009 [2] 
1996-
2001  [3] 
2001-
2012 
Cao et al., 
2017 
  accuracy, 
Nagelkreke’s 
R2 
R   [1] GEO 
database: 
GSE53987, 
GSE21138, 
GSE35977, 
GSE12679, 
GSE38642, 
GSE3489, 
GSE36980 [2] 
GWAS Data: 
GO, KEGG, 
Panther, 
Reactome, 
Target Scan 
[3] Expression 
Atlas: GTEx 
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APA 
Reference 
Machine 
Learning 
Algorithms 
Model 
Performance 
Metrics 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset 
Name or 
Source 
Dataset 
Time 
Frame 
Casanova et 
al., 2016 
random 
forest, 
logistic 
regression 
area under the 
curve, standard 
panel - 
accuracy, 
sensitivity, 
specificity 
 
  United 
States 
Jackson Heart 
Study, 
University of 
Mississippi 
Medical 
Center 
  
Chen et al., 
2015 
artificial 
neural 
networks  
(back 
propagation)  
  MATLAB 
2011A 
China Third 
Affiliated 
Hospital of 
Sun Yatsen 
University 
  
Dagliati et 
al., 2017 
logistic 
regression, 
naïve Bayes, 
support 
vector 
machines, 
random 
forest  
accuracy, area 
under the 
curve, 
matthew’s 
correlation 
coefficient, 
negative 
predictive 
value, positive 
predictive 
value, 
sensitivity, 
specificity, 
area under the 
curve 
 
 
 
 
  Italy [1] Istituto di 
Ricovero e 
Cura a 
Carattere 
Scientifico - 
Research 
hospital 
 
[2] Istituto 
Clinico 
Scientifico 
Maugeri 
(ICSM) 
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APA 
Reference 
Machine 
Learning 
Algorithms 
Model 
Performance 
Metrics 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset 
Name or 
Source 
Dataset 
Time 
Frame 
Dong et al., 
2017 
decision 
tree, class 
analogy, 
random 
forest, 
support 
vector 
machines 
F1 score, 
number of 
features, 
sensitivity, 
specificity, 
accuracy 
R  [1] 1000 
Genome 
Project 
[2] ENCODE; 
Roadmap 
Epigenomics 
Project, 
expression 
quantitative 
trait loci data 
in T2DC 
relevant issues 
from the GTEx 
database 
[3] genomic 
regions from 
the GERP++ 
 
  
EITanboly 
et al., 2017 
deep 
learning 
(compared 
with K-Star, 
K-Nearest, 
Random 
Tree, 
Random 
Forest) 
 
Accuracy, area 
under the 
curve, 
sensitivity, 
specificity 
Waikato 
Environ-
ment for 
Knowledge 
Analysis 
workbench 
      
Farran et al., 
2013 
logistic 
regression, 
k-nearest 
neighbors, 
support 
vector 
machines  
classification 
accuracy  
MATLAB -
MATrix 
LABoratory 
Kuwait Kuwait Health 
Network 
(KHN)  
(12 years) 
Han et al., 
2017 
k means 
variants 
(base, PSC, 
Seeded, 
COP, PCK, 
MPCK, 
Supervised, 
Constrained, 
FSCL), 
random 
forest  
ratio of 
minimum to 
expected, 
sensitivity, 
specificity, 
standard 
deviation in 
cluster sizes,  
Youden index, 
standard 
deviation in 
cluster sizes 
R China Chinese 
Hospital Data  
(7 years)  
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APA 
Reference 
Machine 
Learning 
Algorithm 
Model 
Performance 
Metric 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset 
Name or 
Source 
Dataset 
Time 
Frame 
Hertroijs et 
al., 2017 
k-nearest 
neighbor, 
Fisher, 
Parzen, 
quadratic 
discriminant 
classifier, 
linear 
discriminant 
classifier, 
support 
vector 
machine, 
logistic 
regression, 
stacked 
support 
vector 
machine 
Akaike 
Information 
Criterion, 
Bayesian 
Information 
Criterion, Lo-
Mendel-
Rubin-
likelihood 
ratio test, 
predicted and 
observed 
trajectory, 
calibration 
slopes, 
sensitivity, 
specificity, 
positive 
predictive 
values, 
negative 
predictive 
values 
  Nether-
lands 
[1] Zwolle 
Outpatient 
Diabetes 
Project 
Integrating 
Available Care 
(ZODIAC) 
 
[2] ZIO, a 
regional care 
group 
[1] 2006-
2013 
 
[2] 2009-
2013 
Kagawa et 
al., 2017 
Support 
vector 
machine, 
PheKB 
sensitivity, 
area under the 
curve, 
specificity, 
sensitivity  
R (kernlab, 
ROCR, 
caret) 
Japan University of 
Tokyo 
Hospital 
2009-
2014 
Kim et al., 
2017 
apriori    2012 Cerner 
database 
  
Lee et al., 
2016 
naïve Bayes, 
logistic 
regression 
area under the 
curve  
SPSS 19, 
Waikato 
Environmen
t for 
Knowledge 
Analysis 
data mining 
tool  
Korea Korean 
Health and 
Genome 
Epidemiolog
y Study 
Database 
Nov 2006 
- August 
2013 
Lee et al., 
2014 
naïve Bayes, 
logistic 
regression 
area under the 
curve, 
sensitivity, 
specificity  
SPSS 19, 
Waikato 
Environmen
t for 
Knowledge 
Analysis 
data mining 
tool  
Korea     
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APA 
Reference 
Machine 
Learning 
Algorithms 
Model 
Performance 
Metrics 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset Name 
or Source 
Dataset 
Time 
Frame 
Leung et al., 
2013 
decision 
tree, random 
forest, naïve 
Bayes, 
neural 
networks, 
partial least 
squares 
regression, 
support 
vector 
machine 
ROC, 
sensitivity, 
specificity 
R for ML, 
but SPSS for 
statistical 
analysis 
China Hong Kong 
Diabetes 
Registry 
1 July 
1994 - 30 
June 1998 
Li et al., 
2016 
AdaBoost 
(local 
learner) 
area under the 
curve, F 
measure, 
sensitivity, 
precision 
   Practice 
Fusion 
Diabetes 
Classification 
Challenge 
(2002) 
  
Lo-Ciganic 
et al., 2015 
random 
survival 
forest  
  SAS 9.3 and 
R 
United 
States 
Pennsylvania 
Medicaid 
program  
2007-
2011  
Lopez et al., 
2017 
classify: 
random 
forest, 
support 
vector 
machine, 
logistic; 
predict: 
regression, 
k-nearest 
neighbor  
area under the 
curve, 
prediction 
accuracy 
    Biomedical 
Research of 
Girona 
  
McCoy et 
al., 2017 
random 
forest 
 R   OptumLabs 
Data 
Warehouse 
2001-
2013 
Moreno et 
al., 2017 
random 
forest, 
gradient 
boosting, 
linear 
discriminant 
analysis  
area under the 
curve, 
sensitivity, 
septicity 
MATLAB Spain 6 Clinics 
around 
Barcelona 
2013 
Neugebauer 
et al., 2013 
super 
learning  
      EHR from 
patients of four 
sites of the 
HMO research 
network 
consortium 
January 
2006 - 
June 2008 
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APA 
Reference 
Machine 
Learning 
Algorithms 
Model 
Performance 
Metrics 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset Name 
or Source 
Dataset 
Time 
Frame 
Neugebauer 
et al, 2016 
super 
learning 
      real-world 
comparative 
effectiveness 
research  
  
Olivera et 
al., 2017 
logistic 
regression, 
artificial 
neural 
network, 
naïve Bayes, 
k-nearest 
neighbor, 
and random  
forest 
accuracy, area 
under the 
curve, 
balanced 
accuracy, 
sensitivity, 
specificity,  
R Brazil Longitudinal 
Study of Adult 
Health (ELSA- 
Brazil) 
2008-
2010  
Ozery-Flato 
et al., 2016 
k-nearest 
neighbor, 
support 
vector 
machine 
          
Ozery-Flato 
et al., 2013 
logistic 
regression 
area under the 
curve  
MATLAB Lithuani
-a 
Lithuanian 
High 
Cardiovascul
ar Risk 
primary 
prevention 
program 
2007-
2011 
Peddinti et 
al., 2017 
            
Pedersen et 
al., 2016 
 artificial 
neural 
network 
 Area under 
the curve, 
accuracy, 
integrated 
discrimination 
improvement 
 R, Plink  United 
States 
CardioMetabo
chip, 
eMERGE, 
GIANT, 
DIAGRAM, 
MAGIC 
  
Pimentel et 
al., 2016 
regularized 
least squares 
area under the 
curve  
R Finland Botnia 
Prospective 
Study (BPS) 
1990-
2000 
Pazavian et 
al., 2015 
logistic 
regression  
area under the 
curve, 
sensitivity, 
specificity, 
positive 
predictive 
value 
  United 
States 
cohort study of 
beneficiaries 
of 
Independence 
Blue Cross 
2005-
2013 
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APA 
Reference 
Machine 
Learning 
Algorithms 
Model 
Performance 
Metrics 
Machine 
Learning 
Software 
Dataset 
Origin 
Dataset Name 
or Source 
Dataset 
Time 
Frame 
Pamezankha
ni et al., 
2016 
probabilistic 
neural 
networks, 
decision 
trees, naïve 
Bayes 
accuracy, F- 
measure, 
precision, 
sensitivity, 
specificity, 
precision, 
Youden's 
index  
Konstanz 
Information 
Miner 
(KNIME) 
Iran Tehran Lipid 
and Glucose 
Study (TLGS) 
(12 years) 
Sudharsan et 
al., 2015 
random 
forest, 
support 
vector 
machine, k-
nearest 
neighbor, 
naïve Bayes 
accuracy, 
sensitivity, 
specificity  
    De-identified 
patient data 
from a clinical 
trial of patients 
with T2DM  
(1 year) 
Vyas et al., 
2016 
support 
vector 
machine 
accuracy, area 
under the 
curve, 
precision, 
accuracy, 
recall 
LibSVM United 
States 
    
Zheng et al., 
2017 
k-nearest 
neighbor, 
naïve Bayes, 
decision 
tree, random 
forest, 
support 
vector 
machine, 
logistic 
regression 
accuracy, 
precision, area 
under the 
curve, 
sensitivity, 
specificity  
Weka  China Regional 
distributed 
EHR in 
Shanghai 
China 
2012-
2014 
 
 171 
REFERENCES 
Acciaroli, G., Sparacino, G., Hakaste, L., Facchinetti, A., Di Nunzio, G. M., Palombit, 
A., Tuomi, T., Gabriel, R., Aranda, J., Vega, S. & Cobelli, C. (2018). Diabetes and 
prediabetes classification using glycemic variability indices from continuous glucose 
monitoring data. Journal of diabetes science and technology, 12(1), 105-113. 
Agarwal, V., Podchiyska, T., Banda, J. M., Goel, V., Leung, T. I., Minty, E. P., Sweeny, 
T., Gyang, E. & Shah, N. H. (2016). Learning statistical models of phenotypes using 
noisy labeled training data. Journal of the American Medical Informatics Association, 
23(6), 1166-1173. 
Allalou, A., Nalla, A., Prentice, K. J., Liu, Y., Zhang, M., Dai, F. F., Ning, J. X., 
Osborne, L. R., Cox, B. J., Gunderson, E. P., & Wheeler, M. B. (2016). A predictive 
metabolic signature for the transition from gestational diabetes to type 2 diabetes. 
Diabetes, db151720. 
American Association for Clinical Chemistry. (2017). Reference Ranges and What They 
Mean. Retrieved from https://labtestsonline.org/understanding/features/ref-ranges 
American College of Cardiology. (2017). New ACC/AHA High Blood Pressure 
Guidelines Lower Definition of Hypertension. Retrieved from 
https://www.acc.org/latest-in-cardiology/articles/2017/11/08/11/47/mon-5pm-bp-
guideline-aha-2017 
American Diabetes Association. (2017). Classification and diagnosis of diabetes. 
Diabetes Care, 40(Supplement 1), S11-S24. 
American Diabetes Association. (2017). Standards of medical care in diabetes—2017 
abridged for primary care providers. Clinical Diabetes, 35(1), 5-26. 
American Diabetes Association. (2013). Economic costs of diabetes in the US in 2012. 
Diabetes care, 36(4), 1033-1046. 
American Diabetes Association. (2015). The Cost of Diabetes. Retrieved from 
http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html? 
American Heart Association News. (2017). Nearly half of US adults could now be 
classified with high blood pressure, under new definitions. Retrieved from 
https://www.acc.org/latest-in-cardiology/articles/2017/11/08/11/47/mon-5pm-bp-
guideline-aha-2017 
 
 172 
American Red Cross. (2017). History of Blood Transfusions. Retrieved from 
http://www.redcrossblood.org/learn-about-blood/blood-transfusions/history-blood-
transfusions. 
Amit, Y., & Geman, D. (1997). Shape quantization and recognition with randomized 
trees. Neural computation, 9(7), 1545-1588. 
Anderson, A. E., Kerr, W. T., Thames, A., Li, T., Xiao, J., & Cohen, M. S. (2016). 
Electronic health record phenotyping improves detection and screening of type 2 
diabetes in the general United States population: a cross-sectional, unselected, 
retrospective study. Journal of biomedical informatics, 60, 162-168. 
Anderson, J. P., Parikh, J. R., Shenfeld, D. K., Ivanov, V., Marks, C., Church, B. W., 
Laramie, J. M., Mardekian, J., Piper, B. A., Willke, R. J., & Rublee, D. A. (2016). 
Reverse engineering and evaluation of prediction models for progression to type 2 
diabetes: an application of machine learning using electronic health records. Journal 
of diabetes science and technology, 10(1), 6-18. 
Apache Incubator. (n.d.). Welcome to Apache SINGA. Retrieved from 
https://mahout.apache.org/ 
Appold, K. (2009). Determining Laboratory Reference Intervals: CLSI Guideline Makes 
the Task Manageable. Laboratory Medicine, 40 (2), 75-76. doi: 
10.1309/LMEHV3HP39QOFJPA 
Arellano-Valle, R.B., Gomez, H.W., & Quintana, F.A. (2004). A new class of skew 
normal distributions, Communications in Statistics-Theory and Methods; 33(7): 1465-
1480. doi: 10.1081/STA-120037254 
Ashley, E. A. (2015). The precision medicine initiative: a new national effort. Jama, 
313(21), 2119-2120. 
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. Lancet, 
383(9911), 69–82. http://doi.org/10.1016/S0140-6736(13)60591-7 
AWS. (2018). Machine Learning on AWS. Retrieved from 
https://aws.amazon.com/machine-learning/ 
Azzalini, A. (1985). A Class of Distributions Which Includes the Normal Ones, 
Scandinavian Journal of Statistics; 12(2), 171–178.Azzalini, A., & Dalla Valle, A. 
(1996). The multivariate skew normal distribution, Biometrika; 83(4), 715-726. doi: 
https://doi.org/10.1016/S0047-259X(03)00131-3 
Azzalini, A., & Dalla Valle, A. (1996). The multivariate skew-normal distribution. 
Biometrika 83 715–726. Mathematical Reviews (MathSciNet): MR1440039 
Zentralblatt MATH, 885. 
 173 
Basu, S., Raghavan, S., Wexler, D. J., & Berkowitz, S. A. (2018). Characteristics 
Associated With Decreased or Increased Mortality Risk From Glycemic Therapy 
Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine 
Learning Analysis of the ACCORD Trial. Diabetes care, 41(3), 604-612. 
Basu, S., Sussman, J. B., Berkowitz, S. A., Hayward, R. A., & Yudkin, J. S. (2017). 
Development and validation of Risk Equations for Complications Of type 2 Diabetes 
(RECODe) using individual participant data from randomised trials. The Lancet 
Diabetes & Endocrinology, 5(10), 788-798. 
Bera, A.K., & Bilias, Y. (2002). The MM, ME, ML, EL, EF, and GMM approaches to 
estimation: a synthesis, Journal of Econometrics; 107(1-2), 51-86. doi: 
10.1016/S0304-4076(01)00113-0. 
Berwick, D. M., Nolan, T. W., & Whittington, J. (2008). The triple aim: care, health, and 
cost. Health affairs, 27(3), 759-769. 
Boylan, G. (2013). Robust Parameter Design in Complex Engineering Systems. (Doctoral 
dissertation). Retrieved from Tiger Prints, Clemson University. 
Boylan, G.L., & Cho, B.R. (2012). The Normal Probability Plot as a Tool for 
Understanding Data: A Shape Analysis from the Perspective of Skewness, Kurtosis, 
and Variability, Quality and Reliability Engineering International; 28: 249-264. Doi: 
10.1002/qre.1241. 
Box, G. (1988). Signal-to-noise ratios, performance criteria, and transformations, 
Technometrics; 30(1), 1-17. doi: 10.2307/1270311  
Brewster, L. M., Mairuhu, G., Sturk, A., & van Montfrans, G.A. (2007). Distribution of 
creatine kinase in the general population: Implications for statin therapy, American 
Heart Journal, 154(4), 655-661. doi: 10.1016/j.ahj.2007.06.008 
Breiman, L., & Cutler, A. (2007). Random forests-classification description. Department 
of Statistics, Berkeley, 2. 
Bughin, J., Hazen, E., Ramaswamy, S., Chui, M., Allas, T., Dahlstrom, P., Henke, N., 
and Trench, M. (2017). Artificial Intelligence: The Next Digital Frontier?. McKinsey 
Global Institute. Retrieved from 
https://www.mckinsey.com/~/media/McKinsey/Industries/Advanced%20Electronics/
Our%20Insights/How%20artificial%20intelligence%20can%20deliver%20real%20va
lue%20to%20companies/MGI-Artificial-Intelligence-Discussion-paper.ashx. 
Burt, V. L., Whelton, P., Roccella, E. J., Brown, C., Cutler, J. A., Higgins, M., & 
Labarthe, D. (1995). Prevalence of hypertension in the US adult population. 
Hypertension, 25(3), 305-313. 
 174 
Cao, H., Chen, J., Meyer-Lindenberg, A., & Schwarz, E. (2017). A polygenic score for 
schizophrenia predicts glycemic control. Translational psychiatry, 7(12), 1-9. 
Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb 
JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, 
Weinstein R, Swinton M, Djulbegovic B. (2012). Clinical Transfusion Medicine 
Committee of the, AABB. "Red Blood Cell Transfusion: A Clinical Practice 
Guideline From the AABB". Annals of Internal Medicine. 157: 49–58. 
doi:10.7326/0003-4819-157-1-201206190-00429. PMID 22751760. 
Casanova, R., Saldana, S., Simpson, S. L., Lacy, M. E., Subauste, A. R., Blackshear, C., 
Wagenknecht, L., & Bertoni, A. G. (2016). Prediction of incident diabetes in the 
Jackson Heart Study using high-dimensional machine learning. PloS one, 11(10), 
e0163942. 
Centers for Disease Control and Prevention. (2018). Diabetes Report Card 2017. Atlanta, 
GA: Centers for Disease Control and Prevention, US Department of Health and 
Human Services. 
Centers for Disease Control and Prevention. (2016). High Blood Pressure Facts. 
Retrieved from https://www.cdc.gov/bloodpressure/facts.htm 
Centers for Disease Control and Prevention. (2017). National Diabetes Statistics Report, 
2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of 
Health and Human Services; 2017. 
Center for Disease Control Newsroom. (2014). Up to 40 percent of annual deaths from 
each of five leading causes were preventable. Retrieved from 
https://www.cdc.gov/media/releases/2014/p0501-preventable-deaths.html. 
Ceriotti, F. (2012). Establishing Pediatric Reference Intervals: A Challenging Task, 
Clinical Chemistry, 58(5), 808-810. doi: 10.1373/clinchem.2012.183483 
Ceriotti, F. (2017). Quality specifications for the extra-analytical phase of laboratory 
testing: Reference intervals and decision limits, Clinical Biochemistry, 50(10-11), 
595-598. doi: 10.1016/j.clinbiochem.2017.03.024 
Ch’ng, C.K., Quah, S.H., & Low, H,C. (2005). The MM-Estimator in Response Surface 
Methodology, Quality Engineering; 17(4), 561-565. doi: 
10.1080/08982110500225323 
Chen, J., Tang, H., Huang, H., Lv, L., Wang, Y., Liu, X., & Lou, T. (2015). Development 
and validation of new glomerular filtration rate predicting models for Chinese 
patients with type 2 diabetes. Journal of translational medicine, 13(1), 317. 
 175 
Cho, B.R. Optimization issues in quality engineering, Ph.D. diss. University of 
Oklahoma: Norman, OK, 1994. 
Cho, B.R., & Park, C. (2005). Robust design modeling and optimization with unbalanced 
data, Computers & Industrial Engineering; 48(2), 173-180. doi: 
10.1016/j.cie.2005.01.004  
ClinLab Navigator, LLC. (2017). Reference Ranges. Retrieved from 
http://www.clinlabnavigator.com/reference-ranges.html.  
CLSI. (2008). Defining, Establishing, and Verifying Reference Intervals in the Clinical 
Laboratory; Approved Guideline -Third Edition. CLSI document EP28-A3c. Wayne, 
PA: Clinical and Laboratory Standards Institute. 
Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New 
England Journal of Medicine, 372(9), 793-795. 
Copeland, K.A., & Nelson, P.R. (1996). Dual response optimization via direct function 
minimization, Journal of Quality Technology, 28(3). 331-336. 
Costa, N.R.P.(2010). Simultaneous optimization of mean and standard deviation, Quality 
Engineering, 22(3), 140-149. doi: 10.1080/08982110903394205. 
Cox, L., & Peck, P. (2009). The Top 10 Medical Advances of the Decade. Medpage 
Today. Retrieved from 
https://www.medpagetoday.com/infectiousdisease/publichealth/17594. 
Cruz, J. A., & Wishart, D. S. (2006). Applications of machine learning in cancer 
prediction and prognosis. Cancer informatics, 2, 59. 
Dagliati, A., Marini, S., Sacchi, L., Cogni, G., Teliti, M., Tibollo, V., De Cata, P., 
Chiovato, L., & Bellazzi, R. (2017). Machine Learning Methods to Predict Diabetes 
Complications. Journal of diabetes science and technology, 1932296817706375. 
Davidoff, F., Haynes, B., Sackett, D., & Smith, R. (1995). Evidence based medicine. 
BMJ: British Medical Journal, 310(6987), 1085. 
Davis, K. (2013). Statistical Brief #404: Expenditures for Hypertension among Adults 
Age 18 and Older, 2010: Estimates for the U.S. Civilian Noninstitutionalized 
Population. Retrieved from 
https://meps.ahrq.gov/data_files/publications/st404/stat404.shtml 
DeJesus, R. S., Breitkopf, C. R., Rutten, L. J., Jacobson, D. J., Wilson, P. M., & Sauver, 
J. S. (2017). Incidence rate of prediabetes progression to diabetes: modeling an 
optimum target group for intervention. Population health management, 20(3), 216-
223. 
 176 
Del Castillo, E. & Montgomery, D.C. (1993). A nonlinear programming solution to the 
dual response problem, Journal of Quality Technology, 25(3), 199-204. 
Deng, L., & Li, X. (2013). Machine learning paradigms for speech recognition: An 
overview. IEEE Transactions on Audio, Speech, and Language Processing, 21(5), 
1060-1089. 
Dieleman, J. L., Baral, R., Birger, M., Bui, A. L., Bulchis, A., Chapin, A., Hamadvid, H., 
Horst, C., Johnson, E.K., Joseph, J., Lavado, R., Lomsadze, L., Reynolds, A., Squires, 
E., Cambell, M., DeCenso, B., Dicker, D., Flaxman, A., Gabert, R., Highfill, T., 
Naghavi, M., Nightingale, N., Templin, T., Tobias, T., Vos, T., & Murray, C.(2016). 
US spending on personal health care and public health, 1996-2013. Jama, 316(24), 
2627-2646. 
Ding, R., Lin, D.K.J., & Wei, D. (2004). Dual Response Surface Optimization: A 
Weighted MSE Approach, Quality Engineering, 16(3), 377-385. Doi: 10.1081/QEN-
120027940. 
Dong, S. S., Guo, Y., Yao, S., Chen, Y. X., He, M. N., Zhang, Y. J. Chen, X., Chen, J., & 
Yang, T. L. (2017). Integrating regulatory features data for prediction of functional 
disease-associated SNPs. Briefings in bioinformatics. 
Du, J., Park, Y.-T., Theera-Ampornpunt, N., McCullough, J. S., & Speedie, S. M. (2012). 
The use of count data models in biomedical informatics evaluation research. Journal 
of the American Medical Informatics Association, 19(1), 39–44. 
http://doi.org/10.1136/amiajnl-2011-000256.  
ElTanboly, A., Ismail, M., Shalaby, A., Switala, A., El‐Baz, A., Schaal, S.,Gimel’farb, 
G.,  & El‐Azab, M. (2017). A computer‐aided diagnostic system for detecting 
diabetic retinopathy in optical coherence tomography images. Medical physics, 44(3), 
914-923. 
Farran, B., Channanath, A. M., Behbehani, K., & Thanaraj, T. A. (2013). Predictive 
models to assess risk of type 2 diabetes, hypertension and comorbidity: machine-
learning algorithms and validation using national health data from Kuwait—a cohort 
study. BMJ open, 3(5), e002457. 
Fowler, M. J. (2008). Microvascular and macrovascular complications of diabetes. 
Clinical diabetes, 26(2), 77-82. 
Galindo, J., & Tamayo, P. (2000). Credit risk assessment using statistical and machine 
learning: basic methodology and risk modeling applications. Computational 
Economics, 15(1-2), 107-143. 
 177 
Goethals, P.L., & Cho, B.R. (2012). Designing the optimal process mean vector for 
mixed multiple quality characteristics, IIE Transactions, 44(11), 1002-1021. doi: 
10.1080/0740817X.2012.655061 
Goethals, P.L., & Cho, B.R. (2011). Solving the optimal process target problem using 
response surface designs in heteroscedastic conditions, International Journal of 
Production Research, 49(12), 3455-3478. doi: 10.1080/0740817X.2012.655061. 
Graves, A., Mohamed, A. R., & Hinton, G. (2013, May). Speech recognition with deep 
recurrent neural networks. In Acoustics, speech and signal processing (icassp), 2013 
ieee international conference on (pp. 6645-6649). IEEE. 
Hamada, M., & Nelder, J.A. (1997). Generalized linear models for quality improvement 
experiments, Journal of Quality Technology, 29(3), 292-304. 
Han, L., Luo, S., Wang, H., Pan, L., Ma, X., & Zhang, T. (2017). An Intelligible Risk 
Stratification Model Based on Pairwise and Size Constrained Kmeans. IEEE journal 
of biomedical and health informatics, 21(5), 1288-1296. 
Harpaz, R., Chase, H. S., & Friedman, C. (2010, October). Mining multi-item drug 
adverse effect associations in spontaneous reporting systems. In BMC bioinformatics 
(Vol. 11, No. 9, p. S7). BioMed Central. 
Harvard Health Publishing (2009). Medications for Treating Hypertension. Harvard 
Women’s Health Watch.  Retrieved from https://www.health.harvard.edu/heart-
health/medications-for-treating-hypertension  
Hasenkamp T., Arvidsson M., & Gremyr I. (2009) A review of practices for robust 
design methodology. Journal of Engineering Design, 20(6), 645-657, doi: 
10.1080/09544820802275557  
Health Sciences South Carolina (2017). Our Tools and Services. Retrieved from 
https://www.healthsciencessc.org/our-tools-services 
Hertroijs, D. F., Elissen, A. M., Brouwers, M. C., Schaper, N. C., Köhler, S., Popa, M. 
C., Asteriadis, S., Hendriks, S. H., Bilo, H. J., & Ruwaard, D. (2017). A risk score 
including body mass index, glycated haemoglobin and triglycerides predicts future 
glycaemia control in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 
Horn, P.S., & Pesce, A.J. (2003). Reference intervals: an update. Clinica Chimica Acta, 
334(1-2), 5-23. Doi: 10.1016/S0009-8981(03)00133-5 
Hothorn, T. (2018). CRAN Task View: Machine Learning. Retrieved from https://cran.r-
project.org/web/views/MachineLearning.html 
 178 
Huber, P.J. (1973). Robust Regression: Asymptotics, Conjectures, and Monte Carlo, The 
Annals of Statistics, 1(5), 799-821. 
Hudson, K., Lifton, R., & Patrick-Lake, B. (2015). The precision medicine initiative 
cohort program—Building a Research Foundation for 21st Century Medicine. 
Precision Medicine Initiative (PMI) Working Group Report to the Advisory 
Committee to the Director, ed. 
Howard, A. (2012). Coding for Hypertension. For the Record 24(8), 28. Retrieved from 
http://www.fortherecordmag.com/archives/042312p28.shtml 
H2O.ai. (2018). #1 Open-source machine learning platform for enterprises. Retrieved 
from https://www.h2o.ai/h2o/ 
Jameson, J. L., & Longo, D. L. (2015). Precision medicine—personalized, problematic, 
and promising. Obstetrical & Gynecological Survey, 70(10), 612-614. 
Jeong, I., Kim, K., & Chang, S.Y. (2005). Optimal Weighting of Bias and Variance in 
Dual Response Surface Optimization, Journal of Quality Technology, 37(3), 236-247. 
Johnson, C. (2017, February 15). Why America’s health-care spending is projected to 
soar over the next decade. The Washington Post. Retrieved from 
https://www.washingtonpost.com/news/wonk/wp/2017/02/15/u-s-health-care-
spending-projected-to-soar-to-5-5-trillion-by-2025/?utm_term=.2672f2b90e9a 
Kagawa, R., Kawazoe, Y., Ida, Y., Shinohara, E., Tanaka, K., Imai, T., & Ohe, K. (2017). 
Development of Type 2 Diabetes Mellitus Phenotyping Framework Using Expert 
Knowledge and Machine Learning Approach. Journal of diabetes science and 
technology, 11(4), 791-799. 
Kahn, R. (2003). Follow-up Report on the Diagnosis of Diabetes Mellitus: The Expert 
Committee on the Diagnosis and Classifications of Diabetes Mellitus, Diabetes Care, 
26(11), 3160-3167.  
Karst, O.J. (1958). Linear Curve Fitting Using Least Deviations, Journal of the American 
Statistical Association, 53(281), 118-32. doi: 10.2307/2282572 
Katayev, A., Balciza, C., & Seccombe, D. (2010). Establishing Reference Intervals for 
Clinical Laboratory Test Results: Is There a Better Way? American Journal of 
Clinical Pathology, 133(2), 180-186. doi: 10.1309/AJCPN5BMTSF1CDYP 
Kavakiotis, I., Tsave, O., Salifoglou, A., Maglaveras, N., Vlahavas, I., & Chouvarda, I. 
(2017). Machine learning and data mining methods in diabetes research. 
Computational and structural biotechnology journal. 15, 104-116. 
 179 
Kibaya, R.S., Bautista, C.T., Sawe, F.K., Shaffer, D.N., Sateren, W.B., Scott, P.T., 
Nelson, L.M., Robb, M.L., Birx, D.L., & de Souza, M.S. (2008). Reference Ranges 
for the Clinical Laboratory Derived from a Rural Population in Kericho, Kenya. 
PLOS One, 3(10), e3327. doi: 10.1371/journal.pone.0003327  
Kim, K., & Lin, D.K.J. (2006). Optimization of multiple responses considering both 
location and dispersion effects, European Journal of Operations Research; 169(1), 
133-145. doi: 10.1016/j.ejor.2004.06.020 
Kim, K., & Lin, D.K.J. (1998). Dual Response Surface Optimization: A Fuzzy Modeling 
Approach, Journal of Quality Technology, 30(1), 1-10. 
Kim, Y.J., & Cho, B.R. (2002). Development of Priority-Based Robust Design, Quality 
Engineering, 14(3), 355-363. doi: 10.1081/QEN-120001874 
Kim, Y. M., Kathuria, P., & Delen, D. (2017). Machine Learning to Compare Frequent 
Medical Problems of African American and Caucasian Diabetic Kidney 
Patients. Healthcare informatics research, 23(4), 241-248. 
Koksoy, O., & Yalcinoz, T. (2008). Robust Design using Pareto-type optimization: A 
genetic algorithm with arithmetic crossover, Computers & Industrial Engineering, 
55(1), 208-218. doi: 10.1016/j.cie.2007.11.019 
Koutrouvelis, I.A. & Canavos, G.C. (2000). A comparison of moment-based methods of 
estimation for the log Pearson type 3 distribution, Journal of Hydrology, 234(1-2), 
71-81. doi: 10.1016/S0022-1694(00)00241-9 
Kovach, J., & Cho, B.R. (2007). Development of a D-optimal robust design model for 
restricted experiments, International Journal of Industrial Engineering – Theory 
Applications and Practice, 14(2), 117-128. 
Kovach, J., & Cho, B.R. (2008). Development of a multidisciplinary-multiresponse 
robust design optimization model, Engineering Optimization, 40(9), 805-819. doi: 
10.1080/03052150802046304. 
Krauss, C., Do, X. A., & Huck, N. (2017). Deep neural networks, gradient-boosted trees, 
random forests: Statistical arbitrage on the S&P 500. European Journal of 
Operational Research, 259(2), 689-702. 
Kubat, M., Holte, R. C., & Matwin, S. (1998). Machine learning for the detection of oil 
spills in satellite radar images. Machine learning, 30(2-3), 195-215. 
Kudyba, S. P. (2010). Healthcare informatics: improving efficiency and productivity. 
CRC Press. 
 180 
Kutner, M.H., Nachtsheim, C.J., Neter, J., & Li, W. (2003). Applied Linear Statistical 
Models (5th edn). McGraw-Hill: Boston, MA, 429. 
Lee, B. J., & Kim, J. Y. (2016). Identification of type 2 diabetes risk factors using 
phenotypes consisting of anthropometry and triglycerides based on machine learning. 
IEEE journal of biomedical and health informatics, 20(1), 39-46. 
Lee, B. J., Ku, B., Nam, J., Pham, D. D., & Kim, J. Y. (2014). Prediction of fasting 
plasma glucose status using anthropometric measures for diagnosing type 2 diabetes. 
IEEE journal of biomedical and health informatics, 18(2), 555-561. 
Lee, Y., & Nelder, J.A. (2003). Robust Design via Generalized Linear Models, Journal of 
Quality Technology; 35(1) 2-12.  
Lee, S.B., Park, C., & Cho, B.R. (2007). Development of a highly efficient and resistant 
robust design, International Journal of Production Research, 45(1) 157-167. doi: 
10.1080/00207540600649202. 
Leung, R. K., Wang, Y., Ma, R. C., Luk, A. O., Lam, V., Ng, M., So, W.Y., Tsui, S. K. 
W., & Chan, J. C. (2013). Using a multi-staged strategy based on machine learning 
and mathematical modeling to predict genotype-phenotype risk patterns in diabetic 
kidney disease: a prospective case–control cohort analysis. BMC nephrology, 14(1), 
162. 
Lesko, L. J. (2007). Personalized medicine: elusive dream or imminent reality? Clinical 
Pharmacology And Therapeutics, 81(6), 807-816. 
Li, Y., Bai, C., & Reddy, C. K. (2016). A distributed ensemble approach for mining 
healthcare data under privacy constraints. Information sciences, 330, 245-259. 
Ligthart, S., van Herpt, T. T., Leening, M. J., Kavousi, M., Hofman, A., Stricker, B. H., 
van Hoek, M.m Sijbrands, E., Franco, O., & Dehghan, A. (2016). Lifetime risk of 
developing impaired glucose metabolism and eventual progression from prediabetes 
to type 2 diabetes: a prospective cohort study. The lancet Diabetes & endocrinology, 
4(1), 44-51. 
Lin, D.K.J., & Tu, W. (1995). Dual Response Surface Optimization, Journal of Quality 
Technology, 27(1), 34-39. 
Lo-Ciganic, W. H., Donohue, J. M., Thorpe, J. M., Perera, S., Thorpe, C. T., Marcum, Z. 
A., & Gellad, W. F. (2015). Using machine learning to examine medication 
adherence thresholds and risk of hospitalization. Medical care, 53(8), 720. 
López, B., Torrent-Fontbona, F., Viñas, R., & Fernández-Real, J. M. (2017). Single 
Nucleotide Polymorphism relevance learning with Random Forests for Type 2 
diabetes risk prediction. Artificial intelligence in medicine. 
 181 
Malka, R., Nathan, D. M., & Higgins, J. M. (2016). Mechanistic modeling of hemoglobin 
glycation and red blood cell kinetics enables personalized diabetes monitoring. 
Science translational medicine, 8(359), 359ra130-359ra130. 
Mahout. (2018). Mahout: For Creating Scalable Performant Machine Learning 
Applications. Retrieved from https://mahout.apache.org/ 
Marshall, W. J., & Bangert, S.K. (Eds.). (2008). Clinical Biochemistry: Metabolic and 
Clinical Aspects, Second Edition. Churchill Livingstone, Philadelphia, PA.  
Martin, A. B., Hartman, M., Washington, B., Catlin, A., & National Health Expenditure 
Accounts Team. (2016). National health spending: faster growth in 2015 as coverage 
expands and utilization increases. Health Affairs, 36(1), 166-176. 
Mayo Clinic (2018). Type 1 Diabetes. Retrieved from 
https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-
causes/syc-20353011 
May Clinic (2018). Type 2 Diabetes. Retrieved from 
https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-
causes/syc-20351193 
Mayo Clinic. (2018g). Test ID: STSH. Retrieved from 
https://www.mayomedicallaboratories.com/test-
catalog/Clinical+and+Interpretive/8939 
McCoy, R. G., Ngufor, C., Van Houten, H. K., Caffo, B., & Shah, N. D. (2017). 
Trajectories of Glycemic Change in a National Cohort of Adults With Previously 
Controlled Type 2 Diabetes. Medical care, 55(11), 956-964. 
Merriam-Webster (2017). Analyte. Retrieved from https://www.merriam-
webster.com/dictionary/analyte.  
 
Moreno, E. M., Luján, M. J. A., Rusinol, M. T., Fernández, P. J., Manrique, P. N., 
Trivino, C. A., Miquel, M. P., Rodriguez, M. A.,  & Burguillos, M. J. G. (2017). Type 
2 diabetes screening test by means of a pulse oximeter. IEEE Transactions on 
Biomedical Engineering, 64(2), 341-351. 
Muhlbauer, A., Spichtinger, P., & Lohmann, U. (2009). Application and Comparison of 
Robust Linear Regression Methods for Trend Estimation, Journal of Applied 
Meteorology and Climatology, 48(9), 1961-1970. doi: 10.1175/2009JAMC1851.1 
Myers, R.H., Montgomery, D.C., and Vining, G.G. (2002). Generalized Linear Models: 
With Applications in Engineering and the Sciences. Wiley: New York, 2002. 
 182 
Myers, R.H., & Montgomery, D.C. (1997). A Tutorial on Generalized Linear Models, 
Journal of Quality Technology, 29(3), 274-291. 
National Academy of Engineering. (2018). Introduction to the Grand Challenges for 
Engineering. Retrieved from 
http://www.engineeringchallenges.org/challenges/16091.aspx 
National Center for Biotechnology Information. (2018, March 22). Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/. 
National Center for Health Statistics. (2016). Health, United States, 2015: with special 
feature on racial and ethnic health disparities. 
National Center for Health Statistics, & Centers for Medicare and Medicaid Services. 
(2010). ICD-10-CM official guidelines for coding and reporting. Washington (DC): 
US GPO. 
National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.) Diabetes Tests 
& Diagnosis. Retrieved from https://www.niddk.nih.gov/health-
information/diabetes/overview/tests-diagnosis 
National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Symptoms & 
Causes of Diabetes. Retrieved from https://www.niddk.nih.gov/health-
information/diabetes/overview/symptoms-causes 
NET Framework. (2018). Accord.NET Framework. Retrieved from http://accord-
framework.net/ 
Neugebauer, R., Fireman, B., Roy, J. A., Raebel, M. A., Nichols, G. A., & O'Connor, P. 
J. (2013). Super learning to hedge against incorrect inference from arbitrary 
parametric assumptions in marginal structural modeling. Journal of clinical 
epidemiology, 66(8), S99-S109. 
Neugebauer, R., Fireman, B., Roy, J. A., Raebel, M. A., Nichols, G. A., & O'Connor, P. 
J. (2013). Super learning to hedge against incorrect inference from arbitrary 
parametric assumptions in marginal structural modeling. Journal of clinical 
epidemiology, 66(8), S99-S109. 
Obama, B. (2015). President Obama's 2015 State of the Union Address. WhiteHouse. 
gov, https://www. whitehouse. gov/sotu (accessed April 29, 2015). Notes, 259. 
O'Hagan, A., & Leonhard, T. (1976). Bayes estimation subject to uncertainty about 
parameter constraints, Biometrika, 63(1), 201-202. doi: 10.2307/2335105 
Olivera, A. R., Roesler, V., Iochpe, C., Schmidt, M. I., Vigo, Á., Barreto, S. M., & 
Duncan, B. B. (2017). Comparison of machine-learning algorithms to build a 
 183 
predictive model for detecting undiagnosed diabetes-ELSA-Brasil: accuracy 
study. Sao Paulo Medical Journal, 135(3), 234-246. 
Oryx 2. (n.d.). Overview. Retrieved from http://oryx.io/ 
Ozery-Flato, M., Ein-Dor, L., Parush-Shear-Yashuv, N., Aharonov, R., Neuvirth, H., 
Kohn, M. S., & Hu, J. (2016). Identifying and investigating unexpected response to 
treatment: a diabetes case study. Big data, 4(3), 148-159. 
Ozery-Flato, M., Parush, N., El-Hay, T., Visockienė, Ž., Ryliškytė, L., Badarienė, J., 
Solovjova, S., Kovaite, M., Navickas, R., & Laucevičius, A. (2013). Predictive 
models for type 2 diabetes onset in middle-aged subjects with the metabolic 
syndrome. Diabetology & metabolic syndrome, 5(1), 36. 
Paauw, D. (2017). Double the Dose of antihypertensive drugs? Internal Medicine News.  
Retrieved from 
http://www.mdedge.com/internalmedicinenews/article/138365/cardiology/double-
dose-antihypertensive-meds 
Pazzani, M., & Billsus, D. (1997). Learning and revising user profiles: The identification 
of interesting web sites. Machine learning, 27(3), 313-331. 
Pedersen, H. K., Gudmundsdottir, V., Pedersen, M. K., Brorsson, C., Brunak, S., & 
Gupta, R. (2016). Ranking factors involved in diabetes remission after bariatric 
surgery using machine-learning integrating clinical and genomic biomarkers. NPJ 
genomic medicine, 1, 16035. 
Pimentel, A., Carreiro, A. V., Ribeiro, R. T., & Gamboa, H. (2016). Screening diabetes 
mellitus 2 based on electronic health records using temporal features. Health 
informatics journal, 1460458216663023 
Pegues, K.K., Boylan, G. L., & Cho, B. R. (2017). Decision making in health care using 
robust parameter design with conditions‐based selection of regression estimators. 
Quality and Reliability Engineering International, 33(8), 2151-2169. 
Peddinti, G., Cobb, J., Yengo, L., Froguel, P., Kravić, J., Balkau, B., Tuomi, T., 
Aittokallio, T., & Groop, L. (2017). Early metabolic markers identify potential targets 
for the prevention of type 2 diabetes. Diabetologia, 60(9), 1740-1750. 
Phillips, M.D., Madduri, K.S., & Cho, B.R. (1995). Enhanced optimization strategies for 
robust design, Fourth Industrial Engineering Research Conference, Nashville, TN. 
Plebani, M. (2016). Harmonization in laboratory medicine: Requests, Samples, 
Measurements and Reports. Critical reviews in Clinical Laboratory Sciences, 53(3), 
184-196. doi: 10.3109/10408363.2015.1116851. 
 184 
Pippitt, K., & Li, M. (2016). Diabetes mellitus: screening and diagnosis. American 
Academy of Family Physicians, 93(2), 103-109 
Polio. (2017). Centers for Disease Control and Prevention. Retrieved from 
https://www.cdc.gov/features/poliofacts/.  
Polio: Global Eradication Initiative. (n.d.). Retrieved from 
http://polioeradication.org/polio-today/history-of-polio/.   
R Core Team. (2012). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing: Vienna, Austria.  ISBN 3-900051-07-0, URL 
http://www.R-project.org/. 
Rachana, P. R., & Anuradha, H. V. (2014). Anti hypertensive prescribing patterns and 
cost analysis for primary hypertension: a retrospective study. Journal of clinical and 
diagnostic research: JCDR, 8(9), HC19. 
Rafey, M. (2013). Hypertension. Cleveland Clinic: Center for Continuing Education. 
Retrieved from 
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/
arterial-hypertension/ 
Ramezankhani, A., Pournik, O., Shahrabi, J., Azizi, F., Hadaegh, F., & Khalili, D. 
(2016). The impact of oversampling with SMOTE on the performance of 3 classifiers 
in prediction of type 2 diabetes. Medical decision making, 36(1), 137-144. 
Raschka, S. (2015). Python machine learning. Packt Publishing Ltd. 
Razavian, N., Blecker, S., Schmidt, A. M., Smith-McLallen, A., Nigam, S., & Sontag, D. 
(2015). Population-level prediction of type 2 diabetes from claims data and analysis 
of risk factors. Big Data, 3(4), 277-287. 
Ricos, C., Cava, F., García‐Lario, J. V., Hernandez, A., Iglesias, N., Jimenez, C.V., 
Minchinela, J., Perich, C., Domenech, M.V., & Alvarez, V. (2004). The reference 
change value: a proposal to interpret laboratory reports in serial testing based on 
biological variation. Scandinavian Journal of Clinical and Laboratory Investigation, 
64(3), 175-184. doi: 10.1080/00365510410004885 
Rish, I. (2001, August). An empirical study of the naive Bayes classifier. In IJCAI 2001 
workshop on empirical methods in artificial intelligence (Vol. 3, No. 22, pp. 41-46). 
IBM. 
Robinson, T.J., Borror, C.M., & Myers, R.H. (2004). Robust Parameter Design: A 
Review, Quality and Reliability Engineering International; 20(1), 81-101. doi: 
10.1002/qre.602 
 185 
Robinson, T.J., Wulff, S.S., Montgomery, D.C., & Khuri, A.I. (2006). Robust Parameter 
Design Using Generalized Linear Mixed Models, Journal of Quality Technology; 
38(1), 66-75. 
Rousseeuw, P.J. (1984). Least median of squares regression, Journal of American 
Statistical Association; 79, 871-880. doi: 10.2307/2288718 
Rousseeuw, P.J. & Yohai, V.J. (1984). Robust regression by means of S-estimators in 
Robust and Nonlinear Time Series Analysis. In Lecture Notes in Statistics No. 26, 
Franke J, Hardle, W and Martin D (eds). Springer: Berlin, Germany, 256-272. 
Ryan, T.P. (2009). Modern Regression Methods, 2nd ed. Wiley: Hoboken, NJ, 2009. 
Shaibu, A.B., & Cho, B,R. (2009). Another view of dual response surface modeling and 
optimization in robust parameter design, International Journal of Advanced 
Manufacturing Technology, 41(7), 631-641. 
Shaibu, A.B, Cho, B.R., & Kovach, J. (2009). Development of a Censored Robust Design 
Model for Time-Oriented Quality Characteristics, Quality and Reliability 
Engineering International, 25(2), 181-197. doi: 10.1002/qre.961. 
Shin, S., & Cho, B.R. (2008). Development of a sequential optimization procedure for 
robust design and tolerance design within a bi-objective paradigm, Engineering 
Optimization, 40(11), 989-1009. 
Shin, S., & Cho, B.R. (2009). Studies on a bi-objective robust design optimization 
problem, IIE Transactions; 41: 957-968. doi: 10.1080/07408170902789084  
Shin, S., Samanlioglu, F., Cho, B.R., & Wiecek, M.M. (2011). Computing trade-offs in 
robust design: Perspectives of the mean squared error, Computers & Industrial 
Engineering, 60, 248-255. doi: 10.1016/j.cie.2010.11.006 
Shogun. (n.d.). Unified and efficient machine learning library. Retrieved from 
http://www.shogun-toolbox.org/ 
Simpson, J.R. & Montgomery, D.C. (1998). A performance-based assessment of robust 
regression methods, Communication in Statistics – Simulation and Computation, 
27(4), 1031–1049. doi: 10.1080/03610919808813524 
Skolnik, N. S., Beck, J. D., & Clark, M. (2000). Combination antihypertensive drugs: 
recommendations for use. American family physician, 61(10), 3049-3056. 
Sudharsan, B., Peeples, M., & Shomali, M. (2014). Hypoglycemia prediction using 
machine learning models for patients with type 2 diabetes. Journal of diabetes 
science and technology, 9(1), 86-90. 
 186 
Sunderman, F.W. (1975). Current Concepts of “Normal Values,” “Reference Values,” 
and “Discrimination Values” in Clinical Chemistry. Clinical Chemistry, 21(13), 
1873-1877. 
Tang, L.C., & Xu, K. (2002). A Unified Approach for Dual Response Surface 
Optimization, Journal of Quality Technology, 34(4), 437-447. 
Taguchi, G. (1986). Introduction to Quality Engineering. UNIPUB/Kraus International: 
White Plains, NY. 
Taguchi, G. (1987). System of Experimental Design: Engineering Methods to Optimize 
Quality and Minimize Cost. UNIPUB/Kraus International: White Plains, NY. 
Taguchi, G., Chowdhry, S., & Wu, Y. (2004). Taguchi’s Quality Engineering Handbook, 
Wiley, New York, NY. 
Tsai, A. (2015, September). 6 Tests to Determine Diabetes Type. Retrieved from: 
http://www.diabetesforecast.org/2015/sep-oct/tests-to-determine-diabetes.html 
Tsui, K. (1992). An Overview of Taguchi Method and Newly Developed Statistical 
Methods for Robust Design, IIE Transactions, 24(5), 44-57. doi: 
10.1080/07408179208964244 
Vining, G.G., & Myers, R.H. (1990). Combining Taguchi and Response Surface 
Philosophies: a Dual Response Approach, Journal of Quality Technology, 22, 38-45. 
Vyas, R., Bapat, S., Jain, E., Karthikeyan, M., Tambe, S., & Kulkarni, B. D. (2016). 
Building and analysis of protein-protein interactions related to diabetes mellitus using 
support vector machine, biomedical text mining and network analysis. Computational 
biology and chemistry, 65, 37-44. 
WEKA. (.n.d). Weka 3: Data Mining Software in Java. The University of Waikato. 
Retrieved from https://www.cs.waikato.ac.nz/ml/weka/ 
Willinger, W., Alderson, D., & Lun, L. (2004). A Pragmatic Approach to Dealing with 
High-Variability in Network Measurements, ACM SIGCOMM Conference on 
Internet Measurement, Taormina, Sicily, Italy. doi: 10.1145/1028788.1028800 
World Health Organization. (2016). Global report on diabetes: World Health 
Organization. 
Yohai, V.J. (1987). High Breakdown-Point and High Efficiency Robust Estimates for 
Regression, The Annals of Statistics, 15(2), 642-656. 
Zheng, T., Xie, W., Xu, L., He, X., Zhang, Y., You, M., Yang, G., & Chen, Y. (2017). A 
machine learning-based framework to identify type 2 diabetes through electronic 
health records. International journal of medical informatics, 97, 120-127. 
